




Pedro Gustavo Marchã Canhão Costa 
 




Towards a bioinspired 3D triculture 
hiPSC-derived cardiac tissue model for 
human heart microenvironment 
recapitulation and drug testing 
  
 




Supervisor: Dr. Paula Marques Alves, PhD, Principal Investigator, 
CEO of iBET and Director of Animal Cell Technology Unit, 
iBET/ITQB-NOVA 
 
Co-Supervisor: Dr. Maria Margarida de Carvalho Negrão Serra, PhD, 


















President: Dr. Rui Manuel Freitas Oliveira, FCT/UNL 
  
Examiner: Dr. Susana Carvalho Rosa, CNC, UC 
  
Supervisor: Dr. Paula Marques Alves, iBET/ITQB-NOVA 


















































































































































































































Pedro Gustavo Marchã Canhão Costa 
 




Towards a bioinspired 3D triculture 
hiPSC-derived cardiac tissue model for 
human heart microenvironment 
recapitulation and drug testing 
  
 




Supervisor: Dr. Paula Marques Alves, PhD, Principal Investigator, 
CEO of iBET and Director of Animal Cell Technology Unit, 
iBET/ITQB-NOVA 
 
Co-Supervisor: Dr. Maria Margarida de Carvalho Negrão Serra, PhD, 


















President: Dr. Rui Manuel Freitas Oliveira, FCT/UNL 
  
Examiner: Dr. Susana Carvalho Rosa, CNC, UC 
  
Supervisor: Dr. Paula Marques Alves, iBET/ITQB-NOVA 
















































































































































Towards a bioinspired 3D triculture hiPSC-derived cardiac tissue model for human heart 
microenvironment recapitulation and drug testing 
 
Copyright © Pedro Gustavo Marchã Canhão Costa, Faculdade de Ciências e Tecnologia, 
Universidade Nova de Lisboa, September, 2018. All rights reserved. 
 
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo 
e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares 
impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou 
que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua 
cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que 
seja dado crédito ao autor e editor. 



















































This thesis is dedicated to my mother and also to 
my buddy, my grandfather João, who reminds 
me every day that age is no more than a state of 
mind:  
 

















 “No good fish goes anywhere without a porpoise” 
 (Lewis Carroll) 
 
 
“You have to have an idea of what you are going to do, but it should be a vague idea” 
 (Pablo Picasso) 






































 This space is dedicated to those who, in one way or another, have contributed, directly or indirectly, 
to the conclusion of this project. Since it is not feasible to name them all, there are, nevertheless, some 
whom I could not fail to express my sincere gratitude and deep recognition:  
 
First and foremost, to my supervisor, Dr. Paula Alves, for inviting me to carry out my master's 
thesis project in the Animal Cell Technology Unit, at iBET/ITQB-NOVA, in the midst of a thought-
provoking and refreshing atmosphere, where you can easily breathe science and 
professionalism. I would like to thank you for the opportunity and for being a strong example of 
leadership and perfectionism.  
 
Also to my co-supervisor, Dr. Margarida Serra, for all the rewarding scientific debates, perpetual 
encouragement, support and guidance, confidence and gentle motivation words during this 
one-year journey. A special thank you for the knowledge you have given me and for the patience 
and tolerance you have had, at certain times, to deal with me, since I know that I am a very 
demanding person with myself and sometimes with some difficulty in relating with the fact that 
everything does not always go as we originally idealized. I am fully aware of this. Thank you for 
the challenge – fortunately, I am proud to say that I was up to it – and for having trusted me and 
in my work. I have always tried to give my best and to overcome every challenge. Undeniably, 
your contribution was vital to the extension of my growth as a young scientist and enabled me 
to potentiate my skills and go further. 
 
To Bernardo Abecasis, for all the help, scientific discussions and to have eased my integration, 
in the context of a whole new research area for me, in addition to all the marathons we have 
worked together on, in the initial conception and characterization of this original and exciting 
3D cardiac model.  
 
To Henrique Almeida, for all the companionship, friendly words and, of course, for the great 
support provided in the development of methods that allowed us to characterize the 
microcapsule scaffold. Also to the “atomic force microscopy guy”, Tomás Calmeiro, from 
CENIMAT-I3N (FCT/UNL), for the technical support provided, as a result of our collaboration, but 
also for the constant good disposition and sense of humour. 
 
To all the ACTU researchers and colleagues, in particular to the Stem Cell team, for the sympathy, 
scientific discussions and knowledge sharing.   
 
To the hosting institutions, iBET and ITQB-NOVA, for the outstanding working conditions. 
 
To all the Advanced Imaging Facility staff, from Instituto Gulbenkian de Ciência, but, essentially, 
to Hugo Pereira and also to Gaby, for the endless support and help in the different types of 
microscopy that I worked with during this year. To Hugo, a genuine and special thanks, for the 
countless hours spent around the light-sheet, with the aim of developing a personalized method 
that would allow the characterization of my 3D cell-based models. And also for having 
P.G.M. Canhão Costa, September 2018 | vi  
 
accompanied me in the introduction to confocal and multiphoton microscopies. Thank you for 
your availability, which was often beyond simple technical assistance.  
 
Besides all the people I have worked with, during this year, I also want to acclaim FCT/UNL, 
because it is a hub where new ideas, knowledge and innovation are very much alive. Similarly, 
to all the teachers that I have met during these 5 years and who have positively enlarged my 
skills, both professionally and personally, a sincere thank you. 
 
À minha mãe e à minha irmã por sempre me entusiasmarem e motivarem perante os desafios 
e a adversidade, assim como a fazer mais e melhor. Quero também partilhar convosco a 
determinação de os conseguir ultrapassar constantemente! 
 
À Mara por estar incondicionalmente presente. 
 
A todos os meus amigos que pacientemente me ouviram falar, durante horas a fio, sobre células 
estaminais, modelos 3D, esferóides cardíacos, cardiotoxicidade, biomateriais, entre outros – 
mesmo quando não queriam! 
 
E para terminar, como não podia deixar de ser, um imperioso obrigado aos meus avós, Arminda 
e João, por tudo aquilo que me ensinaram e, acima de tudo, por serem enormes exemplos. 
 
Mais uma vez, a todos,  












































Graphical abstract caption. Schematic illustration of the long-term bioinspired 3D triculture hiPSC-derived cardiac tissue 
model complexity, in the final day of culture, as well as some of the major readouts developed for its characterization (right 
panel). The model representation (right panel) is not to scale. The key model players are also depicted (beneath, left). 
Highlighted: light-sheet immunofluorescence microscopy of whole 3D tricultures (left) immunostained for the endothelial marker 
VE-cadherin (green) and the mesenchymal marker Vimentin (red) and counterstained with DRAQ5 (cyan). The author wish to 
thank Servier Medical Art for their image bank used to create the illustrations. 


































Background and Aim 
 In the human heart, cardiomyocytes (CMs), endothelial cells (ECs) and mesenchymal cells (MCs) are in 
close proximity and constant dialogue. Predictive models that reliably mimic the native physiology of the 
human heart in vitro would ideally incorporate this cardiomyocyte–non-myocyte crosstalk. Human 
pluripotent stem cells (hPSC) are an attractive candidate cell platform for in vitro cardiac modelling. 
However, the predictive power of such models is currently constrained by the immature phenotype of 
hPSC-CM. Hence, the generation of mature hPSC-CM is mandatory for an accurate recapitulation of the 
human heart microenvironment.  
 Herein we describe a bioinspired 3D triculture hiPSC-derived cardiac tissue model for human heart 
microenvironment recapitulation and drug testing. 
 
Methodology 
 Cardiomyocytes (hiPSC-CM spheroids) and non-myocytes (hiPSC-EC and hiPSC-MC single cells) were 
differentiated from hiPSC and then microencapsulated in an alginate hydrogel-based scaffold (tricultures). 
3D models composed only of encapsulated spheroids (monocultures) or, alternatively, encapsulated 
single cells (co-cultures), were also engineered.  
 
Principal Findings 
 After only 15 days of culture, RT-qPCR and immunofluorescence revealed evidence of a higher 
structural maturation of triculture’s hiPSC-CM, specifically increased MYL2/MYL7 and TNNI3/TNNI1 gene 
expression ratios and upregulation of cardiac ion channels, and overexpression of gap junction and ECM 
proteins. Ultrastructural analysis disclosed a remarkably organized ultrastructure in both models and 
confirmed improvements in sarcomere length and myofibrillar alignment in triculture. Calcium imaging 
exposed that hiPSC-CM were pharmacologically responsive to cardioactive drugs (norepinephrine, 
heptanol and propranolol). A dose-dependent response to cardiotoxic chemotherapeutic drugs 
(doxorubicin and paclitaxel) constitutes another sign hiPSC-CM functionality. Furthermore, AFM showed 
that our scaffold exhibits a suitable Young's modulus to recapitulate the human heart microenvironment, 
while suggesting a dynamic refashioning of the triculture’s cardiac microenvironment. Lastly, we 
performed the upscaling of the cardiac models using perfusion stirred tank bioreactors. 
 
Conclusions 
 Overall, this thesis represents a step forward in the study of myocyte–non-myocyte heterotypic 
communication and cardiomyocyte maturation, in a scenario that simulates essential features of the 
cardiac microenvironment and is compatible with the high-throughput requirements of preclinical 
studies. 
 
Keywords: hiPSC-CM spheroids, hiPSC-ECMC, 3D cardiac models, alginate microencapsulation, 

















































Contexto e Objectivo 
 Os cardiomiócitos (CMs), as células endoteliais (ECs) e as células mesenquimais (MCs) encontram-se 
próximas e em interacção constante no coração humano. Modelos preditivos, que mimetizem 
eficazmente a fisiologia nativa do coração humano in vitro, deverão incorporar esse diálogo entre 
cardiomiócitos e não-miócitos. No seguimento da modelação do microambiente cardíaco humano, 
surgem, como candidatos promissores, as células estaminais pluripotentes humanas (hPSC). Todavia, o 
poder preditivo deste tipo modelos é actualmente limitado pelo fenótipo imaturo exibido pelos hPSC-CM, 
pelo que a geração de hPSC-CM maturados é indispensável para uma recapitulação precisa do 
microambiente do coração humano. 
 Nesta tese é descrito um modelo cardíaco 3D de tricultura, totalmente derivado de hiPSC para a 
recapitulação do microambiente do coração humano e ensaios farmacológicos. 
 
Metodologia 
 Diferenciações celulares com o intuito de obter cardiomiócitos (esferóides de hiPSC-CM) e não-
miócitos (hiPSC-EC e hiPSC-MC, como células individualizadas), seguindo-se a microencapsulação num 
hidrogel de alginato, foram levadas a cabo. Modelos cardíacos respeitantes somente aos esferóides 
encapsulados (monoculturas) ou, alternativamente, às células individualizadas (co-culturas), foram, de 
igual forma, desenvolvidos.  
 
Principais Resultados 
 Após 15 dias em cultura, RT-qPCR e imunofluorescência denotaram evidências de um estádio de 
maturação de hiPSC-CM mais avançado nas triculturas, particularmente um aumento da expressão génica 
de MYL2/MYL7 e TNNI3/TNNI1 e de canais iónicos cardíacos, bem como um incremento das junções 
célula-célula e de proteínas da matriz extracelular. Análises ultraestruturais revelaram uma ultraestrutura 
extremamente organizada em ambos os modelos e confirmaram aumentos no comprimento sarcomérico 
e alinhamento miofibrilar nas triculturas. A técnica de imagem de cálcio demonstrou que os hiPSC-CM 
possuem capacidade de responder a fármacos com afinidade cardíaca (norepinefrina, propranolol e 
heptanol). A capacidade de resposta a fármacos anti-cancerígenos cardiotóxicos (doxorrubicina e 
paclitaxel) constitui mais um indício da funcionalidade de hiPSC-CM. Adicionalmente, AFM demonstrou 
que o scaffold utilizado exibe um módulo elástico adequado para mimetizar o microambiente do coração 
humano, indiciando uma reorganização dinâmica do microambiente cardíaco na tricultura. Para ultimar, 
efectuou-se um aumento de escala da produção dos modelos aludidos, mediante a utilização 
biorreactores de tanque agitado. 
 
Conclusões 
 Em suma, esta tese representa um passo em frente no estudo da comunicação celular heterotípica 
entre miócitos e não-miócitos e do fenómeno de maturação cardíaca, providenciando uma envolvente 
capaz de mimetizar aspectos-chave do microambiente cardíaco humano e apresentando compatibilidade 
com os requerimentos high-throughput de ensaios pré-clínicos. 
 
Palavras-chave: Esferóides cardíacos, hiPSC-ECMC, modelos cardíacos 3D, microencapsulação em 
alginato, maturação, ensaios farmacológicos. 
 
 











































 The work, presented in this dissertation, was carried out in the Animal Cell Technology Unit (ACTU) of 
iBET/ITQB-NOVA, within the scope of the Fundação para a Ciência e Tecnologia (FCT)-funded projects 
CARDIOSTEM (Grant number: MITP-TB/ECE/0013/2013): “Engineered cardiac tissues and stem cell-based 
therapies for cardiovascular applications” and NETDIAMOND (Grant number: SAICTPAC/0047/2015): 
“New targets in diastolic heart failure: from comorbidities to personalized medicine”; and also in the 
context of iNOVA4Health Research Unit (Grant number: UID/Multi/04462/2013), a program financially 
supported by Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência, through national 
funds and co-funded by FEDER, under the PT2020 Partnership Agreement. 
 In general terms, the key objectives of these projects are as follows: 
(i) Development of stem cell-based therapeutics for cardiac regeneration (cellular and non-cellular). 
(ii) Establishment of an in vitro engineered cardiac tissue model for drug screening and toxicology 
assessment. 
This thesis contributed fundamentally to accomplish the objective (ii). 
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 Given that several experiments were carried out, leading to models with different degrees of 
complexity, we have established a reaction code (recurrently used during the course of this dissertation), 
which systematises, in an easily perceptible way: (i) the model identification, (ii) the connexion between 
two models (biological replicates, or not), (iii) whether they are microencapsulated models or not, and, if 
so, which conditions were encapsulated and, lastly, (iv) the implemented culture strategy (shake flask or 
small-scale stirred-tank bioreactor culture). Each one of these codes unambiguously identifies one, and 
only one, of the prepared models. 
 The identification of the three-dimensional models follows the alphanumeric system: Designation of 
the Model (#number-letter) – Encapsulated Conditions – Culture Strategy. 
 Exemplifying for a specific example: Model #1-a-MCT-SF and Model #1-b-MCT-SF constitute two 
biological replicates, identified by the letters a and b (the only difference in the designation of the two 
replicas), in which mono- (M), co- (C) and tricultures (T) were encapsulated, being always cultivated in 
shake flask (SF). For simplicity and merely for the bioreactor-based experiments, Model #2-a-BR-1 and 
Model #2-b-MT-BR-2, will be referred to as BR-1 and BR-2, respectively. 
 
3D Model Description Schematic illustration 




Single pilot experiment, leading to the microencapsulation of only 






Microencapsulation of hiPSC-CM mono- (M), hiPSC-ECMC co- (C) and 
hiPSC-CM/ECMC tricultures (T) (first of two independent 
experiments; culture strategy: shake flask; relevant features: higher 
average microcapsule diameter and lower spheroid size, meaning an 







Microencapsulation of hiPSC-CM mono- (M), hiPSC-ECMC co- (C) and 
hiPSC-CM/ECMC tricultures (T) (second of two independent 
experiments; culture strategy: shake flask; relevant features: lower 
average microcapsule diameter and higher spheroid size, suggesting 
a reduced empty space inside the capsule, when compared to the 
biological replicate. 
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Single exploratory experiment with the aim of optimizing hiPSC-CM 
aggregation in small-scale stirred-tank bioreactors (culture strategy: 
bioreactor-based; relevant features: none of the abovementioned 








Microencapsulation of hiPSC-CM mono- and hiPSC-CM/ECMC 
tricultures (T) (one independent experiment; culture strategy: 
bioreactor-based; relevant features: fine aggregation and 





Main abbreviations: M – Microencapsulated 3D hiPSC-CM Monoculture, C – Microencapsulated 3D hiPSC-ECMC Co-culture, T – 
Microencapsulated 3D hiPSC-CM/ECMC Triculture, SF – Shake Flask, BR – Bioreactor (for the remaining ones, consult List of 


























































Towards a bioinspired 3D triculture hiPSC-derived cardiac tissue model for human heart microenvironment recapitulation and 
drug testing 






 1.1.1. Motivation – in vitro myocardial cell-based models in the landscape of cardiovascular 
preclinical research  
ardiovascular disease (CVD)[1–7] and heart failure (HF)[1–3,5,7–9] are today a global epidemic and still 
represent the major causes of mortality and morbidity in the Western world[1–4,8]. CVD and HF can 
derive primarily from myocardial infarction (MI)[1–3,7,9,10], chemotherapy-induced 
cardiotoxicity[1,3,7,10–13] and inherited abnormalities affecting cardiac function[1–3,10].  
 According to data published in the latest annual World Health Statistic report of the World Health 
Organization (WHO, June 2016), the number of deaths arising from CVD is already 17.7 million per 
year[1,2,7], thereby representing a shocking number of 30% of all global deaths[2].  
 Furthermore, notwithstanding the new scientific and medical progresses, the number is unfortunately 
projected to rise to more than 23.6 million per year until 2030[2]. Hence, it is unquestionably clear that 
CVDs represent a massive problem in our contemporary society[1–7], even from an economic point of 
view[1,5,14], with a cost to the world healthcare sector estimated at about eight hundred and sixty billion 
dollars per year[5,15]. Thus, there is an imperative and urgent need to discover innovative, efficient, 
personalized and cost-effective cardiac therapies that allow this problem to be reached on a global scale[1–
6,14,15].  
 Similarly, contributing to the abovementioned scenario, is the fact that drug discovery and 
development is a very challenging road, with high failure rates[14,16], along with the cost-ineffectiveness[14] 
and inadequacy[14] of the prevailing methods, used to estimate their safety[2,7,14,17], efficacy[2,7,14,17] and 
mode of action[2,17]. In this context, mention should be made of the example stated by Mathur (2016) and 
Zeevi-Levin (2012), concerning that the average period between the discovery and actual 
commercialization of a drug varies between 10 to 15 years, with median costs exceeding $5 billion[14,18].  
 
 1.1.1.1 Cardiotoxicity paves the way for more predictive in vitro cardiac models 
 Cardiovascular toxicity[3,11,14,19] (Fig.1.1), which leads to numerous cardiovascular adverse 
pharmacological events (Fig.1.1a), is one of the major causes of drug recalls[3,14], post-approval 
withdrawals[3,14,16] (Fig.1.1b) and regulatory approval delays[3,14] during preclinical and clinical 
development[3,11,14,16,19]. Cardiotoxicity is especially crucial for chemotherapeutic drugs[3,11,14,16,19–21] (or 
simply anticancer drugs) (Fig.1.1b), although it is also observed with other drug classes[7,16,19,21] (Fig.1.1b), 
such as antimicrobials[16] (Fig.1.1b), antihistamines[16] (Fig.1.1b), antidiabetics[7], antidepressants[16] and 
antipsychotics[16] (Fig.1.1b).  
Recently, several non-cardiovascular drugs, including the first non-sedating antihistamine, 
terfenadine[3,16] (Triludan, in the United Kingdom), famous nowadays for the fact that 100 million people 
used it before its risks were entirely recognised, have been withdrawn from the major markets because 
of cardiotoxicity concerns[3,16]. This is just a single example, with a list of a priori withdrawn drugs or 
modified to re-enter the market, rather extensive[3,11,16,21]. 
 This phenomenon can be mostly attributed to several obstacles that currently hinder human drug 
investigation[3,14].  
C 
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 On one side of the coin, in vivo human experimental interventions pose unnecessary and unacceptable 
risks to the person undergoing clinical trials[1,3], in addition to displaying a restricted applicability[3] (owing 
to the requirement of a necessarily small sample of individuals) and intraspecies genetic and phenotypic 
differences[3,10,11,21].  
 On the other side of the coin are animal models[3,14,22], which fail to adequately recapitulate the human 
physiology (including that of the human heart)[3], due to notorious interspecies differences[3,10,14,22], with 
respect to key biochemical pathways[14], ion channels[14] and pharmacokinetic and pharmacodynamic 
behaviour[14]. Differences in cardiac structure[3,22] and electrophysiological properties[3,22] between human 
cardiomyocytes (hCM) and animal cardiomyocytes are also vital factors that, in agreement with Feric and 
Radisic (2016) and Sharma et al. (2017), restrict the relevance of the latter in preclinical animal 
studies[3,22].  
Figure 1.1 | Current picture of cardiovascular toxicity [adapted from Magdy et al. (2018)[21]].  
(a) Summary of the prevailing drugs on the market, as well as the related cardiovascular adverse pharmacological events.  
(b) Drug discovery and development in the cardiovascular context: withdrawal from the market of sixty-three drugs, in different 
pharmacological classes, between 1953 and 2013, as a result of severe cardiotoxic effects. Highlighted (light grey arrows): from 
left to right, antipsychotics, antihistamines and antimicrobials.  
Figure 1.2 | Schematic overview of the conditions to 
be considered in the design of novel in vitro cardiac 
tissue models and its main current applications 
[adapted from Mathur et al. (2016)[14]]. 
Conditions (circles in the inverted cone): biomaterial, 
physiological, CM source and design criteria. Applications, 
concerning basic science and translational research: 
biological assessment, disease modelling, drug discovery 
and development, drug screening and precision medicine 
are just some of the many potentialities that are already 
beginning to emerge in this sort of models. Highlighted 
(white rectangle): human pluripotent stem cells (hPSC), viz. 
human induced (hiPSC) and human embryonic stem cell 
(hESC) sources. 
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 Therefore, it is critical to develop novel human in vitro cell-based cardiac tissue models (Fig.1.2) that 
recapitulate certain physiological functions and reproduce key details of the heart anisotropic 3D 
architecture (Fig.1.2), so that they can be applied in preclinical and clinical settings[2,3,14,17] (Fig.1.2). In 
other words, the solution that this thesis intends to explore are three-dimensional (3D) in vitro human 
induced pluripotent stem cell (hiPSC)-derived cardiac tissue models.  
 Hopefully this will simplify cardiotoxic effects’ identification, when evaluating the efficacy and safety 
of drug candidates, as well as studying and understanding the mode of action and pharmacokinetic and 
pharmacodynamic properties of the therapeutic agents. Regardless of being a difficult task to mimic the 
structure and functionality of the human heart[2,17] and even though these models also have limitations[17], 
they are a viable alternative to the foregoing state-of-the-art strategies, as will be later discussed. 
 
 1.1.2. In vivo cardiac microenvironment – getting to the heart of the matter 
 Since this dissertation focuses on the establishment of 3D in vitro hiPSC-derived cardiac models, it is 
similarly relevant to address the in vivo scenario, regarding (i) the cellular composition and interactions 
between the key in vivo players (myocytes and non-myocytes) and, particularly, between (ii) the 
cardiomyocyte-endothelial cell duo, (iii) structure and physiology of the human heart and (iv) estimated 
cell numbers of the different cardiac populations, as those models attempt to faithfully recapitulate key 
aspects of its physiology and tissue-specific architecture. However, in this context, they should be 
understood not as a medicinal product, but as a drug testing platform. Besides, modelling human cardiac 
physiology in vitro is a difficult task, not yet attained with any type of cellular or tissue-based system. 
 
 1.1.2.1. Cellular composition and cardiomyocyte–non-myocyte interactions 
 The heart is a multicellular[23] organ composed of three layers[24,25]: i) myocardium[17,24–26], ii) 
endocardium[24–26] and iii) the epicardium[1,2,24,25], enclosed by an endomysial collagen network[24,27] . 
Within these layers, there is a complex arrangement of cells, organized into different functions and with 
distinct properties, including cardiomyocytes (CMs)[17,24–26,28] and nonmyocytes[17,24–26,28] (Fig.1.3), which 
comprise endothelial cells[17,24–26]  (ECs), pericytes[17,24,25]  (PCs), cardiac fibroblasts[17,24–26] (CFs), vascular 
smooth muscle cells[17,24–26,29]  (VSMCs), epicardial cells[17,24,25], neurons[24,25] and a transient population of 
immune cells[24,25,27]. 
 CMs are the cardiac muscle cells[23,25,27], responsible for all the mechanical contractile force[23,25,27] 
generation in the heart and are located in the myocardium[24,25], constituting approximately only 25 to 
35%[17,25,26,30] of its total cells. There are several CM subtypes, specifically nodal[31], ventricular[17,31] and 
atrial[17,31]. These subtypes arise from different cardiac mesodermal populations[31] (which emerge from 
the anterior region of the primitive streak during gastrulation[32,33]) and are inherent in different 
locations[31,34] – ventricular and atrial CMs, as indicated by their designation, in the ventricles and 
atria[31,34], respectively, while the nodal CMs are found in the sinoatrial node (SAN)[31,34]. 
 Albeit the most renowned, CMs are not, as formerly stated, the only population residing in the heart 
and, during development stage and normal homeostasis, interact with other cell types[17,28,35]. For 
instance, as recently stated by Dunn and Palecek (2018), epicardial cells (cells covering the outer layer of 
the heart)[33] undergo epithelial-to-mesenchymal transition (EMT)[2,25,28], throughout the phases of cardiac 
development and repair[25], so as to produce VSMCs, CFs and plausibly ECs[25].  
The latter (VSMCs, CFs and ECs non-myocytes) interact with CMs (Fig.1.3), in the myocardium, and 
influence their functionality and survival[23,25,26,28].  
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 CFs have a structural role[36], contributing for the deposition of extracellular matrix (ECM) in the 
heart[24,25,36]. VSMCs assist the coronary arteries[29,34] and regulate the inflow and outflow 
microvasculature[25,29,33,34].  
 In the case of ECs, they delineate this microvasculature[34], establishing the endocardium and the 
interior of blood vessels and cardiac valves[33,34], and also aid in delivery of nutrients and removal of 
toxicants and waste[25]. They can be of two types: (i) endocardial ECs[25,26], that delineate heart chambers 
and (ii) myocardial ECs[25,26], which comprise the capillaries that interact dynamically with CMs.  
 More importantly, this dynamic crosstalk between CMs and non-myocytes (Fig.1.3) is critical in cardiac 
development[31,33,34] and regulation of postnatal morphology[28,37] phases and vital to support the 
biochemical, structural, mechanical and electrical properties of a functional heart[23,25,26,28,34]. 
 
 1.1.2.2. Cardiomyocyte-endothelial cell duo – interactions and signalling pathways 
 Regarding the crosstalk between CMs and non-myocytes, we will now address the interactions 
amongst the endocardium and the myocardium[26,28,38] (Fig.1.4). Understanding how ECs and CMs 
communicate is a vital starting point for the creation of in vitro cardiac models, that favour normal 
structural and functional aspects of CMs, in the long term, and that can ultimately be used in cardiac 
regeneration applications. 
 Communication between ECs and CMs controls not only aspects of early cardiac development[28,35,38,39], 
but also adult CMs’ function[35,38,39], survival[35,38,39] and proliferation[35,38,39], including cardiac growth[26], 
contractile performance[26] and rhythmicity[26]. Besides, CMs depend on ECs not only for oxygenated blood 
Figure 1.3 | Simplified scheme of the organization and interactions between cellular key players in the in vivo 
mammalian heart microenvironment [adapted from Dostal et al. (2015)[24]].  
Myocytes and non-myocytes – highlighted (blue circles): cardiomyocytes, endothelial cells and cardiac fibroblasts – may interact 
through cell surface receptors and cell adhesion molecules (CAMs), such as cadherins, homo- or heterotypic gap junctions (which 
are comprised of one or more types of connexins) and ions and molecules (growth factors, cytokines or hormones), that can act 
via paracrine and/or autocrine signalling. Cardiomyocytes–non-myocyte crosstalk may lead to the activation or silencing of 
certain cell signalling pathways and consequently induce dramatic changes in gene and protein expression. 
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supply, but also because of local protective signals[38,40] that promote CM organization and 
survival[28,35,38,40]. However, this interaction is mutual: whilst ECs secrete certain factors, CMs respond, 
reciprocally secreting factors that have a decisive impact on EC function[24,28,35,38–41] (Fig.1.4).  
NRG-1/ErbB2/ErbB4, IGF-1, Notch, Ang-1/Tie-2 and FGF are some of the signalling pathways involved 
in the endocardium role of orchestrating the function and maturation of myocardial cells[28,38–41]. 
 Neuregulins or neuroregulins (NRG) are a family of four structurally related growth factors, EC-
synthesized, that are part of the epidermal growth factor (EGF) family[28,35,38,42]. These proteins have 
several functions in the development of the nervous system[35] and have been shown to play an important 
role in the embryogenesis of vertebrates[35], including in cardiac development[35]. 
 Particularly, it is described that NRG-1 has the capacity to promote cell survival and growth[28,35,38], via 
activation of ErbB receptors[28,35,38], in the neuregulin-ErbB signalling pathway[28,35,38] (Fig.1.4). NRG-1 is 
expressed in the endocardium, where it is released as a paracrine signal that activates the tyrosine kinase 
receptor ErbB4 and its co-receptor, ErbB2, expressed on adjacent CMs[26,28,35,38,41,43]. NRG-1-induced 
paracrine communication, between ECs and CMs, has been confirmed in in vitro co-culture studies[26,35], 
with impact on the cardiovascular function regulation[26,35]. Also, it has been recently demonstrated that 
the NRG-1/ErbB4 pathway promotes the proliferation of already differentiated CMs[28,34,38]. 
 Furthermore, NRG-1 induces the proliferation[43], survival[43] and hypertrophic growth[43] of cultured 
neonatal CMs[43] and, therefore, this is why the activation of the ErbB2/ErbB4 heterodimeric receptor 
complex (NRG-1-mediated) is one of the factors required for the formation of myocardial 
trabeculae[28,38,43] (Fig.1.4) and cardiac cushions[38,43]. 
Figure 1.4 | Schematic model of reciprocal myocardial-endocardial interactions and major signalling pathways 
involved in cardiac development, proliferation and maturation [adapted from Tian and Morrisey (2012)[28]]. 
(a) Mutual signalling during the formation of myocardial trabeculae. 
(b) (left panel) myocardial (CM)-endocardial (EC) signalling: CMs may secret signalling mediators modulating ECs survival, 
proliferation, differentiation and assembly (Ang-1 and VEGF-A); (right panel) endocardial (EC)-myocardial (CM) signalling: 
reciprocally, ECs may also promote CMs survival and proliferation, via IGF-1 and NRG-1. Highlighted (red rectangles): (left panel) 
Ang-1/Tie-2; (right panel) NRG-1/ErbB2/ErbB4 and IGF-1. 
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 Insulin-like growth factor 1 (IGF-1), also termed somatomedin C, is a protein that is also secreted by 
the endocardium[28]. IGF-1 interrelates synergistically with NRG-1 and potentiates the proliferation and 
maturation of ventricular CMs[28,35] (Fig.1.4). Moreover, IGF-1 signalling is also linked with adaptive and 
cardioprotective response[28,35].  
 Another quite important pathway is Notch signalling[28,44], which is likewise associated with CM 
proliferation[28] (Fig.1.4), being responsible for ventricular chamber morphogenesis and 
development[28,44]. 
 On the other hand, with regard to myocardial repercussion in endocardium, it is important to highlight 
Tie-2 (previously known as TEK), which is a tyrosine kinase receptor expressed in endocardial cells[26,28]. 
When its ligand, angiopoietin-1 (Ang-1), expressed in the myocardium, binds to Tie-2 receptor, in the 
endocardium, differentiation and proliferation of the endocardium are triggered[26,28] (Fig.1.4). 
 Lastly, fibroblast growth factors (FGFs) are also essential in the regulation of cardiac 
development[28,34,45,46], via the paracrine activity of ligands expressed in the endocardium[25,28,45,46]. 
 FGF-9, FGF-16, and FGF-20 are all expressed in the endocardium during cardiac development[25,45,46]. 
These FGFs signal the myocardium through specific receptors, FGFR1 and FGFR2, thus stimulating the 
proliferation and differentiation of CMs[25,45,46]. Contrariwise, FGF-1 and FGF-2 induce EC proliferation and 
their physical organization into tube-like structures[45,46]. Therefore, FGF-1 and FGF-2 promote 
angiogenesis and the formation of novel blood vessels from the pre-existing microvasculature[45,46]. They 
are also more potent angiogenic factors than vascular endothelial growth factor (VEGF) or platelet-
derived growth factor (PDGF)[45,46].  
 Altogether, these signalling pathways demonstrate that there is a reciprocal regulation between CMs 
and ECs, mostly in a paracrine way (Fig.1.4). 
 
 1.1.2.3. Fundamentals of heart structure and physiology 
 As schematically depicted in Fig.1.5, 
structurally, the heart, in all mammals, is 
constituted of four separate 
chambers[2,34,47] – the left and right 
atria[2,47] and, correspondingly, the left 
and right ventricles[2,47] – in addition to 
components of the conduction (or 
pacemaker)[2,34,47] system, that certify the 
heart’s muscle contraction[2,34]. Cardiac 
rhythmicity (contraction/systole together 
with relaxation/diastole cycles) ensures 
the supply of blood and nutrients 
throughout the body[2,47].  
 The left ventricle is in charge of 
pumping blood to the entire body 
(systemic circulation)[2,47], culminating in 
the aorta artery[47] (Fig.1.5), whereas the 
right ventricle only to the lungs[2,47], via 
the pulmonary artery[47]. Intuitively, this 
means that left ventricular CMs should 
Figure 1.5 | Schematic depiction of structural features and major 
cell types of the heart [adapted from Xin et al. (2013)[34]]. 
Abbreviations: AVN –  Atrioventricular node and SAN – Sinoatrial node.  
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produce superior contraction forces and require a greater supply of both oxygen and nutrients[25,47]. On 
the other hand, atrial CMs will require less force generation to pump the blood from the atria into the 
ventricles[25,47]. 
 Heart contraction is mediated by the cardiac pacemaker[2,17,25,34], which involves sinoatrial node 
CMs[2,25,34], positioned at the entrance of the right atrium[34] (Fig.1.5). These cells are responsible for 
monitoring the rhythmicity of the heart beat and are then called pacemaker cells[2,25,34] (Fig.1.5). 
 A given electrical impulse, produced by the sinoatrial node CMs, spreads to the atria, leading to its 
contraction[34]. The electric impulse then travels to the atrioventricular node (AVN) (Fig.1.5), where it is 
decelerated, allowing enough time for the atria to contract[2,34]. Afterwards, the electrical activity is 
conducted to the Purkinje network[2,26,34] (also termed His-Purkinje) (Fig.1.5), which are conduction 
fibres[26,34] located in the inner ventricular walls of the heart[26,34], just beneath the endocardium[26], in a 
space called the subendocardium[26]. In turn, those fibres innervate the muscular walls of the 
ventricles[2,26,34] (Fig.1.5), now leading to their contraction and consequential blood ejection into the 
systemic (left ventricle-mediated) or pulmonary (right ventricle-mediated) circulations[2,26,34].  
 In practice, this allows the electrical activity, which is recorded as an action potential, to unmistakeably 
identify the CM subtype[2,26], as it will be noticeably different[2,26] in the SAN, atria, AVN, ventricles and 
Purkinje network, ultimately leading to dissimilar Ca2+ handling kinetics[1–3,17,23,26] and electrophysiological 
properties[17,25,26]. Any trouble in this rhythm, precisely orchestrated by sinoatrial node CMs (the orchestra 
master) can conduct to fatal arrhythmias[2,23]. 
 
 1.1.2.4. Cardiac cell numbers – a controversial question 
 Notwithstanding non-myocytes being important for normal heart’s homeostasis[26,28,38], either through 
cellular communication pathways[26,28,38] (ECs), or in terms of vascular supply[26,28,38] (ECs and VSMCs), 
impact on myocyte survival[26,28,38] (ECs) or ECM deposition[24,26,28,38] (CFs), there is still some 
misunderstanding and controversy about the cell numbers (Fig.1.6) of each of these populations in the 
mammalian heart[48,49] . 
 As mentioned in the former topic, CMs make up about 25 to 35%[17,25,26,30,49] of the cells in the heart of 
mammals, which means that they have 65 to 75% remaining for the other populations and this is where 
the debate begins.  
 Fundamentally, this is attributable to two aspects: i) dispersion of the methodologies used[48] to assess 
those numbers and ii) absence of specific markers for some mesenchymal populations[24,29,48], such as CFs 
and VSMCs.  
 Although the number of CMs remains constant during the human lifespan[49], ECs and mesenchymal 
cells (MCs), in the myocardium, increase in number into adulthood[49] and show high turnover[49]. Thus, 
the myocardial intrinsic plasticity[26,28,49], which translates into the fact that the human heart does not 
have a static cellular composition as it ages[49], allied to the differential and dynamic turnover[49] of the 
involved populations, are also contributing factors to this lack of definition[48,49]. 
 A study recently published by Bergman et al. (2015), with the aim of quantifying the cell populations 
of human hearts, via stereological methods and flow cytometry (FC), came somehow to uncover the 
curtain to this problem[49] (Fig.1.6). Stereological examination of histological sections estimated the 
frequency of CMs, ECs and MCs at 18, 24 and 58% (Fig.1.6), respectively[49]. On the other hand, by flow 
cytometry of isolated cell nuclei, it was possible to determine frequencies of 33, 24, and 43% (Fig.1.6), 
correspondingly[49]. 
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 Thus, despite the dissimilarities, especially with respect to CM and EC populations, and assuming that 
most MCs are actually CFs[48,49], these findings corroborate the hypothesis that CFs are the predominant 
cell type in the mammalian heart[48], which is in line with the results of other analogous studies[50]. 
 These differences are, in a broader sense, intrinsic to the limitations of the techniques used[48,50]. 
Current state-of-the-art used methods relate to stereology[48], flow cytometry[48,50], heart dissociation 
followed by immunostaining and flow cytometric analysis[48,50] and stereological analysis combined with 
flow cytometry[48]. 
 Even though flow cytometry is an objective, quantitative, reliable and not sampling-biased method, it 
requires a dissociation step[48] (typically chemical or enzymatic), which may lead to an excessive cell 
death[48] or incomplete dissociation[48], inducing errors in the results[48].  
 In contrast, stereological methods avoid the tissue dissociation[48] step and incorporate important 
information regarding cell polarity and morphology[48]; however, histological analysis is generally 
susceptible to sample bias[48], so making an identification based only on this method may equally be prone 
to error[48].  
 Beyond all this, both of the techniques require labelling[48,50] with antibodies or genetic tags, which 
may not be specific[48] (challenging especially in the case of mesenchymal populations) or incompletely 




Figure 1.6 | Cell numbers in the mammalian heart [adapted from Zhou and Pu. (2016)[48]].  
A summary of the studies that measured the proportion of CMs, ECs and fibroblasts (FBs), in the mammalian heart, using 
stereological methods or flow cytometry, is gathered in this figure. In order to allow a comparison between studies, the results 
are expressed as the relative proportion of cells, with CMs fixed in a value of one, and assuming that most MCs are FBs. 
Highlighted (cyan box): CM:EC:FB ratios evaluated by Bergman et al. (2015). Flow cytometry values (bottom, last line) were the 
starting point for the development of the 3D hiPSC-based cardiac models that will be discussed in later sections. Abbreviations: 
CM – Cardiomyocyte, EC – Endothelial cell, FB – Fibroblast, H – Whole heart, LV – Left ventricle, pap – papillary muscle. * fraction 
of CMs not determined (based on stereology study of the indicated reference). 
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1.2. Harnessing human pluripotent stem cells (hPSC) as an attractive candidate cell 
platform for in vitro cardiac modelling 
 1.2.1. Human pluripotent stem cells (hPSC) – characteristics, sources and applications 
 Pluripotent stem cells (PSC)[10,15,18,33,51], and in particular human pluripotent stem cells 
(hPSC)[10,15,18,33,51], are capable to grow unlimitedly (self-renewal)[15,33,51–54] and have the intrinsic ability to 
differentiate into any type of somatic cell (pluripotency)[1,4,18,33,51–57] and, therefore, in all the tissues of 
the three germ layers[58–60]: endoderm, mesoderm and ectoderm –  which establish the precursor layers 
of the cells in adult organisms and form during embryogenesis[59,61]. They do not, however, differentiate 
into extra-embryonic tissue[58–60]. 
 hPSC include (i) human embryonic stem cells (hESC)[10,15,18,33,51,53], isolated from the embryo’s inner cell 
mass[58,62–68] (ICM) at the blastocyst stage[58,62–68], after in vitro fertilization or somatic nuclear transfer[58,62–
68] (with the cells forming its outer layer being called trophectoderm[58,64]); and (ii) human induced 
pluripotent stem cells (hiPSC)[10,15,18,33,51,53], reprogrammed from somatic cells via the ectopic expression 
of a set of defined transcription factors[1,10,15,53]. 
 Owing to these refined characteristics, hPSC are considered the most powerful cell type for tissue 
engineering[2,51], disease modelling[2,56] (Fig.1.7), personalized drug screening[11,20–22,56,69] (Fig.1.7) and cell 
therapy (Fig.1.7) and regenerative medicine applications[51,56].  
 However, their unrestricted capacity for self-renewal also brings up safety barriers, due to the possible 
formation of teratomas[8,33,57] and to the instability of their genetic material[33,57]. One of the major 
challenges to the application of hPSC in therapy is incontestably eradicating these risks in preclinical 
studies before the initiation of clinical trials[8,33,57]. Thus, the efficacious application of hPSC in clinical 
therapy will require control of their pluripotency phenotype and self-renewal ability, which can be 
Figure 1.7 | hPSC as an ideal cell platform in the cardiovascular landscape: emerging applications [adapted from 
Karakikes et al. (2016)[56]]. 
Current applications of human pluripotent stem cell-derived cardiomyocyte (hPSC-CM) platform. Highlighted (cyan boxes): drug 
screening and cell therapy. 
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attained when they are cultured in maintenance media containing self-renewal factors[33]; howsoever, the 
removal of these factors triggers hPSC spontaneous differentiation into a cell mixture representative of 
the three germ layers[33].  
 The first derivation of hESC from pre-implantation embryos was described by Thomson et al. (1998) 
and occurred more than a decade ago[70]. These PSC can be isolated and maintained through well-
established protocols[51,52], with scalable options[18,71–73] and indefinite proliferation associated with their 
ability to differentiate into virtually any cell of the human body[18,32]. 
 Another breakthrough arose when Takahashi and Yamanaka (2006)[66] found that, through the ectopic 
overexpression of four retrovirally transduced transcription factors, OSKM (OCT4, SOX2, C-MYC and KLF4), 
in mouse dermal fibroblasts grown in conditions favouring the ESC expansion, they had the ability to 
generate induced pluripotent stem cells (iPSC)[62,65–67].  
 The promise of applying this technology to human cells did not take too long and a first generation of 
human induced pluripotent stem cells (hiPSC) was obtained from human fibroblasts[74], using the same 
combination of OSKM transcription factors[74] or a slightly different lentivirally transduced gene cocktail 
(OCT4, SOX2, NANOG and LIN28)[74], in which the proto-oncogenes C-MYC and KLF4 were substituted by 
NANOG and LIN28. The iPSC field remains to grow very quickly and pluripotency has now been induced 
with non-integrating viruses[55,75] (e.g. recombinant lentiviruses and adenoviruses), excisable transposon-
based systems[55,75], recombinant proteins[18,55], transfection of modified RNAs[18,55,75] and small organic 
molecules[18,55], in numerous cell types. 
 Additionally, hiPSC do not entail ethical issues[15,55] (contrasting with hESC, resulting from early 
embryos) and can be derived from patient- and disease-specific somatic cells[10,15,53,55,56], which allows 
them to be used in several fields, especially in the cardiovascular[10,15,51,55,56,76] (Fig.1.7) and neuroscience 
areas[51,77]. This is not possible in the case of hESC, because they do not harbour the desired 
mutations[15,53]. 
 Nevertheless, apart from the ethical question[15,55] and some subtle differences in epigenetic 
modifications and gene expression signatures[15], hiPSC and hESC are quite similar in their capacity of 
unrestricted self-renewal and differentiation into any type of somatic cell[1,15]. Also, they are comparable 
in terms of cell morphology, growth profiles, expression of stemness-related markers, DNA methylation 
mode, chromatin status, among others[15]. 
 In this context, one of the areas uppermost in the list of hiPSC-based research arena is the in vitro 
recapitulation of the human heart microenvironment (Fig.1.7), either for fundamental or translational 
research, as well as cell-based cardiac disease models for studying disease progression and treatment 
(Fig.1.7). For this, it is crucial to resort to cardiac hiPSC-derivatives. 
 
 1.2.2. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CM) 
 1.2.2.1. Strategies for the cardiac differentiation of hPSC 
 The first hPSC-based cardiac differentiation protocol was reported by Kehat et al. (2001)[78] and 
involved the formation of embryoid bodies (EBs)[4,18,33,53,55,78,79], which are 3D spheroid-like aggregates that 
produce cells from all the three germ layers[4,53,78]. This strategy depends on the formation of EB 
spontaneous contraction[4,25,53], which has a variable efficiency, oscillating between 5 and 15%[4,25,53]. 
Protocols for generating these EBs were initially developed using fetal bovine serum (FBS) supplemented 
culture media[4,10,55], although defined media formulations are already regularly used[4,10,55]. 
 Beyond this method, two were later established: i) a co-culture of hESC with visceral endoderm-like 
cells (END-2)[1,4,18,53,79,80], derived from mouse P19 embryonal carcinoma cells[10,53,80], described by 
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Mummery et al. (2003)[80]; and, as an alternative, (ii) differentiation in 2D monolayer cultures[1,10,18,79,81,82], 
used in many labs (including ours[83,84]), firstly reported by Laflamme et al. (2007)[81]. 
 Among those three strategies, monolayer differentiation is the gold method, since it offers a superior 
differentiation efficiency and ease of monitoring[53,76]. Refinements, over the last decade, make it possible 
to generate cultures containing 85% of human pluripotent stem cell-derived cardiomyocytes (hPSC-
CM)[53,76]. In addition, several methods, in which these populations can be enrich up to 95%, using, for 
example, sodium lactate containing medium[85,86], or based on cell surface markers[87,88], such as SIRPα/β 
and VCAM-1, have been described. But, in practice, how does the cardiac differentiation work? 
 
 1.2.2.2. How to make a cardiomyocyte: understanding the pivotal steps in cardiac differentiation  
 The principle of hPSC-CM differentiation is to mimic, in vitro, the pivotal steps (Fig.1.8) in embryonic 
cardiogenesis, via the supplementation of hPSC with key stage-specific small molecules that efficiently 
direct them to the cardiac lineage[89,90] (Fig.1.8). 
 In the embryo of vertebrates, the heart is one of the first organs to be formed, which occurs from the 
appearance of the mesoderm, that arises from the primitive streak during gastrulation[1,33,34,76,89]. At 
embryonic day 5, mesoderm forms with Nodal signalling in the proximal epiblast, maintaining BMP-4 
(bone morphogenic protein 4) expression in the extra-embryonic ectoderm[1,32,34]. Other signalling 
Figure 1.8 | Diagram of the pivotal steps and key signalling pathways enrolled in hPSC cardiac differentiation 
[adapted from Kamps and Krenning (2016)[89]].  
Factors that influence the advance over the five pivotal steps of hPSC-CM differentiation: (from left to right) (i) mesoderm 
differentiation, (ii) mesoderm specification, (iii) cardiac specification, (iv) cardiomyocyte differentiation and (v) cardiomyocyte 
maturation. (below) The major markers associated with each one of the seven cell types during differentiation are listed in the 
corresponding boxes. 
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pathways (e.g. Dkk1, Cer1, and Lefty1) are responsible for the Nodal and Wnt (homologous of Drosophila 
Wingless gene) signalling restriction to the posterior epiblast[1,32,34,91]. 
 Hence, a sequence of signals, spatially and temporally regulated, fundamentally bone morphogenetic 
proteins[1,55,89,90,92] (BMPs), Wnt[1,55,89,90,92] proteins, Nodal/Activin[1,55,89,90,92] pathway molecules and 
FGFs[1,55,89,90,92], are crucial for endorsing the in vitro myocardial fate specification[1,55,89,90,92] (Fig.1.8). Built 
on this premise, there are many protocols that induce cardiomyogenesis in hPSC, via activation and 
inhibition of these signalling pathways[53,76,85,92]. 
 In this context, we can mention, as an example, the stimulation of extra-embryonic ectoderm[32,90], 
through BMP-4 and activin A, and posterior primitive streak[1,32,53,90], via Wnt signalling activation 
(specifically Wnt3a), by CHIR99201, during the first 24h of cardiac differentiation, promoting the exit of 
the pluripotency state and induction of cardiac mesoderm[53] (Fig.1.8). Particularly, CHIR99021 is a potent 
inhibitor of the glycogen synthase kinase-3 beta (GSK-3β), activity[5,25,53], functioning as a Wnt 
activator[5,25,53], since it blocks the enzyme activity[1], preventing β-catenin degradation[1], that is thereby 
able to move from the cytoplasm to the nucleus, where it activates the Wnt target genes[1]. 
 Then, to induce the cardiac specification, Wnt signalling pathway must be inhibit[1,32,89] (Fig.1.8) to 
allow the heart development from the Mesp-1+ cells in the anterior mesoderm[1,32], being Mesp1 the 
“master regulator” of cardiac progenitor specification[1,32]. 
 Wnt signalling small molecule inhibitors, such as IWR-1[4,32,53], IWP-3[53], IWP-4[4] and XAV939[53], have 
been shown to have the ability to induce the formation of cardiac progenitor cells (CPCs), when added 
after mesoderm formation[4,32,53,89]. SB-431542, an inhibitor of the TGF-β pathway, has a similar effect, 
when its addition occurs at this stage[5]. Media supplementation with these inhibitors recaps the actions 
of Dkk1-mediated inhibition of Wnt signalling, during embryology[89]. 
 At this stage, the addition of ascorbic acid (AA) (Fig.1.8) boosts CM differentiation, by increasing 
collagen synthesis[93], enhancing the proliferation of CPCs[89,93] and upregulating late stage markers of 
cardiomyogenesis[93]. Furthermore, CPC-derived cultures may still undergo an additional maturation 
round[94] in the presence of NRG-1 and IGF-1[28,35,38,89] (Fig.1.8), as discussed in former sections. 
 
 1.2.2.3. Developmental status and challenges – immaturity concerns 
 Overall, hPSC-CM, obtained from these culture methods, contract spontaneously[53], express 
sarcomeric proteins and ion channels[18,53,56] and exhibit actions potentials[4,33,53] (APs) and Ca2+ 
transients[53,95,96]. Also, they display functional properties comparable to those of the CMs during cardiac 
development[1,53], including dose-dependent response to cardiac affinity drugs[3,19,53,97], to agonists and 
antagonists of β-adrenergic receptors[1,3,17,23,53,97] and to cardiotoxic drugs[11,20–22,98]. 
 Differentiation and purification of hPSC-CM have been gradually optimized, but there are some hurdles 
with respect to: (i) reproducibility of cardiac differentiation between individual hPSC lines[10,53,85], (ii) cost-
inefficiency of reagents[25,32,53,76], (iii) batch-to-batch variability[10,53,85], (iv) hPSC-CM yield and purity[53,85] 
and (v) the immature phenotype displayed[1,3,5,10,17,53,83]. 
 Concerning the latter, the maturation efficacy of hPSC-CM is one of the topics that has visibly escaped 
the field: hPSC-CM exhibit immature phenotypes, evinced by a reduced sarcomeric alignment, small APs, 
in electrophysiological characterizations, and fetal transcriptome and metabolome profiles[4,25,33,53]. 
 The challenge of cardiac maturation has been mitigated with a number of different methodologies, 
which will be covered in sections 1.3.1 and 1.5, yet still far from cracking this issue. 
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 1.2.3. Human pluripotent stem cell-derived endothelial cells (hPSC-EC) 
 In a similar fashion to what has been described for hiPSC-CM, there are basically two methodologies 
for generating human pluripotent stem cell-derived endothelial cells (hPSC-EC): (i) 3D EB-mediated 
differentiation[99,100] and (ii) 2D monolayer-based differentiation[99–101]. 
 As stated in a preceding topic (1.2.2.2), when mesoderm polarization occurs, several types of cells are 
generated in the cardiovascular system[101], including CMs (Fig.1.9), along with those from the 
endocardium (Fig.1.9), vascular endothelium (Fig.1.9) and hematopoietic system[101] (Fig.1.9). So, similarly 
to what happened with CMs, hPSC are also, in this case, differentiated into mesodermal lineages[101] 
(Fig.1.9). 
 The main strategy is the sequential addition of growth factors, such as BMP4 and vascular endothelial 
growth factor A (VEGFA)[99,100]. In EB-based cultures, this method generated low differentiation yields, 
ranging from 2 to 15% of CD31+ cells[99] (a surface marker extensively described for definitive endothelial 
phenotype).  
 Moreover, in this case, it is also possible to modulate the Wnt signalling pathway[99,100], through 
selective small molecule inhibitors of GSK-3β[100] (consult 1.2.2.2), in conjunction with BMP4[99,100], 
translating in 25% to >40% of CD31+ cells[102]. Further defined differentiation conditions, based on 
monolayer cultures coupled with the addition of growth factors and small molecules (e.g. Wnt activators 
and cAMP-elevating agents)[99] resulted in higher differentiation yields, ranging from 20 to 80% of CD31+ 
cells[103].  
 Other studies have revealed that in combinations with VEGFA, SB-431542 (small molecule inhibitor of 
TGF-β) or forskolin lead to higher CDH5 (VE-Cadherin) expression in hPSC-EC[100]. This expression is even 
more pronounced when CHIR99021 is combined with DLL4 (Notch ligand that inhibits the hematopoietic-
lineage differentiation) and with a low concentration of VEGFA[104].  
Figure 1.9 | EC fate decision and related molecular markers [adapted from Palpant et al. (2017)[101]].  
Schematic overview of the fundamental cell-fate choices from the pluripotent state (undifferentiated hPSC) to the vascular 
(hPSC-EC) and cardiac (hPSC-CM) destinations. Molecular markers are identified for each of the populations. Highlighted (cyan 
box): markers for definitive endothelial phenotype (PECAM-1/CD31 and CDH5/VE-Cadherin). Abbreviations: CECs – 
Cardiogenic-mesoderm-derived endothelial cells, CPCs – Cardiac progenitor cells, EryP – Primitive erythroid, H-ECs – Hemogenic-
mesoderm-derived endothelial cells (for the remaining, consult List of Abbreviations and Conventions). 
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 The last step is to select EC lineage via specific surface markers: whereas KDR and CD34 are selective 
for EC progenitors, PECAM-1 (CD31) (Fig.1.9), CDH5 (VE-Cadherin) (Fig.1.9) and von Willebrand factor 
(VWF) are those used to isolate mature ECs[99–101] (Fig.1.9). 
 Some of the major drawbacks of the differentiation protocols towards the endothelial lineage are the 
fact that they are hardly scalable[99], the low differentiation yields[99,104], dependence on undefined 
supplements[104], existence of heterogeneous cell aggregates[104] and lack of reproducibility[99,100,104]. 
Therefore, methods that improve the scalability, reproducibility and fidelity of differentiation towards the 
endothelial fate, are desired.  
 
1.3. State-of-the-heart tissue models 
 1.3.1. Maturity issues boost the creation of more robust and faithful in vitro cardiac models 
 Before discussing the various approaches to assemble a heart in vitro[2,105], it is important to underline 
that the need for such models arises essentially from the immature phenotype exhibited by hPSC-CM[4,32] 
(Fig.1.10), which prevents the use of this cellular platform in translational applications[4,32]. 
 hPSC-CM maturation is a very complex arena, subordinate to the domain of several cues, including 
biochemical[2,23,106,107] (e.g. thyroid hormone stimulation[106,107], Fig.1.10), mechanobiological[108,109], 
topographical[23], electrical[23] (Fig.1.10) and important homo- and heterotypic interactions[4,17,23,30,110,111] 
(Fig.1.10). 
 Hence, an ideal bioinspired, in vitro, cardiac model should be able to faithfully recapitulate the 
physiological (heart in its inherent state) or pathophysiological (disease progression) conditions of the 
human heart, including the 3D anisotropic tissue structure together with cell-cell and cell-extracellular 
environment interactions, ECM orientation and composition, vascularization and circulation[14,23,32,105]. 
These aspects are summarized in Fig.1.11. 
 However, even though several caveats persist, it is only conceivable to recapitulate in vitro a subset of 
the in vivo phenotype (Fig.1.11). 
 
 1.3.2. Shifting the paradigm: conventional 2D monolayers toward 3D cultures 
 Under physiological conditions, cells are part of a versatile and dynamic network that cannot be 
entirely recapitulated in a 2D monolayer system[110]. Conventional 2D culture systems do not satisfactorily 
mimic the in vivo developmental microenvironment of the human heart[14,25,105]. 
Also, their inherent uncontrollability, heterogeneity, low production yields and poor scalability make 
these systems inapt for clinical applications[51,112]. Yet, they can be quite useful, as a starting point, by 
providing important evidence regarding basic cell-cell interactions and ECM composition[14,105]. 
 Cells in a 3D environment behave fundamentally differently from cells in a 2D monolayer 
culture[14,23,32,105] and, therefore, in order to understand the complete picture, we will have to resort to 
more complex models (Fig.1.11). 
 When compared to 2D monolayers, 3D culture systems potentiate cell-cell[14,23,25,32,105] and cell-ECM 
interactions[14,23,25,32,105], establish molecular concentration gradients[23,32] and may disregard the need for 
unnaturally stiff and adherent substrates[23,32].  
 Furthermore, the main benefit of 3D models is to offer a cellular context analogous to that occurring 
in the native tissue[2,17,23,51] (in this case, the heart) (Fig.1.11), driving an increase in cell viability and 
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functionality[51], whereas, at the same time, offer a higher degree of efficiency[51], robustness[51], 
consistency[51] and predictability[51]. 
 
 1.3.3. 3D models: steering the complex architecture of the cardiac tissue 
 Options for 3D model systems comprise: (i) scaffold-free approaches[14,113], such as cells cultured as 
organoids[2,14,84,113–115] (e.g. 3D cardiac spheroids, also named microtissues) and (ii) scaffold-based 
models[2,14,17,32,105], such as cells encapsulated in hydrogels[2,17,105] composed of natural products[2,17,105], 
cells in combination with synthetic materials[14,17,105], cells in peptide-modified scaffolds[116], cells in 
biological scaffolds[2,17,105] (e.g. decellularized hearts), 3D-bioprinted structures[2,17,23], microfluidic 
devices[2,117], among others. 
 Scaffold-free approaches promote and rely on cellular self-assembly and organization, while scaffold-
derived approaches offer natural and/or synthetic matrices as a structural template for cells to attach 
to[14,17,23]. In practice, this means that in scaffold-free approaches cell-to-cell are the predominant 
interactions, contrasting with scaffold-based models, in which cell-to-scaffold interactions prevail[17,23]. 
 
 
Figure 1.10 | Key strategies to induce hPSC-CM maturation in vitro [adapted from Devalla and Passier (2018)[2]].  
The structural, functional and metabolic characteristics of hPSC-CM are consistent with an immature phenotype. Some cues, 
including (i) biochemical, such as (left panel) the addition of tri-iodo-L-thyronine (T3) to the culture medium, (ii) heterotypic 
cellular communication, based on (middle panel) co-cultures with non-myocyte populations (e.g. ECs), or (iii) built on electrical 
stimulation or cycles of mechanical stress, can drive hPSC-CM toward a more definitive and mature phenotype. Highlighted 
(blue arrow and box): co-culture strategy (as a starting point for the work carried out and discussed in the course of this 
dissertation). 
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 1.3.3.1. Scaffold-free cell spheroids 
 Spinner flasks, rotation systems, hanging drops, microfluidic devices and non-adhesive substrates are 
some of the examples used to self-assemble cardiac cells into spheroid-like 3D tissues in vitro[105,112]. 
 Homo- or heterotypic organoids are one of the most common and versatile example of in vitro cardiac 
models in the cardiovascular context[2,83,110,112,114]. The referred self-assembly methods allow the 
generation of homotypic organoids[83,84], typically comprising several CM subtypes[2], or 
heterotypic[2,105,110,114], adding, along with CM, non-myocyte populations[2,105], such as ECs[2,105], 
VSMCs[2,105] and CFs[2,105]. Hence, they are perhaps one of the most relevant cell-based platforms for 
understanding interactions between different cell types[2,105].  
 Since hPSC cultured as EBs, in the presence of certain growth factors (consult 1.2.2.1 and 1.2.2.2), 
generate a mixture of atrial, ventricular and nodal cells, it is thus possible to generate cardiac organoids 
as 3D aggregates[2]. 
 The advantages of 3D spheroids’ self-assembly are organotypic density and architecture, maximization 
of cell-to-cell communication and movement among the different cell types, self-produced ECM and 
Figure 1.11 | Considerations for creating bioinspired in vitro cardiac models [reproduced from Kofron and Mende 
(2017)[23]]. 
In vitro platforms should consider (upper panel) (i) the model purpose (recapitulate physiological or pathophysiological 
conditions) and (lower panel, from left to right) (ii) the cell source (e.g. hPSC), (iii) crosstalk between myocytes and non-myocytes 
(e.g. ECs and FBs) and (iv) environmental cues (e.g. 3D organization, mechanics and electrical stimulation). Outcome: in 
comparison with 2D, pluricellular 3D studies will always favour cellular crosstalk and integrated responses, rather than those 
associated with a single cell type. 
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adrenergic responses similar to those in vivo[14,23,32,110]. Outstandingly, hPSC-CM demonstrate an increased 
cardiac maturation when grown as 3D aggregates, compared to 2D monolayer cultures[83,118,119]. The in 
vitro exogenous electrical stimulation of nanowired hiPSC cardiac spheroids allows to further improve 
cellular maturation and function[120,121]. 
 In addition, as shown by Garzoni et al. (2009)[114] and Stevens et al. (2009)[115], they self-organize with 
ECs and CFs to form vascular networks without the need for exogenous materials[114,115]. Also, the 
inclusion of non-myocyte populations in the spheroids promotes the sarcomeric organization and an 
increased Cx43 expression[122].  
 Recently, Giacomelli et al. (2017) established conditions for the simultaneous differentiation of CMs 
and ECs from hPSC, then enriched and recombined to generate 3D cardiac spheroids[110]. This study 
showed an increased expression of cardiac genes[110], encoding ion channels[110], and Ca2+ handling 
proteins[110], as well as human dose-response to β-adrenoceptor stimulation[110], consistent with cardiac 
maturation. Also, this study contributes to understanding non-myocytes’ role (e.g. ECs) in the 
functionality and maturation of CMs. 
 Despite the numerous advantages, this strategy also entails some hindrances, relating to the difficulty 
in controlling spheroid size[51] and in performing their harvesting[51], which is usually accompanied by 
some associated cell death[51], owing to the dissociation agents used. 
 
 1.3.3.2. Scaffold-based strategies  
 The native heart matrix is a well-organized anisotropic structure that supports CMs and 
nonmyocytes[17,23,24]. The ECM of the adult heart is composed mostly of collagen[7,14,24,32,123], but also 
includes fibronectin[24,32,123], laminin[32,123], vitronectin[32,123] and elastin[7,123], all of which contribute to cell 
adhesion[14,123] and load-bearing capacity of the heart[123]. 
 Biomaterial scaffolds should offer a 3D microenvironment for cells to attach, interact with each other, 
transmit load and conduct electrical signals[17,23]. They should also induce alignment, provide adequate 
stiffness for the cells to generate mechanical strength and have the ability to enzymatically degrade over 
time, to be swapped by cell-secreted ECM, so that a remodelling of the cardiac microenvironment may 
occur within the scaffold[14,17]. 
 A wide variety of scaffolds and matrices[2,14,23,25,105] have been used for the purpose of assembling the 
human heart milieu, in vitro, from different cell sources, including murine and hPSC-cardiac derivatives 
(the latter being those in which we will concentrate more attention). There are two major groups of 
scaffolds for the in vitro development of engineered heart tissues (EHTs): (i) natural[2,14,23,25,105] and (ii) 
synthetic[2,14,23,25,105]. 
 
 1.3.3.2.1. Naturally occurring hydrogel-based EHTs 
 The most widely studied constructs for the seeding of the aforementioned cardiac populations are 
hydrogel systems[2,17,105,116] (Fig.1.12). 
 This method comprises three components[105]: (i) solutions of natural gelling products[2,17], such as 
alginate[105,116], Matrigel[14,17,32,105,116], collagen[105], fibrin[14,105], gelatine[105,116], hyaluronic acid (HA) [105], or 
mixtures of them[105]; (ii) casting molds[105]; and (iii) and anchoring constructs[105]. The hydrogel entraps 
cells in a 3D space during gelling, the mold confers the 3D shape and, lastly, the anchors allow the tissue 
to grow in a controlled space[105]. 
 Hydrogels formed from such materials are particularly suitable for tissue engineering applications, 
because their biomechanical properties can be tuned to the values found in the native heart matrix 
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(approximately 5 kPa)[17]. Another plus of this type of system is that it enables the miniaturization[2] and 
automation[2] of cardiac tissue generation, which is particularly relevant for high-throughput drug 
screening[2,105]. In addition, naturally occurring hydrogels stimulate cells to spread and form intercellular 
connections[17,105].  
 In the cardiac context, hydrogel encapsulation has been used to study heterotypic interactions 
between myocytes and non-myocytes (Fig.1.12). Narmoneva et al. (2004) reported the use of a peptide 
hydrogel, seeded with of murine cardiac cells, in three distinct configurations: CMs alone[124], CMs mixed 
with ECs (co-culture)[124] and CMs seeded on preformed (prevascularized) EC networks[124]. It was found 
that the co-culture was the condition that minimized the CM apoptosis and necrosis, which were far 
superior in the remaining conditions[124]. Similar studies, nonetheless with hiPSC-cardiac derivatives, were 
also carried out[125,126]. 
Figure 1.12 | Important scaffold-based tissue engineering strategies to assemble a human heart in vitro [adapted 
from Devalla and Passier (2018)[2]].  
Human EHTs can be generated by: (left panel) (i) combination of hPSC-cardiac derivatives in naturally occurring hydrogels, 
(middle panel) (ii) decellularization of animal or human hearts, that function as “biological” scaffolds and can be subsequently 
repopulated with hPSC-cardiac derivatives, or (right panel) (iii) bioprinting of hPSC-cardiac derivatives onto a 3D heart scaffold, 
thereby generating a highly robust model of the human heart. . Highlighted (blue arrow and box): hydrogel strategy (as a starting 
point for the work carried out and discussed in the course of this dissertation). 
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 More recently, hydrogel-based engineered heart tissues (EHTs) demonstrated enhanced 
ultrastructural organization, with defined sarcomere striation patterns[17], mRNA expression of specific 
cardiac markers[17] and synchronous contractile behaviour[17], in addition to functional properties 
consistent with a mature phenotype[17].  
 Moreover, cell or aggregate microencapsulation in hydrogels provides a shear stress-free 
microenvironment, avoiding excessive clumping of aggregates in culture[51]. Thus, this 3D strategy turns 
out to be quite attractive for use in large-scale bioprocesses and provides a finer control of the cultures 
and higher cell yields, when compared to non-encapsulated cultures[51]. 
 
 1.3.3.2.2. Synthetic scaffold-based EHTs 
 In contrast, the synthetic materials used may be based on two major classes: (i) polyesters, such as 
PLLA (poly-L-lactic acid)[14,17,105], PGA[14,17,105] (polyglycolic acid), PLLA/PGA[14,17,105] (poly-L-lactic 
acid/polyglycolic acid) composites, polylactones[14,17,105], polyurethanes[14,17,105] and PGS[2,7,14,17,97,105], 
poly(glycerol sebacate), a biodegradable elastomer; or in (ii) polyethers[116]. 
 An obvious advantage of synthetic scaffolds, when compared to the other techniques, is that they may 
be fully customized[17]; however, they are more restricted in terms of functional interactions and, because 
of that, are normally modified to incorporate adhesion peptides or molecules[17]. 
 As an example, we can highlight the study of Caspi et al. (2007), in which multicellular biodegradable 
scaffolds[127], consisting of 50% PLLA/50% PLGA[127], were constructed: hESC-CM were combined with 
hESC-EC or human umbilical vein ECs (HUVECs), with or without embryonic fibroblast (EmFs)[127]. Again, 
the co-culture condition resulted in an enhanced CM proliferation, without affecting elongation, 
orientation or alignment[127]. 
 
 1.3.3.2.3. Peptide-modified scaffolds 
 Typically, to increase cell survival and organization in the aforementioned scaffolds, cardiac cells are 
often seeded mixed with Matrigel (e.g. hybrid constructs) to enable cell adhesion[17,32,116]. However, since 
Matrigel is an undefined gelatinous protein mixture[32,116], derived from a mouse cell line carcinoma[32,116], 
contains unknown growth factors and proteins[32,116], which limits its attractiveness for cell therapy and 
regenerative medicine applications, as they require very precise conditions[116]. 
 In this context, recent research in biomaterials, organic chemistry and chemical biology (e.g. click 
chemistry)[128] has advanced to design, synthesize and modify materials, in a way that they interact 
selectively and spatially with the cells through very specific biomolecular recognition events[116,129]. 
 One of these examples is the functionalization of materials[116,130,131], natural or synthetic, or the 
preparation of pseudopeptide compounds[128], with RGD motifs[116,128,130,131]. 
 RGD is one of the most physiologically ubiquitous binding motifs attached to scaffolds[116]. Corresponds 
to the arginine-glycine-aspartate[116,130,131] peptide sequence, derived from ECM proteins[116,130,131], such 
as fibronectin[116,131], collagen[116,131], vitronectin[116,131] and laminin[116] and is the link between the 
intracellular cytoskeleton and ECM, via cellular integrins[116,131]. It is ultimately responsible for initiating 
cell signalling for cell survival and proliferation[116,131]. 
 However, very few examples exist in the literature reporting the existence of RGD peptide-modified 
scaffolds for the in vitro generation of cardiac models. An important example in the field is that of Shachar 
et al. (2011), which demonstrated that the presence of RGD peptide, immobilized in an alginate scaffold, 
was able to promote neonatal rat CMs’ adhesion, preventing apoptosis and accelerating tissue 
regeneration[116]. 
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1.3.3.2.4. Biological tissue-scaffolds: decellularized whole hearts 
 In addition to strategies based on the self-assembly of cardiac spheroids or in compatible biomaterials, 
several groups have been reporting the use of biological tissues as scaffolds for developing EHTs[2,17] 
(Fig.1.12). 
 The principle of tissue decellularization is the removal of all the cellular elements, leaving the ECM 
“undamaged”[2,105]. 
 Proof that it is possible to use decellularized whole hearts, leaving the microvasculature intact, is given 
by Ott et al. (2008)’s study, which reports the production of EHTs in decellularized rat hearts[132]. More 
recently, this has also been successively shown for human EHT[133], in which an acellular human heart 
scaffold has been repopulated with hiPSC-CM to create an in vitro human EHT[133]. 
 This method has the advantage of providing a combination of local control[17] (conserved through 
protein content and native mechanical properties) and long-range signalling[17] (through the preservation 
of the anisotropic structure and ECM topology). 
 
 1.3.3.2.5. Emerging strategies – 3D bioprinting and microfluidics 
 Finally, highlight two methods that together can alter the way we conceptualize in vitro cardiac models 
(Fig.1.12). 
 The first has already revolutionized the medicine field, with the production of some medical devices, 
such as implants and prostheses[2,23]; we are referring to 3D printing. More recently, a variant of this 
technique, termed 3D bioprinting (Fig.1.12), has been successfully used to print living tissue. A 
thermoreversible support bath was used to allow hydrogel-based bioprinting of a 3D chicken heart[134]. 
 The prospects are that in the future, hPSC-CM can be bioprinted and layered to reproduce the 3D 
architecture of the heart. If we combine this method with microfluidics, which can be used to simulate 
blood flow[2,117,135] in the bioprinted cardiac tissue, we come to a highly robust model of the human heart. 
 
1.4. Reaching clinically significant cell numbers in bioreactors 
 Bioreactors have been broadly used in chemical and biological industries for the production of 
antibodies[51,73] and recombinant proteins[51,73], in addition to other products[51,73]. More recently, 
applications with hPSC, in which hPSC itself or their cardiac derivatives are the major products, have also 
been reported[51,72,73,99,136,137]. 
 Many of these applications, both clinical and industrial, involve the use of hPSC-cardiac derivatives, 
and depend on the constant and controlled production of billions of cells[54,73,136]: note that the human 
heart encompasses about 4 billion CMs[138]. 
 The estimated cell requirements for heart and liver repair, as well as for the treatment of diabetes, 
relate to 109-1010 hPSC-derived progenies per patient[54,71]. This implies a mandatory significant upgrading 
in the bioprocesses, as well as further scale-up[72,73]. 
 Furthermore, unlike, for instance, the production of recombinant proteins in mammalian cell lines, in 
a relatively easy manner, the challenge, in the case of hPSC, is much more complex, requiring more 
sophisticated and innovative bioprocesses[51,73] (Fig.1.13). Thanks to their intrinsic potential, hPSC may 
switch (uncontrollably) from pluripotency toward an undesired differentiated state during the cell 
expansion phase[73]; besides, the differentiation into the desired lineage is highly complex, including the 
effects of the previous expansion[73]. 
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 Bearing in mind this scenario, instead of the conventional “scale-out” (of the 2D approaches) 
(Fig.1.13a), which is relatively cost-[73], space-[73], and labour-intensive[73], the establishment of bioreactor 
systems (Fig.1.13b) provides a technology capable of meeting these needs in the cardiovascular 
context[136,139]. By combining bioprocess automation[51,71,73], monitoring[51,71,73], molecular and fluidic 
control[32,51,71,73] and scalability[51,71,73], bioreactor systems allow a reduced operator-dependent 
variability[73], opening the doors for more robust and cost-effective bioprocesses[51,73].  
 The use of bioreactor systems simplifies the establishment of suspensions of dynamic and 
homogenous cultures, thereby overcoming the heterogeneity, typical of 2D static conditions[51,54,71,73,139]. 
Moreover, they offer a non-destructive sampling[51] (beneficial for continuous monitoring and control).
 There are numerous types of bioreactor systems (Fig.1.13b): wave bioreactors, stirred tank, packed 
bed, hollow fibre, bubble-column and airlift bioreactors are the some of the examples[51,71–73,136,139–141]. 
Amid all these, we will focus on stirred tank bioreactors (STBRs) as a tool for cellular aggregation in a 
controlled microenvironment.  
 STBRs are equipped with integrated probes that allow a tight and tuned monitoring and control of the 
culture environment, including parameters such as temperature, pH, DO, nutrient (e.g. glucose), 
metabolite (e.g. lactate, ammonia) concentrations, gas composition (e.g. O2 and CO2) and vital biomass 
assessment[51,73,136]. 
  
Figure 1.13 | Expansion strategies for hPSC and hPSC-cardiac derivatives [adapted from Kropp et al. (2017)[73]].  
(a) (upper panel) “Scale-out” approaches of the conventional 2D culture methods via increasing the number of cultivation vessels. 
(b) (lower panel) Scale-up approaches using 3D culture methods within bioreactor systems (e.g. rotating Erlenmeyer flasks, in 
addition to wave, rotating wall or stirred tank bioreactors), which allow to increase the entire manufacturing scale. Highlighted 
(blue circle): stirred tank bioreactors. 
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 Hence, STBR technology allows a relatively linear and straightforward up-scaling process[142] and 
supports distinct bioreactor operation modes[73], categorized into four classes[73]: (i) batch, (ii) repeated 
batch, (iii) fed batch and (iv) perfusion (continuous feeding with cell retention). 
 However, it also presents downsides, such as the hydrodynamic shear stress caused by stirring, which 
can adversely affect 3D spheroid cultures and cell differentiation[143]. 
 
1.5. Towards an integrated characterization toolbox for 3D in vitro cardiac models 
 As revealed in the above sections (1.2.2.3 and 1.3.1), the lack of a mature, adult-like phenotype in 
hPSC-CM, countered, in part, by the creation of more faithful and robust 3D cardiac cell-based models 
that recapitulate in vitro certain aspects of the physiology and architecture of the human heart in vivo 
(1.3), is one of the core limiting factors that averts the advance of these models towards clinical settings. 
 However, since there is such a miscellaneous array of models, an equally robust characterization 
toolbox must be developed to study and characterize them, in depth. 
 This section briefly outlines some of the current state-of-the-art methodologies, used to characterize 
these models, covering (i) structural and ultrastructural features, molecular profiling (gene and protein 
expression) and calcium handling; (ii) mechanobiological approaches, particularly atomic force 
microscopy; and, lastly, (iii) microscopy-based phenotypic approaches. 
 
 1.5.1. Structural and ultrastructural features 
 Structurally, hPSC-CM are small[25,144], round[25,144] or multi-angular[144] cells (Fig.1.14), resembling 
embryonic CMs[25,56], with a single nucleus and chaotic myofibrillar alignment[18,144] (Table 1.1). 
Ultrastructurally, they display disorganized and small sarcomeres (with a length of about 1.6 μm[144]) and 
absence of T-tubules[2,18,25,56] (Table 1.1). Typically, it is only possible to detect Z-discs and I-bands, via 
transmission electron microscopy (TEM) characterizations[25,56,144] (Table 1.1).  
 Conversely, adult CMs or mature hPSC-CM exhibit a much more elongated[25,56,144], rod-like 
shape[25,56,144] and about 30-35% of them are multinucleated[25,53] (Fig.1.14, Table 1.1) (this percentage 
does not fluctuate meaningfully throughout life[53]).  
 In addition, several alterations affecting CM contractility occur in sarcomere and myofibril organization 
during maturation[18,25] (Fig.1.14). Specifically, they have highly organized sarcomeres (with a length of 
approximately 2.2 μm; higher than in immature CMs) with longitudinal myofibrillar alignment and 
scattered presence of T-tubules[2,53,144] (Table 1.1). TEM ultrastructural analysis demonstrate CM 
anisotropy[53] and normally detect Z-discs, together with I-, H-, A-bands[25,56,144] (Fig.1.14), albeit the 
presence of M-bands is not clear[56] (Table 1.1). This anisotropic alignment of adult CMs is also important 
to allow an efficient propagation of electrical signals[25,53], which are supported by the formation of 
connexin-43 (Cx43), holding gap junctions between cells[145]. 
 Via TEM it is additionally possible to perceive that, in adult CMs[144], mitochondria are located along 
the cell[144], occupying 20-40% of its total volume[144], whereas in hPSC-CM[144] these numbers are 
noticeably lower and associated with a perinuclear location[144] (Table 1.1).  
 With this in mind, TEM, enabling a high subcellular imaging resolution[53,146–148], to access 
ultrastructure[53,146,147], and scanning electron microscopy (SEM), allowing for topographical imaging (e.g. 
3D spheroids or complex 3D cardiac models) and providing data on the cellular organization and 
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architecture of specific structures[114,149], are the state-of-the-art methodologies for studying 
ultrastructural and structural features.  
 The main structural and ultrastructural properties that have been described, for both immature and 
adult CMs, in addition to aspects related to molecular profiling and calcium handling kinetics, which will 
be discussed beneath, are summarized in Table 1.1.  
Table 1.1. Comparison of phenotypic features between adult and hPSC-CM, in terms of structure, sarcoplasmic 
reticulum (SR), gene expression, metabolism, electrophysiology and calcium handling kinetics [adapted from 
Denning et al. (2016)[144]]. Highlighted (cyan boxes): structure, SR, gene expression and calcium kinetics properties. 
 
Figure 1.14 | Structural and ultrastructural differences between immature hPSC-CM and mature adult CMs, that 
occur during the maturation process [adapted from Dunn and Palecek (2018)[25]]. 
(left) Immature hPSC-CM: small, round or multi-angular shape, mononucleated and chaotic myofibrillar alignment.  
(right) Mature adult CMs: more elongated, rod-like shape, bi- or multinucleated, with highly organized sarcomeres displaying a 
longitudinal myofibrillar alignment. The inset indicates a high magnification image of the corresponding black rectangle: adult 
CMs’ ultrastructural analysis detecting Z-bands, together with I-, A- and M- bands. 
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 1.5.2. Molecular profiling: gene and protein expression 
 Several CM genes are more expressed in adult CMs than in hPSC-CM[25,144] (whose expression is similar 
to that found in the first trimester fetal heart[144]) (Table 1.1). 
These genes encode ion channels[2,4,18,25,56,144] (e.g. L-type calcium: CACNA1C and CACNA1D; sodium: 
SCN5A; potassium: KCNH2 and KCNQ1; and sodium/potassium: HCN4), critical regulators of calcium 
cycling machinery and sarcoplasmic reticulum (SR) transporters[2,4,18,25,56,144] (e.g. IPTR3, RYR2, SERCA2, 
CASQ2, CALR, JPH2, PLN, NCX1 and TRDN), sarcomeric proteins[2,4,18,25,56,144] (e.g. MYL2, MYL3, TNNI3, 
ACTN2, MYH7, MYL3, TNNC1, TNNT2)[2,4,18,25,56,144] and other cardiac specific proteins[4,18,78] (e.g. atrial 
natriuretic factor, ANF). 
 More importantly, the expression of different sarcomeric protein isoforms switches during CM 
maturation[25,53,144], denoting a transition from fetal to postnatal development[53].  
For instance, immature CMs express the slow skeletal isoform of troponin I (TNNI1)[25,53,144] and titin 
isoform N2BA[144], whilst more mature CMs express the cardiac isoform (TNNI3)[25,53,144] and titin isoform 
N2B[144]. In the same way, ventricular CMs express MLC-2a and MHC-α (encoded by MYL7 and MYH6 
genes, respectively), early in development, but upregulate MLC-2v and MHC-β (encoded by MYL2 and 
MYH7 genes, correspondingly), as they mature[4,53,56,144]. 
 Hence, real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and flow 
cytometry (FC) arise as the gold methods to recognise and quantify changes in gene and protein 
expression, respectively[91,144]. 
 
 1.5.3. Calcium handling: functional but immature Ca2+ handling apparatus 
 The aptitude for the in vitro development of a functional Ca2+ handling apparatus, ion channels and 
calcium regulatory proteins is an important feature for a mature phenotype of repolarization[18,95,96]. 
 In adult ventricular CMs, Ca2+ handling exhibits an arrangement of well-defined events[95,96,150,151]. 
Briefly, a small Ca2+ influx into the cells, through depolarization-activated L-type Ca2+ channels, during 
systole, triggers a calcium release from the internal calcium store, sarcoplasmic reticulum (SR), via 
ryanodine receptors (RyRs)[95,96,150,152,153]. This process is known as Ca2+-induced Ca2+ release 
(CICR)[95,96,150,152,153] and constitutes the primary mechanism linking electrical excitation and mechanical 
contraction in CMs[95,96,150,152,153]. Instead, during diastole, repolarization occurs and calcium is actively 
(with ATP expenditure) removed from the cytosol, mostly via SR calcium-ATPase (SERCA) back into SR and 
sodium/calcium exchanger out of cells[153]. 
 However, as expected, hPSC-CM Ca2+ handling properties (e.g. smaller peak amplitude and slower 
kinetics) resemble those of fetal left ventricular (LV) CMs and are significantly different from adult LV 
CMs[95,109] (Table 1.1). RyRs are expressed in hPSC-CM, but lack the organizational pattern observed in 
adult CMs, owing to the lack of T-tubules[95]. Also, regulatory proteins such as triadin (TRDN), calsequestrin 
(CSQ) and junctin (JCTN), that are common in adult CMs, are rarely expressed in hPSC-CM[4,56,95]. 
 Overall, hPSC-CM exhibit an immature calcium machinery, due to the underdeveloped SR and fetal 
expression profiles of important calcium handling proteins[95,109,150,152]. 
 Calcium sparks, waves or transients can be imaged and quantified using fluorescent Ca2+ 
indicators[10,126,154,155] (e.g. Fluo, Fura, Indo 1 and Oregon-Green), which enhance their fluorescence 
intensity in the presence of Ca2+ ions[155], allowing the study of CM functionality[91,95,96,152]. 
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 1.5.4. Mechanobiological dynamic characterization: atomic force microscopy 
 Atomic force microscopy (AFM) is a 3D topographic method that allows for surface roughness 
measurement with superior atomic resolution[156]. It belongs to scanning probe microscopies and its 
principle is based on the interaction between a sharp tip and the atoms on the sample surface[156].  
Importantly, it can be used in biological applications[108,109,148,156] (e.g. Alzheimer's disease process and cell-
based biosensing of drug responses) under native conditions[157] (e.g. liquid environments). 
 Moreover, by modifying AFM scanning probe (the tip), additional surface properties, such as friction, 
adhesion force, hardness, stiffness, Young's modulus and even magnetic or electrostatic features, can be 
determined[108,109] and quantified[158]. 
 The use of AFM to study mechanobiological properties may be particularly useful in the cardiovascular 
context, although few examples are reported in the literature[108,109,159].  
One of these, reported by Lieu et al. (2009), relates to the use of AFM in synergy with calcium imaging[160], 
in order to demonstrate the lack of T-tubules in hESC-CM[160], which, as mentioned in the previous topic 
(1.5.3), are vital for a normal CICR mechanism in adult CMs. In addition, fascinatingly, cardiac 
microenvironment remodelling can be correlated with AFM measurable-biomechanical parameters (e.g. 
Young's modulus, stiffness, hardness, amid others), that can ultimately be used to discriminate between 
healthy and hypertrophic hPSC-CM lines[109]. 
 
 1.5.5. Microscopy-based phenotypic approaches: from conventional widefield to the 
cutting-edge 3D reconstructions 
 Most imaging in cell biology is performed with widefield microscopy, in which the microscope basically 
creates an image of the sample on the camera, without any further optical manipulation[161]. 
 A number of experimental and technical challenges, however, have to be unravelled before 
researchers can take full benefit of the cutting-edge 3D models[161–163].  
 Providing insight into the internal morphology of large and compact spheroids has, undoubtedly, been 
a challenge[164] (Fig.1.15). The traditional preparation technique for immunofluorescence microscopy 
purposes is the physical sectioning of paraffin-embedded or frozen spheroids[164,165]. Then, the 
(cryo)sections are generally analysed in a conventional fluorescence microscope[164,165] (Fig.1.15). 
However, following sectioning, it is challenging and laborious to reconstruct the 3D information[164], in 
addition to these techniques being restricted to fixed samples only[165]. 
 Bearing in mind that conventional wide-field fluorescence microscopy does not allow a faithful 
visualization of 3D cellular spheroids[161], mainly owing to their inhomogeneity[162,163,166] and low 
transparency[162,163,166], one of these challenges is finding improved imaging techniques that can penetrate 
the depth of thick and highly scattering samples with negligible photodamage[162,163,166]. 
 Furthermore, a dynamic quantitative analysis of a 3D biological structure requires the satisfaction of 
several crucial factors[162–167]: (i) excellent signal-to-noise ratio, (ii) optical sectioning capability, (iii) large 
field of view, (iv) good spatial resolution, (v)  a desirable fast image stack recording rate and (vi) low sample 
fluorophore excitation level. 
The options available for such imaging techniques will now be briefly discussed. 
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 1.5.5.1. Confocal microscopy 
 Fluorescence confocal laser scanning microscopy (CLSM) represents the commercially available 
imaging method of moderately thick specimens, such as 3D spheroids[161]. 
 In confocal microscopy, the sample is illuminated by a focused laser beam at a single point in the 
sample focal plane[161,168]. Summarily, the light from this point is detected after passage through a pinhole, 
so that only the light emitted from the focal plane passes through the pinhole and is recorded on the 
photodetector[161,168]. Light from out-of-focus planes is blocked by the pinhole and, therefore, the confocal 
modality only records light from the focal plane of the sample[161,168].  
Thus, it is an imaging modality that allows a high signal-to-noise ratio, optical sectioning capability and 
good spatial resolution[161,168]. 
 However, as in traditional wide-field fluorescence, in confocal imaging the excitation light illuminates 
the entire object, unwittingly extending photobleaching and phototoxic effects to all planes[161,163,168,169]. 
Also, a shortcoming of confocal is the limited penetration depth, when using high numerical aperture (NA) 
lenses[169]. These two limitations limit a regular application of confocal microscopy to in toto studies of 
large and thick 3D spheroids[161,163,168,169]. 
 
 1.5.5.2. Multiphoton microscopy 
 A related technique is multiphoton or two-photon laser scanning microscopy (MPLSM)[170], which 
emerges as an attractive platform when observing large species (usually >200 μm)[161], mainly due to its 
twofold penetration depth, in comparison with confocal microscopy[161,163]. 
Figure 1.15 | Microscopy-based phenotypic approaches for characterizing large and thick 3D spheroids [adapted 
from Pampaloni et al. (2007)[163]]. Examples of 3D cellular spheroids imaged with several microscopic techniques. 
(a) Compilation of LSFM images of a spheroid composed of BxPC-3 human pancreatic cancer cells. Scale bars, 50 μm. (a1) Nuclei 
of the spheroid, stained with Draq5 dye. Maximum projection of a stack obtained from a multi-view reconstruction of twelve 
stacks recorded along different angles (0 to 330o) with an incremental step of 30o. (a2) Maximum projection of the same dataset 
exhibited in (a2), after deconvolution. (a3) Cross-section of the same spheroid. (a4) Same image in (a3) after deconvolution. 
(b) Scanning electron microscopy (SEM) micrograph of a human hepatoma cell line. Scale bar, 10 µm. (c) Transmission electron 
microscopy (TEM) cross-section of a V79 Chinese hamster lung cell spheroid. Scale bar, 250 µm. (d) Immunohistochemical 
staining of the nuclei of a Rat1-T1 spheroid. Scale bar, 250 µm. (e) Multiphoton microscopy autofluorescence images of a 
multicellular tumour spheroid. Scale bar, 100 µm. 
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 Another advantageous feature of multiphoton microscopy is the use of pulsed lasers that allow for 
second harmonic generation imaging of collagen fibres (major component of the native matrix of the 
human heart), flavoproteins and non-centrosymmetric polymers, without sample labelling[171,172]. 
 Hence, multiphoton microscopy is usually recognized as the technique of choice for 3D imaging[169] 
and, particularly, for spheroid analysis[173] (Fig.1.15). 
 Notwithstanding, it offers low resolution and requires huge light intensities, causing bleaching and 
phototoxic effects in the focal plane[163]. Since it is a very sampling-destructive method, multiphoton may 
be particularly valuable when used in combination with other techniques[168]. 
 
 1.5.5.3. Spinning disk confocal microscopy 
 Spinning disk confocal microscopy (SDMC) combine ease of use and high speed (up to hundreds of 
frames per second) and sensitivity and, thereby, has become widely used in cell biology[161]. 
 For very compact samples (thicker than about 30 μm), SDMC is, however, more inefficient at rejecting 
out-of-focus light than confocal, but this is not a limitation for imaging the majority of tissue models[161,168]. 
The high scan speed does not only improve image acquisition rate, but also minimizes the light density 
required for the excitation peak, consequently increasing the fluorescence efficiency and decreasing 
photobleaching and photodamage effects, in comparison with regular confocal microscopy[168]. 
 Owing to these advantages, spinning disk confocal is more live cell-friendly than widefield or confocal 
microscopy, being proper for live imaging[161,168] (e.g. protein or microtubules imaging, organelle 
dynamics, among others). 
 An interesting application, according to the background of this work, is the use of SDCM in live cell 
calcium imaging, with the aim of studying calcium handling machinery and kinetics[174] (in 2D monolayers 
or in 3D aggregates of hPSC-CM). 
 
 1.5.5.4. Light-sheet fluorescence microscopy: heralding a whole picture revolution in 3D 
microscopy 
 Progress in optical microscopy has overcome challenges that prevent high-resolution imaging of thick 
and highly scattering samples, such as 3D spheroids[162,163,166,169]. 
 A revolution in microscopy befell with the development of light-sheet fluorescence microscopy 
(LSFM)[175] (Fig.1.16). These microscopes illuminate the sample from a plane orthogonal to the imaging 
plane[161] (Fig.1.16b and Fig.1.16, lower left corner). This eliminates the problem of out-of-focus light 
because only light from the focal plane or very close to it is excited[165–167] (Fig.1.16b and Fig.1.16, lower 
left corner). 
 Due to the high imaging speed and relatively good penetration depth with remarkably low 
photobleaching and phototoxicity (by virtue of the selective illumination)[162,163,165,166,169,176], LSFM is 
suitable for imaging large spheroids[165,167,177] and 3D complex models[178–181] (Fig.1.16a) (e.g. alginate 
microcapsules containing spheroids and/or single cells). The combination with optical clearing methods 
may further increase the penetration depth by rendering the spheroid transparent[164]. 
 In whole mount immunofluorescence techniques, the use of IgG antibodies (with a molecular weight 
of approximately 150 kDa) leads to poor penetration into 3D species and, consequently, inhomogeneous 
staining[164]. Imagine a spheroidal 3D structure: ordinarily, a good staining quality is only attained for the 
peripheral cells, whereas the staining quality quickly fades for cells in deeper regions. 
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 Hence, LSFM is also an appropriate technique for in toto immunostaining[162–164,166,167,169,180], since, 
besides all the aforesaid advantages, it is able to counter this hindrance, via the possibility of obtaining 
multi-views of the sample (Fig.1.15), by rotating it, with isotropic resolution[161], so that the hidden parts 
Figure 1.16 | Heralding a whole picture revolution in 3D microscopy with LSFM [adapted from Pampaloni et al. 
(2015)[166], Pampaloni et al. (2007)[163] and Weber and Huisken (2011)[175]]. 
(a) Relevant characteristics and major applications of LSFM, in 3D cell culture. (b) Autoclavable cell culture chamber for single 
plane illumination microscopy (SPIM). The temperature is maintained at 37 ± 0.1 oC and the objective lens is immersed into the 
culture medium. (c) Mounting of 3D cellular spheroids for LSFM imaging. The spheroid is suspended into a droplet of low-gelling 
agarose, at 37-40 oC, and sucked into a thin glass capillary. Once the agarose has polymerized and hardened, the sample is pushed 
out of the capillary and imaged. (right, white arrow and circle) image of a cellular spheroid outside the capillary; (right, red arrow 
and circle) a second image of the same spheroid, but inside the capillary, is noticeable. (d) Concept of 3D multi-view 
reconstruction in LSFM. (d1) In a scattering sample the light illumination will only penetrate part of the sample. (d2) Likewise, 
fluorescence only penetrates the side facing the detection optics, so that only the quadrant facing illumination and detection will 
be well imaged. (d3) By adding a second illumination source, quadrant II can be illuminated and imaged as well. (d4) Lastly, by 
adding a second detection unit, quadrants III and IV can be imaged. (d5) Instead, in LSFM, the sample can merely be rotated, 
making all quadrants reachable, even with a single set of illumination and detection. (d6) Datasets are individually recorded and, 
then, (d7) are fused to generate a faithful 3D volume reconstruction of the whole sample, termed multi-view reconstruction. 
Highlighted (lower left corner, blue box): Laser light sheet illumination and orthogonal detection (at 90 oC with respect to 
illumination) provides optical sectioning, disregarding the out-of-focus issues. 
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become visible[162,163,165–167,169,180] (Fig.1.16d, d1-d7). This feature is not offered in the formerly referred 
multidimensional microscopy imaging systems (e.g. confocal and multiphoton) and allows to obtain a 
realistic 3D volume reconstruction, not accomplished by any other type of microscopy technique[165,167,180]. 
 So far this technique has been successfully used to image cell aggregates and zebrafish, not only for 
fixed samples, but also live monitoring of cellular events, like apoptosis and calcium signalling[165,167,180]. 
 Albeit these microscopes start to be commercialized, they are not yet readily available in the market, 
and are usually customized systems[161,166,169,180] (Fig.1.16b and Fig.1.16c). The widening of their 
obtainability, together with the development of other personalized designs may, in a near future, herald 
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2. Aims and Scope of the Thesis 
 
 The scope of this thesis was the establishment of a bioinspired 3D hiPSC-derived cardiac tissue model 
(main aim, Fig.2.1) that recapitulates in vitro certain features of the in vivo physiology and architecture 
of the human heart. Specifically, for the development of this model, cardiomyocytes and, separately, non-
myocyte populations (endothelial cells and mesenchymal cells) were differentiated from hiPSC; 
afterward, hiPSC-CM were aggregated into 3D homotypic spheroids and microencapsulated in a 
biocompatible hydrogel, together with the non-myocyte populations (hiPSC-EC and hiPSC-MC), in order 
to generate a scaffold-based in vitro 3D triculture model, fully derived from hiPSC. As controls, 3D models 
composed only of encapsulated hiPSC-CM spheroids (monocultures) or, alternatively, encapsulated hiPSC-
ECMC single cells (co-cultures), were also developed. 
 Considering the problem of the hiPSC-CM immature phenotype, interrogating heterotypic cellular 
communication between myocytes and non-myocytes (specific aim i, Fig.2.1), especially that between 
hiPSC-CM and hiPSC-EC, and its role in cardiac maturation, is the first of the specific aims. 
 Given the massive difficulty in characterizing the internal morphology of compact and highly scattering 
spheroids, in addition to the fact that they were encapsulated in a microbead, imaging-based phenotypic 
assays were also implemented, based on confocal, spinning disk confocal, multiphoton and LSFM (specific 
aim ii, Fig.2.1). 
 Another of the thesis’ aims was to challenge the models with cardioactive drugs (e.g. norepinephrine, 
propranolol and heptanol) or cardiotoxic anticancer drugs (e.g. doxorubicin and paclitaxel) and evaluate 
the pharmacological responses and their ability to be used in drug screening and toxicology assessment 
(specific aim iii, Fig.2.1). 
 Mechanical dynamic characterization, based on AFM, was also implemented, in order to study the 
hydrogel scaffold (in the absence of cells), mono- and triculture mechanobiological behaviour (specific 
aim iv, Fig.2.1). It was also sought to study cell-ECM interactions (particularly those involving 
mesenchymal cells) and their impact on the remodelling of the cardiac microenvironment. 
 A preliminary study in stirred-tank bioreactors (STBRs), operating in perfusion, in order to perform the 
scale-up of the models, initially generated in shake flask, closes the final aim (specific aim v, Fig.2.1). 
 Hence, the establishment of such a multifaceted model led to a correspondingly robust 
characterization toolbox. In addition to the stated strategies: (i) cryosections (using widefield and 
confocal microscopy) and whole mount (through multiphoton and LSFM) immunofluorescence 
microscopy, (ii) gene expression and flow cytometry, (iii) histological/histochemistry-based methods, (iv) 
live cell calcium imaging (using spinning disk confocal microscopy), (v) ultrastructural assessment via 
TEM, (vi) characterization of the biomaterial-based scaffold via AFM and SEM and, finally, (vii) anticancer 
drug cardiotoxicity evaluation, based on metabolic activity quantification, via PrestoBlue resazurin-based 
dye assay, were some of the major readouts used to in depth characterize it. 
 The aims of this thesis (main and specific), as well as the major readouts used, are summarized in 
Fig.2.1. This figure also displays a schematic depiction of the 3D triculture hiPSC-derived cardiac tissue 
model, together with the key model players (cardiomyocytes and non-myocytes, the biomaterial scaffold, 
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3. Materials and Methods 
 
3.1. Cell culture 
 3.1.1. Human iPSC culture 
 Only one human iPSC line was used: hiPSC DF19-9-11T.H (WiCell, Madison, WI, USA), between 
passages 39 and 47.  
 This human iPSC line was routinely propagated in 2D static adherent conditions (6-well plates), on 
Matrigel™ (Corning, New York, MA, USA; 1 mL/well) Matrix hESC-Qualified-coated plates (prepared 
according to the manufacturer’s instructions), in mTeSR™1 medium (STEMCELL Technologies, Vancouver, 
BC, Canada; 2 mL/well), and kept at 37 oC, in a humidified atmosphere composed of 5% CO2 and 95% air. 
 Culture medium was daily exchanged and cells were non-enzymatically passaged, via incubation, at 37 
oC, for 7-8 min, with, Versene™ (Thermo Fisher Scientific; 1 mL/well) cell dissociation reagent. 1h before 
the passage, the exhausted mTeSR™1 medium, in the wells, was supplemented with 5 µM of rho-
associated protein kinase, ROCK, signalling pathways’ inhibitor (Y-27632, Merck Millipore, Kenilworth, NJ, 
USA; 2 µL/well). Subculturing was performed whenever the cells reached 80-90% confluence (typically 
every 2-3 days). 
 As described by Correia et al. (2018)[83], when the desired cell concentrations and a confluence of 80-
90%[83] were attained, differentiation was induced toward CMs or non-myocytes (ECs and MCs), using the 
corresponding protocols, described underneath. 
 
 3.1.2. Directed differentiation of hiPSC toward CMs 
 Directed differentiation of hiPSC into CMs was started when cell confluence reached 80-90%. 
 Briefly, at day 0, cardiac mesoderm was induced by exchanging mTeSR™1 expansion medium to RPMI 
1640 (Roswell Park Memorial Institute 1640) medium (Thermo Fisher Scientific), supplemented with B-
27™, without insulin (hereinafter referred to as RPMI/B27−ins; Thermo Fisher Scientific), 12 μM GSK-3β 
inhibitor/Wnt activator CHIR99021 (Tocris Bioscience, Madrid, Spain), 80 ng/mL activin A (PeproTech, 
Peterborough, UK) and 50 μg/mL ascorbic acid, AA (Sigma-Aldrich, St. Louis County, MO, USA). At day 1 
(approximately 24h – 24 ± 1h – after differentiation induction), medium was replaced by RPMI/B27−ins 
supplemented with 5 μM of a Wnt signalling small molecule inhibitor (IWR-1, Sigma-Aldrich) and 50 
μg/mL AA (Sigma-Aldrich). At day 3 (72h post-differentiation induction), medium was exchanged for 
RPMI/B27−ins supplemented only with 5 μM IWR-1 (Sigma-Aldrich). At day 7 (when more than 80% of 
the cells spontaneously contract in culture), cells were enzymatically dissociated[N1] via incubation with 
TrypLE Select (5 min at 37 oC)[83] (Thermo Fisher Scientific), followed by culture medium (RPMI/B27−ins) 
addition and centrifugation (220 x g for 5 min).1 
 
 3.1.2.1. Microwell establishment of 3D cardiac homotypic spheroids 
 Most of the cells, harvested at day 7 (already cardiac progenitor cells, CPCs), were seeded into 
microwells (AggreWell™ 400Ex, STEMCELL Technologies), at a cell density of 1500 cell/microwell (chosen 
based on Nguyen et al., 2014[118] and Correia et al., 2018[83] studies, regarding hPSC-CM aggregation), 
centrifuged (100 x g during 3 min), and then cultured in RPMI/B27−ins. 
                                                          
[N1] Similarly to what has been described for human iPSC culture, 1h before the CMs passage, at day 7 the exhausted RPMI/B27-
ins medium, in the wells, was supplemented with 5 µM of rho-associated protein kinase, ROCK, signalling pathways’ inhibitor (Y-
27632, Merck Millipore, Kenilworth, NJ, USA). 
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 After 48 h (at day 9), the spheroids were transferred to rotary orbital suspension culture (i.e. shake 
flasks), with a stirring rate of 90 rpm (selected based on in-house preceding studies performed with PSC 
spheroids[139], with an average diameter oscillating between 100 and 300 μm, which evidenced that this 
stirring rate was suitable for keep cells in suspension without deleteriously affecting them or causing 
diffusional limitations).  
 Lastly, hiPSC-CM were kept in suspension culture for further 6 days under the aforesaid conditions 
(total culture time: 15-18 days). Medium was refreshed every two days, yielding the desired cellular 
product, which was designated as 3D hiPSC-CM. 
 
 3.1.2.2. 2D monolayer culture: control condition 
 Conversely, the other portion of the cells, dissociated at day 7 with TrypLE Select (Thermo Fisher 
Scientific), were replated in 2D static culture plates, in order to function as a cellular control for the 3D 
cardiac spheroid differentiation. Accordingly, the harvested cells were inoculated at 2 x 105 cells/cm2 on 
Matrigel™ Matrix (Corning, New York, MA, USA; 1 mL/well) hESC-Qualified-coated plates (prepared 
according to the manufacturer’s instructions) and cultured in RPMI/B27−ins. Medium was replaced 24h 
later and, then, every two days, until day 15, yielding the desired cellular product, which was termed as 
2D hiPSC-CM. 
 
 3.1.3. Simultaneous differentiation of hiPSC toward ECMCs in a 2D co-culture 
 Concomitant differentiation in endothelial and mesenchymal cell (ECMC) lineages was induced in a 2D 
monolayer co-culture, based on an adaptation of the methodology described by Giacomelli et al. 
(2017)[53]. 
 Summarily, hiPSC were seeded on 6-well plates at 0.0125 x 106 cells/cm2 (roughly 0.04 x 106 cells/mL). 
At day 0, cardiac mesoderm formation was favoured by exchanging mTeSR™1 to APEL™2-LI (Albumin, 
Polyvinylalcohol, Essential Lipids Low-Insulin) differentiation medium (STEMCELL Technologies), 
supplemented with a mixture of cytokines, viz. 20 ng/mL BMP-4 (PeproTech, Peterborough, UK), 20 ng/mL 
activin A, (PeproTech, Peterborough, UK) and 1.5 μM GSK-3β inhibitor/Wnt activator CHIR99021 (Tocris 
Bioscience, Madrid, Spain). At day 3, cytokines were removed and 50 ng/mL VEGF (PeproTech, 
Peterborough, UK) was added.  
 APEL™2-LI medium supplemented with VEGF was refreshed every 3 days, until day 10 of ECMC 
differentiation (total culture time: 10-12 days), yielding the desired cellular product, which was designated 
as 2D hiPSC-ECMC. 
 
3.2. Generation of wholly hiPSC-derived hydrogel-based 3D cardiac tissue models 
 For the generation of the biomaterial-based 3D hiPSC-derived cardiac tissue models, a 
microencapsulation approach, using a biocompatible hydrogel, was used[178,179,182]. 
 3D hiPSC-CM spheroids were collected from the shake flasks and approximately 5.2 x 106 cells were 
dispersed in 1 mL of 1.1% (w/v) of an equimolar mixture (i.e. 1:1) composed of conventional non-RGD 
alginate and a commercially available RGD peptide-coupled alginate, viz. ultrapure MVG alginate 
(Ultrapure MVG, NovaMatrix, PRONOVA™, Oslo, Norway) and NOVATACH MVG GRGDSP peptide-
coupled alginate (GRGDSP-coupled with a high G-content, high MW alginate, NovaMatrix, PRONOVA ™, 
Oslo, Norway), dissolved in NaCl 0.9% (w/v) solution (Merck Millipore). 
 Spheroids (consult 3.1.2.1) were microencapsulated either alone, or together with hiPSC-ECMC 
(consult 3.1.3), in a 1:2 ratio (about 10.4 x 106 ECMC), for an approximate total of 15.6 x 106 CM/ECMC. 
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The cardiac model regarding the microencapsulated hiPSC-CM spheroids, as well as the one 
contemplating the spheroids plus the hiPSC-ECMC monolayer of non-myocyte populations, will 
henceforth be referred to as 3D hiPSC-CM monoculture and 3D hiPSC-CM/ECMC triculture (or simply 
monoculture and triculture, correspondingly). hiPSC-ECMC monolayers (consult 3.1.3) were also 
microencapsulated (approximately 10 x 106 cells) and maintained as controls. Hereinafter, they will be 
termed as 3D hiPSC-ECMC co-culture (or just co-culture). 
 As regards the alginate microencapsulation process itself, it was carried out using an electrostatically 
driven bead generator[178,179,182] (VarV1, Nisco Encapsulation Unit, Zurich, Switzerland), to generate 
microbeads with an average diameter of approximately 1500 μm (Model #1-a-MCT-SF; consult List of 
Models, for further information on the designations and specificities of each of the models) or ranging 
from 700 to 800 μm (Pilot Model-M-SF, Model #1-b-MCT-SF and Model #2-b-MT-BR-2).  
 Alginate polymerization was attained with a solution of 100 mM CaCl2/10 mM HEPES (pH 7.4) (Merck 
Millipore and Sigma-Aldrich, respectively). The calcium alginate microcapsules were further washed 
three times in a 0.9% (w/v) NaCl (Merck Millipore) solution and, finally, equilibrated in culture medium, 
before being transferred to shake flasks. Conversely, when needed, alginate microbeads’ disruption was 
accomplished via incubation (5 min at room temperature, RT, 18–20 oC) in a solution of 50 mM 
Na3C6H5O7/104 mM NaCl (Sigma-Aldrich and Merck Millipore, respectively). 
 The microencapsulated 3D hiPSC-derived cardiac models (mono-, co- and triculture) were then 
transferred to rotary orbital suspension culture (i.e. shake flasks), with a stirring rate of 90 rpm. They were 
maintained in culture at 37 oC, in a humidified atmosphere, with 5% CO2 in air, in a 1:1 mixture of 
RPMI/B27-ins and ECGM2 (Endothelial Cell Growth Medium 2, PromoCell GmbH, Heidelberg Germany). A 
100% medium exchange was performed every 2-3 days, for, at least, 15 days (total culture time: 31-37 
days, from the beginning of hiPSC-CM differentiation). 
 
3.3. Model characterization 
 3.3.1. Viability and cell concentration 
 Two methods were used to estimate cell viability. Samples were collected periodically and used for 
monitoring of cell viability via (i) a fluorescent cell membrane integrity assay (FDA-PI live/dead double 
staining) and (ii) Trypan Blue exclusion method. 
 
 3.3.1.1. Cell membrane integrity assay: FDA-PI live/dead double staining 
 A qualitative assessment of 3D hiPSC-based cardiac tissue models’ (mono-, co- and tricultures) cell 
viability over time (after microencapsulation) was performed using the enzyme substrate fluorescein 
diacetate (FDA, Sigma-Aldrich), which stains viable cells, and the DNA-binding dye propidium iodide (PI, 
Sigma-Aldrich), that labels dead cells, as described in the literature[183]. FDA is taken up by cells which 
convert the non-polar and non-fluorescent FDA into a bright green fluorescent metabolite, fluorescein[184]. 
The measured signal is the result of FDA to fluorescein conversion via the intracellular esterases of viable 
cells. In contrast, the nuclei staining dye, PI, cannot pass through a viable cell membrane, since it is 
polar[184]. It reaches the nucleus by passing through disordered areas of dead cell membranes and 
intercalates within the DNA double helix[184], thereby labelling the dead cell nuclei in red. 
 Briefly, cells were incubated with 20 μg/mL FDA and 10 μg/mL PI, in DPBS (Thermo Fisher Scientific), 
for 2-3 min and then visualized using a conventional widefield fluorescence microscope (DMI6000, Leica 
Microsystems GmbH, Wetzlar, Germany). 
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 3.3.1.2. Trypan Blue exclusion method 
 For the Trypan Blue exclusion method, hiPSC-CM spheroids (before microencapsulation) were 
centrifuged at 300 × g for 5 min and enzymatically dissociated via incubation with TrypLE Select for 5 min 
at 37 oC with agitation (ThermoMixer, Eppendorf). Viable cell concentration was determined by mixing 
the resulting cell suspension with 0.1% (v/v) Trypan Blue dye (Thermo Fisher Scientific), in DPBS, and 
subsequent counting in a Fuchs-Rosenthal haemocytometer chamber (Brand) (colourless cells — viable; 
blue cells –  non-viable)[52,182]. The concept is the same as in the previous assay: viable cells do not take up 
impermeable dyes (e.g. Trypan Blue or PI), instead of dead cells, that are permeable and take up the dye. 
 
 3.3.2. Metabolic activity quantification: PrestoBlue resazurin–based dye assay 
 Metabolic activity was quantified in the different 3D cardiac tissue models over culture time (after 
microencapsulation), using a PrestoBlue™ (#A13262, Life Technologies) resazurin–based dye assay, 
following manufacturer’s recommendations.  
 Samples of 2 to 5 microcapsules were taken from culture into a 96-well plate and then incubated with 
1X PrestoBlue™ Cell Viability Reagent (diluted in a 1:1 mixture of RPMI/B27-ins and ECGM2) for 3h at 37 
oC, with gentle agitation, in the dark. Fluorescence was measured at the excitation and emission 
wavelengths of 560 and 590 nm, respectively, using the micro plate reader Infinite® 200 PRO (NanoQuant, 
Tecan Trading AG) and fluorescence intensity values (RFU, relative fluorescence units) were normalized 
to the number of capsules, counted per well, and to the maximum of fluorescence intensity, verified in 
the timepoints considered. Analyses consisted of three technical replicas. Controls (subtracted from the 
mean of the three technical replicas) were also read and correspond to 1X PrestoBlue™ diluted in the 
culture media mixture. The increase in fluorescence intensity is a result of PrestoBlue™ (which is a 
resazurin-derived blue non-toxic and non-fluorescent reagent) reduction, to resorufin, a red fluorescent 
compound, solely via metabolically viable cells. Therefore, PrestoBlue™ assay provides a quantitative 
measure of cell viability and metabolic activity. 
 
 3.3.3. Spheroid and microcapsule concentration and distribution of spheroids per 
microcapsule 
 The concentration of CM spheroids or microcapsules was determined over the culture time, in a 1 mL 
sample, distributed among 5 wells (200 µL per well) of a 96-well plate. The number of aggregates or 
microcapsules was manually counted in each well, using an inverted microscope (DMI6000, Leica 
Microsystems GmbH; or CKX31, Olympus). The corresponding concentrations, in addition to spheroids 
per microcapsule distribution, were calculated thereafter. 
 
 3.3.4. Spheroid and microcapsule size determination 
 CM spheroid size determination was performed using an inverted-microscope (DMI6000, Leica 
Microsystems GmbH). The acquired images were analyzed via Fiji open source software[185]. In brief, the 
contrast threshold of non-consecutive images was manually adjusted, in order to define the spheroid 
boundaries. Average spheroid diameter was then measured using Feret’s diameter measurement 
algorithm. 
 Average microcapsule diameter was estimated by measuring two perpendicular diameters per 
microcapsule, resorting to non-consecutive images acquired with the mentioned microscope. 
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 3.3.5. Flow cytometry-based phenotypic analysis 
 3.3.5.1. hiPSC 
 For flow cytometric (FC) analysis of common pluripotency stem cell (Oct-3/4, SSEA-4 and TRA-1-60) 
and early differentiation (SSEA-1) markers, before the beginning of the differentiations toward CMs and 
ECMCs, hiPSC were harvested from culture via enzymatically dissociation with TrypLE Select (Thermo 
Fisher Scientific), for 5 min at 37 oC. 
 Cell suspensions of hiPSC (0.5 x 106 cell/marker) were centrifuged (300 x g for 5 min), resuspended 
twice in Washing Buffer, WB (DPBS with 5% (v/v) FBS), and incubated, for 1 h at 4 oC, in the dark, with one 
of the subsequent conjugated primary antibodies: 1:10 anti-TRA-1-60 mouse monoclonal IgM (sc-21705, 
Santa Cruz Biotechnology; diluted in WB), 1:5 anti-SSEA-4–FITC conjugate mouse monoclonal IgG3,k 
(clone MC813-70, 560126, BD Biosciences; diluted in WB) and 1:10 anti-SSEA-1–FITC conjugate mouse 
monoclonal IgM,k (clone MC480, 560127, BD Biosciences; diluted in WB); or isotype controls: 1:40 mouse 
monoclonal IgG3,k–FITC conjugate (clone J606, 555578, BD Biosciences; diluted in WB) and 1:400 mouse 
IgM,k–FITC conjugate (clone G155-228, 553474, BD Biosciences; diluted in WB). 
 In parallel, for the detection of intracellular markers, cells were fixed and permeabilized with Inside 
Stain Kit (#130-090-477, Miltenyi Biotec), according to the manufacturer's instructions, and stained 
intracellularly with 1:5 anti-Oct-3/4–AlexaFluor® 488 conjugate mouse monoclonal IgG1,k (clone 40, 
560253, BD Biosciences; diluted in Inside Perm) and 1:1.19 mouse IgG1,k–AlexaFluor® 488 conjugate, 
isotype control (clone MOPC-21, 557721, BD Biosciences; diluted in Inside Perm), for 10 min at RT, in the 
dark. 
 Cells were washed with buffer (tubes stained with membrane markers – anti-TRA-1-60, anti-SSEA-4 
and anti-SSEA-1 – were washed and diluted in WB, whereas those stained with intracellular markers – 
anti-Oct-3/4 – were diluted in Inside Perm). Subsequently, the non-conjugated marker anti-TRA-1-60 was 
incubated with the corresponding secondary antibody, namely 1:200 goat anti-mouse IgM AlexaFluor® 
488 (A21042, Thermo Fisher Scientific; diluted in WB), for 10 min at RT, in the dark. 
 Finally, at least ten thousand events per sample were registered with the CyFlow® space (Partec 
GmbH, Görlitz, Germany) instrument, equipped with blue (488 nm), yellow (561 nm) and red (638 nm) 
lasers. Data were analysed using FlowJo (Tree Star). Appropriate scatter gates were applied, in order to 
circumvent cellular debris and also to allow direct comparisons between different experimental groups. 
The percentage of positive cells is given by events in which the measured fluorescence intensity surpasses 
the signal obtained in the isotype or unstained cells’ control. 
 
 3.3.5.2. hiPSC-CM 
 For flow cytometric analysis of cardiac differentiation efficacy at day 15 of differentiation, hiPSC-CM 
spheroids were harvested from culture and enzymatically dissociated into single cells, with TrypLE Select 
(Thermo Fisher Scientific), for 5 min at 37 oC. 
 Cell suspensions of hiPSC-CM (0.5 x 106 cell/marker) were centrifuged (300 x g for 5 min), resuspended 
twice in Washing Buffer, WB (DPBS with 5% (v/v) FBS), and incubated, for 1 h at 4 oC, in the dark, with one 
of the subsequent conjugated primary antibodies: 1:20 anti-SIRPα/β–PE conjugate mouse monoclonal 
IgG1,k (anti-CD172α/β–PE conjugate, clone P84, 323805, BioLegend; diluted in WB), 1:5 anti-VCAM-1–PE 
conjugate mouse monoclonal IgG1,k (anti-CD106–PE conjugate, clone 51-10C9, 555647, BD Biosciences; 
diluted in WB) and 1:5 mouse monoclonal IgG1,k–PE conjugate, isotype control (clone MOPC-21, 555749, 
BD Biosciences; diluted in WB). 
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 In parallel, for the detection of intracellular markers, cells were fixed and permeabilized with Inside 
Stain Kit (#130-090-477, Miltenyi Biotec), according to the manufacturer's instructions, and stained 
intracellularly with 1:200 anti-cardiac troponin T mouse monoclonal IgG1 (clone 13-11, MS-295-P1, 
Thermo Fisher Scientific; diluted in Inside Perm) and 1:1.5 mouse monoclonal IgG1, isotype control (sc-
3877, Santa Cruz Biotechnology; diluted in Inside Perm), for 10 min at RT, in the dark. Cells were washed 
with buffer (Inside Perm) and incubated with the secondary antibody, 1:200 goat anti-mouse IgG 
AlexaFluor® 488 (A11001, Thermo Fisher Scientific; diluted in Inside Perm), for 10 min at RT, in the dark. 
Afterwards, two more washes with Inside Perm, followed by centrifugations (300 x g for 5 min), were 
carried out.  
 Data were acquired and analysed as described in 3.3.5.1. The results obtained via this analysis 
constitute an indirect measure of the efficiency of hiPSC-CM differentiation, symbolizing the purity level 
of the culture on the day immediately prior to microencapsulation. 
 
 3.3.5.3. hiPSC-ECMC 
 At day 10 of differentiation, hiPSC-ECMC were harvested from culture via enzymatically dissociation 
with TrypLE Select (Thermo Fisher Scientific), for 5 min at 37 oC. 
 Cell suspensions of hiPSC-ECMC (0.5 x 106 cell/marker) were centrifuged (300 x g for 5 min), 
resuspended twice in Washing Buffer, WB (DPBS with 5% (v/v) FBS), and incubated, for 1 h at 4 oC, in the 
dark, with one of the subsequent conjugated primary antibodies: 1:50 anti-CD31 mouse monoclonal IgG1 
(clone JC70A, M0823, Agilent Technologies/DAKO; diluted in WB) and 1:13 anti-VE-cadherin goat 
polyclonal IgG (AF938, R&D Systems; diluted in WB). 
 In parallel, for the detection of intracellular markers, cells were fixed and permeabilized with Inside 
Stain Kit (#130-090-477, Miltenyi Biotec), according to the manufacturer's instructions, and stained 
intracellularly with 1:100 anti-α-smooth muscle actin mouse monoclonal IgG2a (clone 1A4, M085129-2, 
Agilent Technologies/DAKO; diluted in Inside Perm) and 1:100 anti-vimentin rabbit monoclonal IgG1 
(clone v9, ab16700, abcam; diluted in Inside Perm), for 10 min at RT, in the dark. 
 Cells were washed with buffer (tubes stained with membrane markers – anti-CD31 and anti-VE-
cadherin – were washed and diluted in WB, whereas those stained with intracellular markers – anti-α-
smooth muscle actin and anti-vimentin – were diluted in Inside Perm) and, then, incubated with the 
corresponding secondary antibodies, particularly 1:200 goat anti-mouse IgG AlexaFluor® 488 (A11001, 
Thermo Fisher Scientific; diluted in WB), 1:200 goat anti-mouse IgG AlexaFluor® 488 (A11001, Thermo 
Fisher Scientific; diluted in Inside Perm), 1:200 chicken anti-goat IgG AlexaFluor® 488 (A21467, Thermo 
Fisher Scientific; diluted in WB) and 1:200 goat anti-rabbit IgG AlexaFluor® 488 (A11008, Thermo Fisher 
Scientific; diluted in Inside Perm), for 10 min at RT, in the dark. 
 Data were acquired and analysed as described in 3.3.5.1. 
 
 3.3.6. Microscopy-based phenotypic assays 
 3.3.6.1. Immunofluorescence in 2D cell monolayers 
 At day 10 of hiPSC-ECMC differentiation (prior to microencapsulation), culture samples were collected 
and then transferred onto μ-Slide 4 Well or μ-Slide 8 Well (Ibidi). Culture wells were fixed in 4% (w/v) 
paraformaldehyde (PFA, ≥95%, Fluka) with 4% (w/v) sucrose (≥99.5%, Sigma-Aldrich), in DPBS (Thermo 
Fisher Scientific), for 20 min at RT.  
 ECMC monolayers were simultaneously permeabilized and blocked in 0.1% (w/v) Triton X-100 (TX-100, 
Sigma-Aldrich)/0.2% (w/v) cold water fish skin gelatine (FSG, Sigma-Aldrich), in DPBS (Thermo Fisher 
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Scientific), for 30 min at RT. Subsequently, cells were incubated with the respective primary antibodies, 
diluted in the same solution used for permeabilization and blocking, for 2h at RT. After the 2-hour 
incubation period, they were washed three times with DPBS and incubated with the corresponding 
secondary antibody, in the same solution, for 1h at RT. After three washes with DPBS, nuclei were 
counterstained with DAPI (Thermo Fisher Scientific). Samples were visualized using a conventional 
widefield fluorescence microscope (DMI6000, Leica Microsystems GmbH, Wetzlar, Germany). 
 Details on the characteristics and dilutions of primary and secondary antibodies, as well as the 
counterstain, are fully provided in Annex 1.1, Table S1 and Table S2 (consult the last column of the table 
– Dilution and Analytical Method – and identify 2D IF). 
 
 3.3.6.2. Confocal immunofluorescence in cryosections 
 At the endpoint (day 15 post-microencapsulation) of the microencapsulated 3D hiPSC-CM mono- and 
3D hiPSC-CM/ECMC triculture cardiac tissue models, culture samples were collected and fixed in 4% (w/v) 
paraformaldehyde (Fluka) with 4% (w/v) sucrose (Sigma-Aldrich), in DPBS (+Ca2+/+Mg2+) (Thermo Fisher 
Scientific), for 30 min at RT, under gentle agitation. After washing with DPBS (+Ca2+/+Mg2+) , they were 
then, overnight (o.n.) at 4 oC, dehydrated in 30% (w/v) sucrose (Sigma-Aldrich) in DPBS, embedded in 
Tissue-Tek® O.C.T.™ (Sakura, Alphen aan den Rijn, Netherlands) and frozen at –80 oC, until cryosectioning. 
The frozen samples were sliced with a thickness of 10 µm in a cryostat (Cryostat CM 3050 S, Leica, Wetzlar, 
Germany).  
 In brief, the cryosections were permeabilized with 0.1% (w/v) Triton X-100 (TX-100, Sigma-Aldrich), 
for 10 min at RT, followed by blocking, for 30 min at RT, with 0.2% (w/v) cold water fish skin gelatine (FSG, 
Sigma-Aldrich), in DPBS with Ca2+ and Mg2+. Primary antibodies were diluted in 0.2% (w/v) FSG, in DPBS 
(+Ca2+/+Mg2+), and incubated for 2h at RT, whereas secondary antibodies were diluted in 0.125% (w/v) 
FSG, in DPBS (+Ca2+/+Mg2+), and incubated only for 1h, also at RT. Cryosections were mounted under glass 
coverslips using ProLong™ Gold Antifade Reagent containing DAPI (Thermo Fisher Scientific) and 
visualized either in a confocal laser scanning microscope, CLSM (SP5 Live Upright, Leica) or, for routine 
control, in a conventional widefield fluorescence microscope (DMI6000, Leica Microsystems GmbH, 
Wetzlar, Germany). 
 Details on the characteristics and dilutions of primary and secondary antibodies are fully provided in 
Annex 1.1, Table S1 and Table S2 (consult the last column of the table – Dilution and Analytical Method 
– and identify CLSM, which was the preferred microscopy to visualize the cryosections). 
 
 3.3.6.3. Whole mount immunofluorescence  
 3.3.6.3.1. Multiphoton and LSFM: in toto immunofluorescence protocol 
 At the endpoint (day 15 post-microencapsulation) of the microencapsulated 3D hiPSC-CM mono- and 
3D hiPSC-CM/ECMC triculture cardiac tissue models, culture samples were collected and fixed in 4% (w/v) 
paraformaldehyde (Fluka) with 4% (w/v) sucrose (Sigma-Aldrich), in DPBS (+Ca2+/+Mg2+) (Thermo Fisher 
Scientific), for 30 min at RT, under mild agitation conditions. 
 Briefly, whole microcapsules were simultaneously permeabilized and blocked in 1% (w/v) Triton X-100 
(TX-100, Sigma-Aldrich)/0.2% (w/v) cold water fish skin gelatine (FSG, Sigma-Aldrich), in DPBS 
(+Ca2+/+Mg2+) (Sigma-Aldrich) with 0.01% sodium azide, for 2h at RT, with agitation. 
Primary antibodies were diluted in 0.1% (w/v) TX-100/0.2% (w/v) FSG, in DPBS (+Ca2+/+Mg2+) with 0.01% 
sodium azide, and incubated o.n. at 4 oC, with mild agitation, for two days. Microcapsules were then 
washed three times with DPBS (+Ca2+/+Mg2+) and incubated with the secondary antibodies, diluted in 
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0.1% (w/v) TX-100/0.125% (w/v) FSG, in DPBS (+Ca2+/+Mg2+) with 0.01% sodium azide, o.n. at 4 oC, with 
mild agitation. After three washes with DPBS (+Ca2+/+Mg2+), nuclei were counterstained with DAPI  
(Thermo Fisher Scientific) and DRAQ5 (Cell Signalling Technology). Samples were visualized either in a 
multiphoton laser scanning microscope, MPLSM (Ultima, Prairie Technologies), or, alternatively, in a 
custom-made light-sheet fluorescence microscope, LSFM (OpenSpin, Cell Imaging Unit, IGC, Oeiras, 
Portugal). 
 Details on the characteristics and dilutions of primary and secondary antibodies are fully provided in 
Annex 1.1, Table S1 and Table S2 (consult the last column of the table – Dilution and Analytical Method 
– and identify MPLSM or LSFM, which were the preferred microscopy modalities to in toto visualize the 
whole 3D models). 
 
 3.3.6.3.2. LSFM: image acquisition and light-sheet setup 
 The 3D reconstructed images were acquired with a home-made light-sheet fluorescence microscopy 
(LSFM) system, based on an open software and hardware approach[165,180,186], the OpenSpin project (not 
yet published) (Cell Imaging Unit, Instituto Gulbenkian de Ciência, IGC; for additional information, consult 
http://facilities.igc.gulbenkian.pt/microscopy/microscopy-dslm.php).  
 Light-sheet fluorescence microscopy setup is depicted in Fig.3.1. 
 Images were acquired consecutively, as the samples cross the light-sheet plane (Fig.3.1a, Fig.3.1b and 
Fig.3.1c). The illumination block  consists of a custom-made laser combiner, including three laser lines: 
473 nm (DPSSL  MBL-III-473-50), 561 nm (Coherent OBIS 561-50 LS) and 638 (LuxX 638-150, Omicron 
Laserage), selected using an Arduino. Laser scanning is carried out in the vertical axis using two Arduino 
controlled galvanometric mirrors (GVS201, Thorlabs), in which the optical plane is conjugated with the 
back focal aperture of two objective lens (10x, 0.3NA, WD 16.3 mm, Plan Fluor) using a 4x telescope 
system. For detection, a water immersion objective (16x, 0.8NA, WD 3.0 mm, Nikon), placed 
perpendicularly to the excitation plane, is used to collect fluorescence emission. Excitation light is rejected 
using emission filters placed in infinity space before the camera. Finally, a 200 mm tube lens creates the 
image on the chip of the sCMOS cameras  (Orca-Flash4, Hamamatsu) (Fig.3.1e). Each sample is moved 
across the plane of light created and virtually sectioned for eight different angles. Rotation is controlled 
through custom Java plugin (OPenSpin) for Micromanager (Fig.3.1f). 
 After image  acquisition, images were aligned and reconstructed using the different tools available in 
Fiji’s open source plugin BigStitcher[185].  
 
 3.3.6.3.3. LSFM: sample mounting 
 Fixed samples (consult 3.3.6.3.1) were embedded on 2% Phytagel™ (Sigma-Aldrich) inside a FEP tube 
(O.D. 5 mm) (Fig.3.1d). FEP tubes are ideal for light-sheet fluorescence microscopy, since their refractive 
index is very close to that of water, reducing the optical aberrations and thereby providing a better 
environment to the samples with high optical clarity[166,187]. This is critical in thick, highly scattering and 
inhomogeneous samples (e.g. 3D hiPSC-CM/ECMC triculture model), being a fitting strategy for the 
generated 3D cardiac models[165,166,169,179,180]. The tube is then inserted in a rotational stepper motor for 
sample rotation, which is attached to a linear stepper motor for sample scanning through the light-sheet.  
 Datasets were individually recorded and, then, fused to generate a faithful 3D volume reconstruction 
of the whole models. In order to perform multi-view reconstructions, we acquired eight different angles 
per sample (0o to 360o), with an incremental step of 45o.  
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Figure 3.1 | Light-sheet fluorescence microscopy experimental setup [adapted from Gualda et al. (2014)[165] and 
Gualda et al. (2015)[180]. 
(a) Top view of the light-sheet, including the objective and cell culture chamber for single plane illumination microscopy (SPIM). 
(b) Front view of light-sheet. (c) Perspective view of the light-sheet. (d) Diagram of the sample chamber, where a FEP crosses 
at 45 o. Laser illumination is represented in green and FEP tube in blue. (e) Schematic depiction of the LSFM experimental setup. 
Key elements comprise: Argon/Krypton laser (L), excitation filter wheel (FW1), shutter (S), galvanometric mirror (GM), excitation 
objective (EO), 3.5x lens telescope (LT), detection objective (DO), sCMOS camera (C), tube lens (TL), emission filter wheel (FW2), 
translational stage (TS), stepper motor to rotate the sample (SM), Arduino board (AB) and a sample chamber (SC) for water 
immersion objectives. (f) Front panel of the custom Java plugin (OPenSpin) for Micromanager. It allows a full control of the 






























 3.3.6.3.4. LSFM: fibronectin quantification 
 Since it was possible to obtain realistic 3D volume reconstructions of the 3D hiPSC-CM mono- and 3D 
hiPSC-CM/ECMC triculture microcapsules, as proof-of-concept, an extracellular matrix protein, 
fibronectin, was quantified in both models. 
 In first place, data were sorted by image intensities, using Fiji's "Histogram" tool, in order to 
individualize the microcapsules and despise image artefacts. Subsequently, images containing 
microcapsules and different aggregates per microcapsule were processed with various Fiji tools to 
separate them properly and then estimate the volume of fibronectin. Finally, using Fiji’s open source 
plugin "3D Objects Counter", fibronectin volume was estimated in each of the 3D cardiac tissue models. 
The results are presented as a ratio between the volume of fibronectin and the corresponding volume of 
the selected microcapsule, in both mono- and tricultures. 
 
 3.3.7. RT-qPCR: gene expression profiling 
 One, seven and fifteen days post-microencapsulation, alginate microbeads were dissolved with a 
chelating solution as indicated beforehand (consult 3.2) and centrifuged at 300 x g for 5 min. Pellets were 
snap-frozen and kept at –80 oC until RNA isolation.  
 Total RNA was extracted with High Pure RNA Isolation Kit (#11828665001, Roche), according to 
manufacturer’s instructions. Before proceeding with cDNA synthesis, RNA concentration (ng/mL) and 
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purity (A260/A280 and A260/A230 absorbance ratios) were spectrophotometrically determined in a 
microvolume UV-Vis spectrophotometer (NanoDrop™ 2000c, Thermo Scientific). 
 cDNA was synthesized from 80 ng of RNA per sample, using Transcriptor High Fidelity cDNA Synthesis 
Kit (#081955001, Roche), following manufacturer’s instructions. In brief, reverse transcription comprised: 
(i) an initial step of RNA secondary structures’ denaturation, completed at 65 oC (10 min), (ii) a reverse 
transcriptase incubation step, optimized for 55 oC (30 min) and (iii) a final temperature-mediated enzyme 
inactivation step, at 85 oC (5 min). 
 RT-qPCR relative quantification of gene expression was performed using LightCycler® 480 Probes 
Master (#04707494001, Roche), following manufacturer’s instructions. In short, a 10 µL reaction 
contained 2.5 µL cDNA template (undiluted), 0.5 µL TaqMan® Gene Expression Assay (20X concentrated), 
5 µL LightCycler® 480 Probes Master (2X concentrated) and 2 μL water (PCR-grade). Amplification 
reactions were performed in a 384 well plate format using a LightCycler® 480 Real-Time PCR System 
(Roche). Threshold cycle values (CT) were determined using LightCycler® 480 Software, v.1.5 (Roche). Data 
were analysed using the 2-ΔΔCT method for relative gene expression quantification, as described by Livak 
and Schmittgen (2001)[188], and consist of technical triplicates. Variations in relative expression were 
normalized to GAPDH and RPLP0 housekeeping genes as internal controls. 
 All information regarding TaqMan® Gene Expression Assays, used in RT-qPCR gene expression analysis, 
is displayed in Annex 1.2, Table S3. 
 
 3.3.8. Structural and ultrastructural assessment 
 3.3.8.1. Structural: histological/histochemical-based methods 
 At the start and endpoint (1 and 15 days after microencapsulation, respectively) of the 
microencapsulated 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC triculture cardiac tissue models, culture 
samples were collected and fixed as previously described (consult 3.3.6). Fixed cells were washed twice 
with DPBS and stored at 4 oC, until histochemical staining. 
 Alginate microcapsules were pelleted, embedded in 2% (w/v) high melting temperature agarose 
(Lonza), dehydrated in a graded series of alcohols and then embedded in paraffin wax (Merck Millipore). 
 Paraffin blocks were sectioned (3 μm thickness) on a rotary microtome (RM 2135, Leica) for 
Hematoxylin and Eosin (H&E; Sigma-Aldrich), Toluidine Blue (TB; EMS), Masson Trichrome with Aniline 
Blue (MT; IHC WORLD, Woodstock, MD, USA), Picrosirius Red (PSR; Polysciences Europe GmbH, 
Eppelheim, Germany) and Periodic Acid-Schiff (PAS; Sigma-Aldrich) histochemical staining, following 
manufacturer’s instructions. 
 Histological images were digitalized in a NanoZoomer SQ whole slide scanner (Hamamatsu Photonics) 
and viewed with NDP view software (NDP.view, v.2.3, Hamamatsu Photonics). Fiji was used to linear 
brightness and contrast adjustments[185]. 
 
 3.3.8.2. Structural: scanning electron microscopy (SEM) 
 At the endpoint (15 days after microencapsulation) of the microencapsulated 3D hiPSC-CM mono- and 
3D hiPSC-CM/ECMC triculture cardiac tissue models, culture samples were collected and fixed as 
previously described (consult 3.3.6). Fixed cells were washed twice with DPBS (Thermo Fisher Scientific) 
and stored at 4 oC until preparation for scanning electron microscopy (SEM). 
 After washes with Milli-Q water and further dehydration, samples were dried in adhesive carbon tabs 
(12mm, Agar Scientific), developed to eliminate background noise from SEM imaging. Before 
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visualization, an Au/Pd film of 15 nm was deposited to avoid charging effects. Surface and cross-section 
SEM observations were carried out using a scanning electron microscopy workstation (Carl Zeiss AURIGA 
CrossBeam, FIB-SEM).  
 
 3.3.8.3. Ultrastructural: transmission electron microscopy (TEM) 
 At the start and endpoint (1 and 15 days after microencapsulation, respectively) of the 
microencapsulated 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC triculture cardiac tissue models, culture 
samples were collected and fixed as previously described (consult 3.3.6). Fixed cells were washed twice 
with DPBS and stored at 4 oC until preparation for transmission electron microscopy (TEM). 
 A second fixation was performed using 2% (v/v) paraformaldehyde (EMS) and 2.5% (v/v) 
glutaraldehyde (Polysciences) in 0.1M phosphate buffer (PB), for 1 hour at 4 oC. Cells were washed three 
times with PB and then were embedded in 2% low melting point agarose (OmniPur) for further processing.   
 Post fixation was achieved with 1% osmium tetroxide (w/v) (EMS) in 0.1M PB, for 30 min at 4 oC, in the 
dark. After two washes with 0.1 M PB and two washes with distilled water, samples were incubated with 
1% aqueous tannic acid (w/v) (EMS) for 20 min at 4 oC. After five washes with distilled water, samples 
were contrasted with 0.5% aqueous uranyl acetate (w/v) for 1h at 4 oC, in the dark. Afterwards, they were 
washed three times with distilled water, dehydrated in a graded series of ethanol (30%, 50%, 75% at 4 oC, 
90%, 100%) and embedded in EMbed-812 epoxy resin (EMS). Ultrathin sections of the 3D cardiac tissue 
models were cut on a ultramicrotome (EM UC7, Leica), using a diamond knife. Sections were collected on 
grids coated with 1% (w/v) formvar (Agar Scientific) in chloroform (VWR) and stained with 1% (w/v) uranyl 
acetate and Reynolds lead citrate, for 5 minutes each. Images were acquired on a transmission electron 
microscope (H-7650, Hitachi) at 100 keV, equipped with a XR41M mid mount AMT digital camera.   
  
 3.3.8.3.1. Quantification of ultrastructural features 
 Sarcomere length was estimated by measuring two parallel segments, per sarcomere, joining adjacent 
Z lines. Sarcomere angle dispersion was determined as previously described by Correia et al. (2017)[84].  
In brief, sarcomeric alignment is defined as the inverse of the magnitude of angle dispersion (SEM of 
sarcomere angles), meaning that a low angle dispersion specifies a high degree of alignment. SEM of 
sarcomere angles, σM, was calculated by the quotient between the standard deviation of the distribution 




stands for standard error of the mean. Measurements were performed in Fiji open source software[185]. 
 
 3.3.9. Functional assessment: live cell calcium imaging 
 Live cell calcium imaging was used to evaluate intracellular Ca2+ spontaneous and pharmacologically 
induced-transients, in 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC tricultures, at the endpoint of the 
models. Live cell calcium imaging workflow is schematically represented in Fig.3.2. 
 The technique was performed using the Fluo-4 Direct™ Calcium Assay Kit (Thermo Fisher Scientific), 
according to the manufacturer’s instructions. In brief, alginate microbeads were transferred onto μ-Slide 
4 Well (Ibidi). Subsequently, they were incubated with 1:2 calcium indicator fluorescent dye Fluo-4 
Direct™ calcium assay reagent (Thermo Fisher Scientific; diluted in a 1:1 mixture of RPMI/B27-ins and 
ECGM2), for 45 min at 37 oC, followed by 15 min at RT. Fluo-4 exhibits excitation at 494 nm and emission 
at 516 nm and its fluorescence intensity, at 494 nm, is 100-fold enhanced upon Ca2+ binding. After two 
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more washes with the culture media mixture, cardiac tissue models were analysed either alone or in the 
presence of different cardioactive drugs.  
 In these pharmacological tests, they were incubated with the target compounds for approximately 5 
min before acquisition. Specifically, pharmacological responses of hiPSC-CM, in both mono- and triculture 
models, exposed to 60 µM norepinephrine (β1-adrenergic receptor agonist; norepinephrine bitartrate, 
Sigma-Aldrich), 40 µM heptanol (gap junction uncoupler; Sigma-Aldrich), 4 µM propranolol (β-blocker; 
propranolol hydrochloride, Sigma-Aldrich) and, finally, 4 µM propranolol and thereafter 60 µM 
norepinephrine, were evaluated. 
 Optical recordings of intracellular Ca2+ transients were acquired using a spinning disk confocal 
microscope (system: Revolution XD, Andor; microscope: Eclipse Ti-E, Nikon; confocal scanner: CSU-X1, 
Yokogawa) and 30 sec videos were recorded through Micro-Manager 1.4 software (Fig.3.2, left panel). 
 Fluorescence peaks were extracted from a manually selected whole mount spheroid and then 
generated by the Fiji open source software “Z-axis Profile” plot tool (Fig.3.2, middle panel). Using an in-
house developed MATLAB (version R2016a, MathWorks) script, which has as input Fiji results, the 
different parameters of calcium kinetics are then returned (Fig.3.2, right panel), viz. peak amplitude 
(ΔF/F0), maximal upstroke velocity (ΔF/F0/s), maximal decay velocity (ΔF/F0/s), rise to peak time (s), peak 
to 50% decay time (s), peak to 80% decay time (s). The remaining parameters analysed for calcium kinetics 
– time between peaks (s) and beating rate (beats/min) – were analysed manually afterwards. 
 
 3.3.10. Biomaterial mechanobiological characterization: atomic force microscopy (AFM) 
 AFM-based mechanical dynamic characterization was performed to compare the mechanobiological 
behaviour of the hydrogel-based scaffold (in the absence of cells), mono- and triculture, 15 days after 
microencapsulation. Samples were collected and fixed as indicated beforehand (consult 3.3.6). Fixed 
samples were washed twice with DPBS and stored at 4 oC, until AFM analyses. 
 Alginate microcapsules were embedded in 2% (w/v) high melting temperature agarose (Lonza), 
forming a thin film, which was hydrated immediately prior to AFM acquisitions. 
 AFM measurements were performed in an AFM system (MFP-3D Stand Alone, Asylum Research) 
operated in alternate contact mode (AC mode). For measurements in native conditions (i.e. liquid 
Figure 3.2 | Schematic workflow of live cell calcium imaging: video acquisition and data processing.  
1. Microscopy Videos: Cardiac tissue models were imaged using a spinning disk confocal microscope (system: Revolution XD, 
Andor; microscope: Eclipse Ti-E, Nikon; confocal scanner: CSU-X1, Yokogawa) and 30 sec videos were recorded through Micro-
Manager 1.4 software (consult Annex 5, 5.2. List of videos: spinning disk confocal microscopy, Fig.S12).  
2. Fluorescence Profile: Fluorescence peaks were extracted from a manually selected whole mount spheroid and then generated 
by the Fiji open source software “Z-axis Profile” plot tool.  
3. Parameters: Using an in-house developed MATLAB (version R2016a, MathWorks) script, which has as input Fiji results, the 
different parameters of calcium handling kinetics are then returned. 
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environment), two types of commercially available AFM probes were used: BL-AC40TS (f0 = 110 kHz; k = 
0.09 N/m; Olympus Micro Cantilevers) and AC240TS (f0 = 70 kHz; k = 1.7 N/m; Olympus Micro 
Cantilevers); for measurements in air, only AC160TS (f0 = 300 kHz; k = 26 N/m; Olympus Micro Cantilevers) 
was used. Images were plane-fitted prior to reproduction. Gwyddion, an open-source software 
programme (Gwyddion, v.2.51,  http://gwyddion.net), was used to analyse and construct AFM 2D and 3D 
images (e.g. topographical or phasing imaging). Using AFM images, by measuring two perpendicular 
diameters, per pore, the biomaterial-scaffold average pore diameter was estimated. 
 Force spectroscopy mode-atomic force microscopy (FS-AFM) curve acquisition was performed in 
liquid, relying on the same probes. The resulting curves were analysed using Asylum Research's software 
packages installed in IGOR Pro software (WaveMetrics) and, at least, three capsules per condition were 
considered. Via FS-AFM, relevant biomechanical parameters, that can be correlated with a remodelling 
of cardiac microenvironment, were also quantified –  Young’s modulus, stiffness, hardness and adhesion 
– for the biomaterial-based scaffold and for mono- and triculture models (endpoint quantification). 
 
3.4. Cardiotoxicity assays with chemotherapeutic drugs 
 Doxorubicin (cardiotoxic anthracycline, MW: 579,980 g/mol; doxorubicin hydrochloride, MedChem 
Express) and paclitaxel (cardiotoxic taxane, MW: 853,906 g/mol; Taxol®, Paclitaxel Farmoz) were 
dissolved in stock solutions (10 mg/mL and 6 mg/mL, respectively) and were serially diluted (final 
concentrations: 0.1, 0.5, 1, 5, 10, 50 and 100 µM).  
 At the endpoint, samples of the microencapsulated 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC 
triculture cardiac tissue models were dispensed into 96-well plates and incubated with 1X PrestoBlue™ 
Cell Viability Reagent (diluted in a 1:1 mixture of RPMI/B27-ins and ECGM2) for 3h at 37 oC, with gentle 
agitation, in the dark. As described earlier (consult 3.3.2), fluorescence was measured at the excitation 
and emission wavelengths of 560 and 590 nm, correspondingly. This timepoint was considered as the 0h. 
Then, the exhausted culture medium, containing PrestoBlue™, was removed and the samples were 
incubated with serial dilutions of the anticancer drugs (doxorubicin and paclitaxel, diluted in a 1:1 mixture 
of RPMI/B27-ins and ECGM2 containing 1X PrestoBlue™ Cell Viability Reagent), for 72h at 37 oC, with 
gentle agitation, in the dark. Fluorescence was read again, as previously described. 72 and 0h fluorescence 
intensity values (RFU, relative fluorescence units) were initially normalized per spheroid. Final RFU values 
are the quotient between 72 and 0h (untreated controls). Analyses consisted of three technical replicas. 
Controls (subtracted from the mean of the three technical replicas) were also read, at 72 and 0h, and 
correspond to 1X PrestoBlue™ diluted in the culture media mixture. 
 
3.5. Upscaling the 3D cardiac tissue models to stirred-tank bioreactors 
 At day 7, hiPSC-CM were harvested and dissociated as indicated earlier (consult 3.1.2).  
 hiPSC-CM (100 x 106 cell) were then inoculated in a 200 mL (inoculum: 0.5 x 106 cell/mL) software-
controlled stirred-tank bioreactor (DasGip cellferm-pro bioreactor system, Eppendorf AG, Hamburg, 
Germany) (Fig.3.3). Culture conditions were set to maintain cells under 3% pO2 (15% of air with 21% of 
oxygen; atmospheric hypoxic environment), 37 oC and an initial stirring rate of 60 or 80 rpm (explained 
below). Two independent bioreactor experiments were performed, with the aim of optimizing the  
aggregation of hiPSC-CM in STBRs (preliminary results). In the first, perfusion operation mode was 
activated at day 10, with a dilution rate of 0.30 day-1. Stirring rate was originally set to 60 rpm and, at day 
9, was increased to 70 rpm and thus maintained until day 18. In the second, perfusion was started at day 
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9, with the aforementioned dilution rate. Stirring rate was initially set to 80 rpm and, at day 11, was 
increased to 90 rpm and thus maintained until day 18 (BR culture time: 12 days; day 7 to 18). 
 At day 18 of hiPSC-CM differentiation, 3D hiPSC-CM spheroids were collected from the STBR and 
approximately 14 x 106 cells were dispersed in 3 mL of the 1.1% (w/v) alginate equimolar mixture (consult 
3.2), dissolved in NaCl 0.9% (w/v) solution (Merck Millipore). Then, spheroids were microencapsulated 
either alone (3D hiPSC-CM monocultures), or together with hiPSC-ECMC (3D hiPSC-CM/ECMC tricultures), 
differentiated in parallel as described in 3.1.3, in a 1:2 ratio (about 28 x 106 ECMC), for an approximate 
total of 42 x 106 CM/ECMC, following the procedure described in 3.2. 
 Finally, re-inoculation in two similar bioreactor vessels (working volume: 250 mL; DASbox, Eppendorf 
AG, Hamburg, Germany) was performed: one of them was inoculated with the monoculture 
microcapsules, whilst the other with the triculture ones. As a proof-of-concept, 3D cardiac tissue models 
were both maintained in culture for only 6 days (post-microencapsulation). 
 FDA-PI live-dead double staining, spheroid and microcapsule concentration, distribution of spheroids 
per microcapsule, spheroid and microcapsule size determination, flow cytometry of the starting 
populations and immunofluorescence (in monolayers and in whole capsules) were determined as 
previously described for the primary models established in shake flask (consult 3.3). 
 
3.6. Statistical analysis 
 Statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software). Data are 
mean ± standard deviation (SD) or mean ± standard error of the mean (SEM). The test statistics used to 
infer statistical differences between groups, as well as the number of biological independent experiments 
and technical replicates performed, are indicated in the figure captions of the section 4. Results and 
Discussion and in Annex. The significance level (alpha value) was fixed at 0.05 with a 95% confidence 
interval (CI). Statistical significance was defined based on p-value, P (ns – not significant, *P ≤ 0.05, ***P 
≤ 0.001, ****P ≤ 0.0001). Asterisks (*) denote significant differences. Whenever no statistical significance 
relationship is indicated in the graphs, consider it as ns – not significant, P > 0.05. All results will be 
exhibited with four significant figures. 
Figure 3.3 | Schematic illustration of the STBR apparatus used for hiPSC-CM aggregation (from day 7 to day 18), 
operating under perfusion mode [reproduced from Simão et al. (2016)[226]. 
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4. Results and Discussion 
 
4.1. Steps toward microencapsulation: experimental strategy, culture monitoring and 
phenotypic assessment, before microencapsulation 
 A 3D triculture cardiac tissue model, completely hiPSC-derived, was implemented. For this, a two-step 
strategy, based on (i) two separate hiPSC differentiations, toward CM or non-myocytes (endothelial and 
mesenchymal cells), encompassing (ii) a subsequent microencapsulation step in a biocompatible 
hydrogel, was employed. This experimental strategy is schematically summarized in Fig.4.1.  
Also, this type of dual strategy has already been used in our group (e.g. cancer 3D models)[178,179,182,189], 
yet never in the cardiac context. Accordingly, the model we are describing arises as a whole new concept. 
 The use of AggreWell™ plates was the primary strategy chosen for generating 3D hiPSC-CM spheroids, 
because it offers the benefit of obtaining spheroids with a very reduced size dispersion (Fig.4.2e; average 
spheroid diameter at day 18, prior to microencapsulation: 142.1 ± 26, 24 μm), as well as high cell 
viabilities, as can be seen in the FDA-PI live/dead double staining (Fig.4.2d). In addition, it is a user-friendly 
and standardized approach, consistent with high-throughput assays[1,79,91]. A uniform average spheroid 
diameter is indispensable for maintaining comparable mass and oxygen diffusional gradients between 
spheroids under similar culture conditions and, particularly, for ensuring reproducibility and a low batch-
to-batch variability, for instance, in high-throughput screening (HTS) assays[190]. Spheroids with diameters 
greater than 400-500 μm, typically lead to the formation of necrotic centres in their core, owing to oxygen 
and/or nutrients deprivation of the inner cells[190].  
With regard to other aggregation methods, such as those in stirred tank bioreactors, average spheroid 
diameter dispersion may be a very difficult factor to control, as will be demonstrated in section 4.9. 
 In parallel, at day 5 of hiPSC-CM differentiation (corresponding to day 0 of hiPSC-ECMC differentiation), 
the second differentiation was started (Fig.4.1, bottom), in 2D monolayer co-culture conditions. 
 The principle is similar to that of the myocyte differentiation, aiming for the initial 
formation/polarization of cardiac mesoderm, so as to engender the various types of cells of the 
cardiovascular system (consult 1.2.3). The focal difference will be the induction of endothelial and 
mesenchymal lineages through VEGF supplementation, which is one of the main factors responsible for 
initiating and regulating angiogenesis[191]. Furthermore, it has been widely reported in the literature that 
VEGF has the ability to induce differentiation into ECs[55,99,100,110]. 
 hiPSC phenotype before differentiations (Fig.4.2a) and those of hiPSC-cardiac derivatives (hiPSC-CM’s 
in Fig.4.2b and hiPSC-ECMC’s in Fig.4.2c), at the end of the differentiation/prior to microencapsulation, 
was routinely determined via flow cytometry. Unsurprisingly, hiPSC exhibited common 
pluripotency/stemness-related markers (Fig.4.2a; OCT4+: 64.16 ± 5.459, SSEA-4+: 91.90 ± 5.233 and TRA-
1-60+: 88.20) and absence of early differentiation markers (Fig.4.2a; SSEA-1: 0).  
 At day 15 of hiPSC-CM differentiation, spheroids displayed a phenotype agreeing with the 
differentiation protocol used[83,84], explicitly an expression of CM markers larger than 75% (Fig.4.2b, 3D 
hiPSC-CM, pink, black stripes; SIRPα/β+: 83.13 ± 3.635, cTnT+: 76.60 and VCAM-1+: 73.23 ± 6.746). A 2D 
cell control (Fig.4.2b, 2D hiPSC-CM, pale pink, black dots) was also maintained for comparison with 3D 
hiPSC spheroid differentiation (consult 3.1.2.2); however, at day 15, there was no significant statistical 
difference in SIRPα/β and VCAM-1’s expressions between 2D and 3D (Fig.4.2b, 2D hiPSC-CM and 3D hiPSC-
CM; P > 0.05, ns).  
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  With respect to the non-myocyte hiPSC-ECMC phenotype, evaluated at day 10 (day 15 of hiPSC-CM 
differentiation), it can be concluded that this differentiation consistently generates (data from four 
biologically independent experiments) a mixture of approximately 25% of ECs (Fig.4.2c; CD31+: 28.55 ± 
7.033 and VE-cadherin+: 19.87 ± 5.759), as demonstrated by the EC surface markers CD31 and VE-
cadherin, whereas the remaining 75% express concomitantly Vimentin and α-SMA, (Fig.4.2c; Vimentin+: 
89.98 ± 2.445 and α-SMA+: 34.98 ± 16.55), probably corresponding to cells of a mesenchymal lineage. 
 Almost 90% of the cells in the mixed ECMC population express Vimentin, which clearly reveals the 
prevalence of MCs, with only about 35% of cells expressing α-SMA, a marker for CFs and VSMCs[192]. For 
simplicity, we will always refer to a mesenchymal population, which most likely will not be pure; as such, 
we may even be in the presence of a “quadriculture” cell-based model, in which, along with CMs, there 
are also ECs, CFs and VSMCs. Identification of the mesenchymal subpopulations is also hampered by the 
fact that there are no fully specific markers for CFs or VSMCs[29,36,192–195].  
These FC results correspond to all the cell populations used to develop the models that will be discussed 
afterwards (consult List of Models). 
 To further characterize the ECMC phenotype, the expression of specific markers for ECs (VE-cadherin) 
together with MC markers (Vimentin, α-SMA or DDR2) was evaluated by immunofluorescence of the 
ECMC monolayers (Fig.4.2f). Nevertheless, it was not possible to draw much more conclusions than those 
already gotten via FC, namely the presence of an endothelial population (VE-cadherin+) and a larger 
mesenchymal population, which expresses Vimentin or DDR2, but does not express VE-cadherin. 
 Lastly, both hiPSC-CM spheroids and hiPSC-ECMC single cells were microencapsulated in 
biocompatible hydrogel scaffold (composed of a 1:1 mixture of conventional non-RGD alginate and RGD 
peptide-coupled alginate), which provides a 3D controllable, inert and chemically defined 
microenvironment (unlike, for instance, Matrigel) for the cells to physically attach and communicate. 3D 
hiPSC-derived cardiac tissue models were then kept in shake flask culture for, at least, 15 days (Fig.4.1). 
  
Figure 4.1 | Experimental strategy – in vitro reconstruction of the in vivo heart microenvironment. 
Schematic illustration of the culture strategy for the final 3D triculture hiPSC-derived cardiac tissue model, as well as for the 3D 
mono- and co-culture models. Defined cardiovascular cell populations (hiPSC-CM spheroids and hiPSC-ECMC) were systematically 
differentiated from hiPSC. Representations of the models are not to scale. The key model players are also exhibited.  
Towards a bioinspired 3D triculture hiPSC-derived cardiac tissue model for human heart microenvironment recapitulation and 
drug testing 
P.G.M. Canhão Costa, September 2018 | 49 
 
Figure 4.2 | Monitoring and phenotypic characterization of hiPSC and hiPSC-derived cultures, before 
differentiation and prior to microencapsulation, respectively. (a-c) hiPSC and hiPSC-based cultures – hiPSC-CM and hiPSC-
ECMC – flow cytometry phenotypic characterization. Data are mean ± SD from two independent experiments (n = 2), for hiPSC 
and hiPSC-CM (a-b), and four (n = 4), concerning hiPSC-ECMC (c). (a) Percentage of positive hiPSC for the expression of common 
pluripotency stem cell markers (Oct-4, SSEA-4 and TRA-1-60) and spontaneous differentiation ones (SSEA-1), before 
differentiations. (b) Percentage of positive hiPSC-CM for SIRPα/β, VCAM-1 and cTnT cardiac specific markers, at day 15, prior to 
microencapsulation, in 2D monolayer (2D hiPSC-CM, control condition; pale pink, black dots) and 3D spheroid (3D hiPSC-CM; 
pink, black stripes) cultures. Ordinary two-way ANOVA analysis with Sidak’s post hoc test for multiple comparisons (ns – not 
significant, P > 0.05). (c)  Percentage of positive hiPSC-ECMC for CD31 and VE-cadherin endothelial specific markers and Vimentin 
and α-SMA mesenchymal markers, at day 10, prior to microencapsulation. (d) Evaluation of hiPSC-CM spheroids viability, 
through a live/dead assay, at day 18, prior to microencapsulation (Model #1-a–MCT-SF). Spheroids were stained with FDA 
(fluorescein diacetate) – live cells, green, and PI (propidium iodide) – dead cells, red. Scale bar, 200 µm. (e) Scatter dot plot 
displaying the hiPSC-CM average spheroid diameter, at day 18, prior to microencapsulation. Line at mean with SD. Data are 
mean ± SD from one independent experiment (Model #1-a–MCT-SF) (n = 92 spheroids). (f) Wide-field immunofluorescence 
microscopy representative images of the 2D hiPSC-ECMC co-culture, at day 10, prior to microencapsulation. 2D hiPSC-ECMC 
immunostained for the endothelial marker VE-cadherin (cyan) and for the mesenchymal markers Vimentin (green), α-SMA (red) 
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 Therefore, a heterotypic 3D hiPSC-CM/ECMC triple cardiac tissue model, encompassing the three 
aforementioned cardiac populations, in a cellular ratio (Fig.4.1) of around 33% hiPSC-CM spheroids to 
66% hiPSC-ECMC (i.e. 1 CM to 2 ECMCs), microencapsulated in this alginate hydrogel (consult 3.2), was 
generated (Fig.4.1, right, dashed text box). This cell ratio was selected in order to mimic the numbers of 
the different cardiac populations in the adult human heart, according with Bergmann et al. (2015)’s 
studies (for further detail, consult 1.1.2.4). 3D hiPSC-CM monocultures (only spheroids 
microencapsulated) and 3D hiPSC-ECMC co-cultures (microencapsulated hiPSC-ECMC monolayers) were 
also established (Fig.4.1, right, dashed text box) and in depth characterized for comparison with the 
triculture model, as will be demonstrated throughout this section.  
 hiPSC-CM spheroids viability characterization (Fig.S1a for Model #1-b–MCT-SF; and Fig.S1b for Pilot 
Model–M-SF), likewise evaluated via live/dead assays, as well as their average diameter (Fig.S1c for both 
Model #1-b–MCT-SF and Pilot Model–M-SF), concerning to two more independent experiments, are 
compiled in Annex 2.1. Model #1-b–MCT-SF is a biological replicate of Model #1-a–MCT-SF (Fig.4.2d and 
Fig.4.2e), whilst Pilot Model–M-SF consisted of a study in which only monocultures were 
microencapsulated and it was a relevant first step for the transition to the heterotypic triculture model 
(for supplementary information about the mentioned models, consult List of Models). 
 Again, these results demonstrate a high cell viability of the cardiac spheroids (Fig.S1a and Fig.S1b) and 
a slightly higher average spheroid diameter (221.6 ± 55.15) before microencapsulation, conferring 
reproducibility and validating the chosen aggregation method. 
 
4.2. After microencapsulation scenario: cell viability, metabolic activity and model 
monitoring and characterization 
 4.2.1. A heterotypic cellular crosstalk between hiPSC-CM and hiPSC-EC favours the survival 
of hiPSC-EC in the triculture model 
 Owing to the fact that the different cell populations – myocytes and nonmyocytes – are 
compartmentalized in close proximity within the biomaterial-based construct, one of the central 
hypotheses of this study is that a heterotypic crosstalk, mimicking certain features of the myocardium-
endocardium interactions taking place in the human heart[17,25,26,28] (consult 1.1.2 and 1.1.2.1), would be 
established, especially amongst hiPSC-CM and hiPSC-ECs, in the 3D triculture model.  
 Consequently, it is expected that there is a higher survival of hiPSC-EC in the triculture model, where 
they are in close contact with hiPSC-CM, instead of the coculture model. In both, hiPSC-EC are in the 
presence of hiPSC-MC, at a similar ratio and culture circumstances. 
 In order to substantiate our hypothesis, a qualitative assessment of the microencapsulated 3D hiPSC-
derived cardiac tissue models’ cell viability (Model #1-a–MCT-SF) over time (days 0, 1, 7, and 15 post-
microencapsulation) was performed using the FDA-PI live/dead assay (Fig.4.3a). 
 In Fig.4.3a it is possible to perceive that 3D hiPSC-CM monoculture and 3D hiPSC-CM/ECMC triculture 
conditions sustain a high cell viability during 15 days of culture. However, when looking at the 3D hiPSC-
ECMC model, we can observe that, at days 0 and 1, hiPSC-ECMC display high viabilities (Fig.4.3a, 
Coculture); however, from day 7 (Fig.4.3a, Coculture, red boxes), the cells begin to die, as shown by the 
intensification in PI’s red staining, with this tendency being extended until day 15.  
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Figure 4.3 | hiPSC-ECMC are not capable to survive in the absence of hiPSC-CM, denoting positive evidence of 
heterotypic cellular communication in the triple model (Model #1-a–MCT-SF). (a) Qualitative assessment of 3D hiPSC-
based cardiac tissue models’ (hiPSC-CM mono-, hiPSC-ECMC co- and hiPSC-CM/ECMC triculture) cell viability over time (from left 
to right: 0, 1, 7 and 15 days after microencapsulation), cultured under similar circumstances. Highlighted (red boxes): co-culture 
on days 7 and 15, post-microencapsulation. Cultures were stained with FDA (fluorescein diacetate) – live cells, green, and PI 
(propidium iodide) – dead cells, red. Scale bars, 500 µm. (b) Cell viability quantification in the different 3D cultures, throughout 
the culture time (days 2, 7, and 15 post-microencapsulation), using a PrestoBlue resazurin–based dye assay. Data are mean ± SD 
from one independent experiment and consist of three technical replicates (n = 3). Ordinary two-way ANOVA analysis with 
Tukey’s post hoc test for multiple comparisons (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). Fluorescence intensity 
values (RFU, relative fluorescence units) were normalized to the number of capsules, counted per well, and to the maximum of 
fluorescence intensity, verified in the three timepoints considered. Excitation and emission wavelengths were 560 and 590 nm, 
respectively; gain was 176. (c) Spheroids per microcapsule distribution, in mono- and triculture, 1 day after microencapsulation. 
(d) Characterization of the behaviour of the encapsulated models in terms of (d1) spheroid (mono- and triculture) and (d2) 
microcapsule (mono-, co- and triculture) concentration, over time (0, 1, 7 and 15 days after microencapsulation). 
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This result seems to be in line with hypothesis put forward: hiPSC-EC are communicating with hiPSC-CM, 
in the triple model, and this communication is vital for their survival, since, in the coculture, they do not 
subsist in CMs absence. 
 Aiming to validate these results, we quantified cell viability over time (days 2, 7, and 15 post-
microencapsulation) using PrestoBlue™ resazurin-based dye assay (for further detail, consult 3.3.2), as 
shown in Fig.4.3b.  
 At day 2, both 3D mono- and coculture cardiac models exhibit comparable metabolic activities 
(Fig.4.3b, Monoculture and Coculture), with the triculture demonstrating higher values (Fig.4.3b, 
Monoculture vs. Triculture at day 2, *). Nonetheless, at day 7, as hypothesized and in agreement with 
live/dead results (Fig.4.3a), there is an sudden decrease (Fig.4.3b, indicated by the red down arrow) in 
metabolic activity in the coculture model (day 2 vs. day 7, **), extendable until day 15 (day 2 vs. day 15, 
**). Hence, we ended up focusing on mono- and triculture models: the coculture, as will be realized, was 
then abandoned in many of the performed characterizations.  
 Regarding the remaining models, monoculture maintains its metabolic activity over the 15 days (there 
are no significant statistical differences in monoculture over this period; Fig.4.3b), whereas the triculture, 
from day 7 to 15, discloses a significant increase of metabolic activity (Fig.4.3b, day 7 vs. day 15, **).  
 Thus, it should be emphasized that, at day 15 (endpoint), the triculture model displays a metabolic 
activity significantly higher than that of its control counterparts (Fig.4.3b, Triculture vs. Monoculture at 
day 15, ** and Triculture vs. Coculture, ****), which may be linked with hiPSC-ECMC proliferation in this 
model.  
 Spheroids per microcapsule distribution (Fig.4.3c) at day 1 post-microencapsulation, as well as the 
behaviour of the encapsulated models (Fig.4.3d), in terms of spheroid (Fig.4.3d1) and microcapsule 
(Fig.4.3d2) concentration over time (0, 1, 7 and 15 days after microencapsulation), were also evaluated.  
 These results reveal the absence of empty capsules (Fig.4.3c); nevertheless, a wide dispersion of 
spheroids per microcapsule is verified (Fig.4.3c). This may be due to the fact that in Model #1-a–MCT-SF 
the average microcapsule diameter is much higher (1546 ± 62.05 µm, instead of 700-800 µm, for the 
remaining models, as shown in Annex 2.2, Table S4 and Fig.S2), thereby tolerating the storing of a bigger 
number of spheroids per microcapsule. 
 This could be a disadvantageous factor when using this sort of models for high-throughput drug 
screening assays, which require fairly standardized responses[21,22,190]. The way to circumvent this obstacle 
will be, prior to the incubation of a given compound, counting the number of microcapsules and 
corresponding spheroids, in each well, and carry out a subsequent normalization.  
 Concerning the models’ behaviour, it is possible to notice that both spheroid (Fig.4.3d1) and 
microcapsule concentrations (Fig.4.3d2) slightly decrease at day 1 post-encapsulation, and then remain 
constant until day 15, indicating the stability of the engineered cardiac models. This initial decrease may 
be explained by a certain adaptation of the cell populations in the first days of culture (Fig.4.3d1) and by 
the mechanical disruption of some microcapsules during the microencapsulation and succeeding 
inoculation step in shake flasks (Fig.4.3d2).  
 
 4.2.2. Depending on the RGD peptide-coupled alginate proportion, RGD motifs exert agonist 
or antagonistic effects on hiPSC-EC 
 To study the impact of the scaffold’s RGD motifs on cell survival and proliferation (for further detail, 
consult 1.3.3.2.3), a new batch was generated (Model #1-b–MCT-SF), in which, in addition to the 
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mentioned models (mono-, co- and triculture, microencapsulated in a mixture containing 50% RGD 
peptide-coupled alginate), the new ones were established in 100% RGD peptide-coupled alginate. 
 Pursuing a similar strategy, the same trend was detected for the replicates of the previous batch 
(Fig.4.4a, Monoculture50, Coculture50, Triculture50), in which the viability of mono- and tricultures was 
maintained over the culture time, whilst the coculture’s noticeably decreases after day 7 post-
microencapsulation (Fig.4.4a, Coculture50). 
 Increasing RGD peptide-coupled alginate proportion does not appear to impact the survival of 
monocultures, which continuously maintain a high cell viability, regardless of whether they are 
encapsulated in a peptide-modified scaffold with 50% or 100% RGD motifs (Fig.4.4a, Monoculture50 and 
Monoculture100). Though, contrariwise to what would be expected, when using a scaffold consisting solely 
of 100% RGD peptide-coupled alginate, it is found that the co-culture’s cell death tendency, on days 7 and 
15, is now also extended to the triculture model (Fig.4.4a, Coculture50, Coculture100 and Triculture100). 
 Hence, we can conclude that increasing RGD peptide-coupled alginate ratio up to 100% in the 
microcapsule scaffold does not entail benefits for hiPSC-ECMC and is even detrimental, since it inhibits 
the heterotypic crosstalk in the triple model. 
 Albeit RGD (arginine-glycine-aspartate peptide sequence) is one of the most regularly found binding 
motifs attached to scaffolds[116,131], because of its ability to ultimately lead to the initiation of cell signalling 
for survival and proliferation[116,131], there is some disagreement regarding some of the its functions.
 Maubant et al. (2018)’s study[196], examining the impact of non-peptide mimetic RGD on human 
endothelial cells, demonstrates that these motifs, in addition to the declared agonist functions, may also 
exert an antagonistic activity, inducing detachment, caspases activation and apoptosis in HUVECs[196]. On 
the other hand, Matsuki et al. (2018)[197] also demonstrated that RGD peptides, at high concentrations, 
may exert an antagonistic effect, inducing apoptosis, via direct activation of caspase-3[197]. This leads us 
to conclude about the existence of an hypothetical threshold concentration (which will probably depend 
on the RGD-modified material), from which there is a modification in the nature of the promoted effects.  
 Moreover, a 50% RGD peptide-coupled alginate appears to be ideal to promote an agonist effect of 
hiPSC-EC survival, in the triple model (Fig.4.4a). 
 The metabolic activity of the biological replicas of the models shown in Fig.4.3b (50% RGD peptide-
coupled alginate) was also evaluated (Fig.4.4b), at days 7 and 14 post-microencapsulation, with similar 
results to those previously attained (Fig.4.3b). In these models, microcapsules with approximately half of 
the size (average microcapsule diameter: 832.7 ± 28.30 μm; consult Annex 2.2, Table S4 and Fig.S2) were 
obtained, which allowed a more compact spheroid per microcapsule distribution (Fig.4.4c), but also led 
to the existence of more empty microcapsules. 
 Model behaviour’s results also corroborate the inefficiency of the scaffold formed by 100% RGD-
peptide coupled alginate in encapsulating the triple model, with extremely low values of spheroid and 
microcapsule concentrations (Fig.4.4d1, Triculture-100: 1.500 ± 0.7071 spheroids/mL; and Fig.4.4d2, 
Triculture-100: 9.000 ± 1.414 microcapsules/mL). 
 Pilot experiment’s (Pilot Model–M-SF) results, relating to cell viability, metabolic activity, spheroid 
distribution per microcapsule and concentration of spheroids and microcapsules, are shown in Annex 2.2, 
Fig.S3. The microcapsule average diameters resulting from the different experiments (Pilot Model–M-SF, 
Model #1-a–MCT-SF, Model #1-b–MCT-SF and Model #2-b–MT-BR-2) is compiled in Annex 2.2, Table S4 
and Fig.S2. 
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Figure 4.4 | Increasing RGD peptide-coupled alginate proportion up to 100% in the microcapsule scaffold does not 
entail benefits for hiPSC-ECMC, inhibiting heterotypic communication in the triple model (Model #1-b–MCT-SF). 
(a) Qualitative assessment of 3D hiPSC-based cardiac tissue models’ (with 50 or 100% of RGD peptide-coupled alginate) cell 
viability over time (from left to right: 0, 1 and 14 days after microencapsulation), cultured under similar conditions. Highlighted 
(red boxes): co-culture50 and triculture100 on days 7 and 14, post-microencapsulation. Cultures were stained with FDA (fluorescein 
diacetate) – live cells, green, and PI (propidium iodide) – dead cells, red. Scale bars, 500 µm. (b) Cell viability quantification in 
the different 3D models over time (days 7 and 14 post-microencapsulation), using a PrestoBlue resazurin–based dye assay. Data 
are mean ± SD from one independent experiment and consist of three technical replicates (n = 3). Ordinary two-way ANOVA 
analysis with Tukey’s and Sidak’s post hoc tests for multiple comparisons (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). 
Fluorescence intensity values (RFU, relative fluorescence units) were normalized per capsule and to the maximum of fluorescence 
intensity. Excitation and emission wavelengths were 560 and 590 nm, respectively; gain was 176. (c) Spheroids per microcapsule 
distribution, in mono- and tricultures (50 and 100% of RGD peptide-coupled alginate), 1 day after microencapsulation. (d) 
Characterization of the behaviour of the encapsulated models, in terms of (d1) spheroid (monocultures and tricultures) and (d2) 
microcapsule concentration (monocultures, co-culture and tricultures). Error bars are mean ± SEM from one independent 
experiment, corresponding to the mean values of days 1, 7 and 14, post-microencapsulation (n = 3). Ordinary one-way ANOVA 
analysis with Tukey’s post hoc test for multiple comparisons (ns – not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). 
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4.3. RT-qPCR gene expression profiling unveils the first evidences of cardiac maturation  
 One way to circumvent hiPSC-CM immaturity is to create in vitro co-culture models comprising 
myocytes and non-myocytes (consult 1.3.1 and 1.3.2). Hence, another hypothesis to be tested would be 
that hiPSC-CM would disclose a more advanced maturation stage in the triculture model. 
 So, to investigate this hypothesis, we compared the expression of a broad panel of genes in mono- and 
triculture cardiac tissue models. Specifically, we quantified, via RT-qPCR, the relative expression of 
(Figs.4.5a-i) key structural genes involved in sarcomere assembly (MYL2, MYL7, MYH7, MYH6, TNNI3 and 
TNNI1) and (Fig.4.5j and Fig.4.5k) ion channels (L-type calcium: CACNA1C and sodium: SCN5A), over time. 
Expression ratios for gene isoforms associated with an adult/definitive ventricular phenotype, viz. 
MYL2/MYL7, MYH7/MYH6 and TNNI3/TNNI1 (Figs.4.5c,f,i, correspondingly) were also evaluated. 
 Gene expression profiling revealed positive evidence of cardiac maturation over time in both 3D hiPSC-
CM mono- and 3D hiPSC-CM/ECMC triculture. 
 MYL2 (Fig.4.5a), MYH7 (Fig.4.5d) and TNNI3 (Fig.4.5g) (isoforms more expressed in mature CMs) 
revealed an upregulated gene expression over the course of 15 days. Gene expression of the mature 
isoforms, at day 7, with the exception of MYL2 (Fig.4.5a, Monoculture vs. Triculture, **), revealed no 
differences between mono- and triculture, which indicates that 7 days in culture are not sufficient for 
hiPSC-ECMC to cause significant differences in hiPSC-CM maturation, in the triple model. At day 15, there 
are significant differences between the two models in the expression of all the adult isoforms 
(Figs.4.5a,d,g; MYL2: ****, MYH7: **** and TNNI3: ****). 
 Conversely, changes in fetal isoforms were also observed: MYL7 (Fig.4.5b), MYH6 (Fig.4.5e) and TNNI3 
(Fig.4.5h) maintained their expression approximately constant over the 15 days in the monoculture 
model, whereas, contrariwise to what would be expected, in the triculture model seems to exist a 
tendency of upregulation of these isoforms over time. 
 Therefore, to inspect whether or not there were differences in the maturation of hiPSC-CM between 
the two cardiac models, we decided to look at the expression ratios between adult and fetal isoforms 
(Figs.4.5c,f,i; MYL2/MYL7, MYH7/MYH6 and TNNI3/TNNI1). 
 Altogether, these ratios demonstrate a clear increase in expression at day 15, compared to day 7, 
indicative of cardiac maturation in both models over time and symbolizing chief structural changes 
associated with progression of heart development and fetal-to-postnatal transition[25,53,144]. Furthermore, 
MYL2/MYL7 (Fig.4.5c, Triculture vs. Monoculture, ****) and TNNI3/TNNI1 (Fig.4.5i, Triculture vs. 
Monoculture, ****) denote, at day 15, evidence of a more developed maturity stage of hiPSC-CM in the 
triple model. However, MYH7/MYH6 (Fig.4.5f) seems to indicate the opposite. 
 Giacomelli et al. (2017)[53] also obtained similar results, namely the upregulation of sarcomeric 
structural genes (e.g. MYL2, TNNT2 and ACTN2), increased MYL2/MYL7 ratio and upregulation of ion 
channel genes (e.g. SCN5A and CACNA1C) in cardiac microtissues (MTs) composed of hPSC-CM and hPSC-
EC, compared to those composed only of hiPSC-CM monocultures[53]. 
 Finally, the expression of transcripts of calcium (Fig.4.5j, CACNA1C) and sodium (Fig.4.5k, SCN5A) 
cardiac ion channels was also evaluated. Gene expression analysis, at day 15, agrees with the hypothesis 
of a higher maturation stage in the triple model (Fig.4.5j, CACNA1C: **** and Fig.4.5k, SCN5A: *). 
 These results are in line with those of Vuorenpää et al. (2017)[30], which also demonstrate an increased 
expression of SCN5A and CACNA1C, between days 7 and 18, in hPSC-CM cultured in the presence of a  
vascular-like network formed by human foreskin fibroblasts and HUVECs, in comparison to CMs alone[30]. 
In addition, as demonstrated by Burridge et al. (2014)[126], the expression of CACNA1C was shown to be 
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Figure 4.5 | RT-qPCR gene expression analysis discloses evidence of cardiac maturation over time, in both mono- 
and triculture cardiac tissue models (Model #1-a–MCT-SF). RT-qPCR gene expression analysis for (a-i) key sarcomeric 
genes (myosins: MYL2, MYL7, MYH7 and MYH6; and troponins: TNNI3 and TNNI1) and (j-k) ion channels (CACNA1C and SCN5A), 
in 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC triculture, over time (a-i: 1, 7 and 15 days post-microencapsulation; and j: 1 and 
15 days post-microencapsulation) and (k) 15 days post-microencapsulation. (c, f, i) Expression ratios for gene isoforms linked 
with an adult/definitive ventricular phenotype: MYL2/MYL7, MYH7/MYH6 and TNNI3/TNNI1, correspondingly. Data are mean ± 
SD from one independent experiment and consist of technical triplicates (n = 3). Ordinary one-way ANOVA analysis with Tukey’s 
post hoc test for multiple comparisons (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). Colour code of the asterisks indicates 
the experimental group. All values are normalized to GAPDH and RPLP0 housekeeping genes as internal controls. Monoculture: 
normalization to monoculture on day 1; triculture: normalization to triculture on day 1. 
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increased in hPSC-CM in co-culture with hPSC-EC and human amniotic mesenchymal stem cells (hAMSCs) 
[126]. Higher expression of SCN5A is achieved, for instance, in hPSC-CM matured by electrical stimulation, 
with a higher expression of SCN5A being therefore concerted with a more mature phenotype[198].  
 Still, further characterization is needed for us to be able to accurately state that, in fact, hiPSC-CM are 
in a more mature stage in the triculture model. 
 
4.4. Imaging-based phenotypic platform 
 To in depth characterize the morphology, cellular architecture and phenotype of the different 
populations involved in both mono- and triculture cardiac models, as well as to provide insight into the 
conjecture of a more advanced hiPSC-CM maturation stage in the triculture, an extensive imaging-based 
phenotypic platform has been implemented. 
 
 4.4.1. Confocal immunofluorescence in cryosections discloses novel evidences of hiPSC-CM 
maturation and cardiac microenvironment remodelling in the triculture 
 At the endpoint, both 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC triculture were evaluated for the 
expression of cardiac (Fig.4.6; cTnT, sarcomeric α-actinin and titin), cardiac maturation (Fig.4.7, Cx43, 
MLC-2a and MLC-2v), cytoskeletal (Fig.4.6; F-actin), ECM (Fig.4.8, collagen type I, collagen type IV and 
fibronectin), endothelial (Annex 3.1, Fig.S4; CD31) and mesenchymal (Annex 3.1, Fig.S4; Vimentin, α-SMA 
and DDR2), and cell polarity (Annex 3.1, Fig.S5; ZO-1) and proliferation (Annex 3.1, Fig.S5; Ki-67) proteins. 
 Confocal analysis (for further detail, 1.5.5.1) of cryosections demonstrate that, at day 15, cardiac 
spheroids express specific structural cardiac markers, viz. cTnT, sarcomeric α-actinin and titin, both in 
mono- (Fig.4.6a) and triculture (Fig.4.6b). F-actin staining displays assembly of an organized and striated 
myofibrillary structure, typical of developed sarcomeres in both models (Fig.4.6a and Fig.4.6b; observe 
insets). Based on the confocal immunofluorescence images and using only these markers, it was not 
possible to distinguish differences in the maturation level of hiPSC-CM spheroids from the two models. 
This analysis has been complemented with a quantitative ultrastructural characterization, via 
transmission electron microscopy (results presented in section 4.5). 
 In order to complement the discussed RT-qPCR gene expression results (consult 4.3), Cx43 expression 
(component of gap junctions; Fig.4.7), as well as MLC-2a’s (encoded by MYL7, representing an immature 
ventricular/atrial/nodal CM phenotype; Fig.4.7) and MLC-2v’s (encoded by MYL2, indicating a definitive 
ventricular phenotype; Fig.4.7) were similarly assessed.  
 Although quantifications of confocal images have not been carried out (given that they derive from 10 
μm’s cryosections and the corresponding reconstructions are laborious and difficult), Cx43 appears to be 
overexpressed in the triculture, meaning an increase in cell-cell contacts and occasionally formation of 
larger junctional plates (Fig.4.7b). 
 Moreover, this protein, in the triple model, is consistently distributed in the periphery of the cells 
(Fig.4.7b; observe insets), while, in monoculture, it seems to present a more arbitrary and disorganized  
pattern (Fig.4.7a, observe insets). Together with RT-qPCR results, this could symbolize another indication 
of a higher maturation of triculture’s cardiac spheroids. Regarding the expression of MLC-2a and MLC-2v 
(fetal and adult isoform, respectively), it was not possible to perceive substantial differences between the 
two cardiac models (Fig.4.7a and Fig.4.7b). 
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 Interestingly, when evaluating the expression of ECM proteins (Fig.4.8), hiPSC-CM/ECMC, in the triple 
model, seem to produce greater amounts of ECM proteins (Fig.4.8b, collagen type I, collagen type IV and 
fibronectin; observe insets), than hiPSC-CM in monoculture (Fig.4.8a; observe insets). 
 This arises as another hint of heterotypic cellular communication in the triculture model.  
 In this particular case, hiPSC-MC (e.g. CFs) may play a key role in the production of these proteins, 
inducing a remodelling within the scaffold (replicated cardiac microenvironment), via self-produced ECM. 
Hence, we demonstrate that alginate microcapsules allow the accumulation of collagen type I and IV, 
forming collagen fibres that are interspersed in the spheroids (Fig.4.8a and Fig.4.8b; observe insets), and 
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fibronectin (very notorious in the triculture; Fig.4.8b), mimicking a tissue-like architecture and 
contributing to cardiac remodelling within the capsules. Changes in matrix structural components 
Figure 4.6 | Mono- and triculture confocal imaging-based phenotypic characterization: cardiac markers (Model 
#1-a–MCT-SF). (a-b) Confocal immunofluorescence microscopy of 3D hiPSC-CM mono- (a) and 3D hiPSC-CM/ECMC triculture 
(b) microcapsules, in 10 µm thick cryosections, at the endpoint of the models (day 15 post-microencapsulation), in similar culture 
circumstances. Data are representative maximum intensity z-projections from one independent experiment. Mono- (a) and 
triculture (b) immunostained (from left to right) for the cardiac markers cTnT, sarcomeric α-actinin and titin (red), and for F-
actin (phalloidin, green). Nuclei were counterstained with DAPI (blue). (a-b) Insets indicate high magnification images of the 
corresponding white rectangles. All images acquired with a 63x 1.3NA (consult List of Abbreviations and Conventions) oil 
immersion objective (Leica Microsystems). Scale bars, 50 µm.  
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Figure 4.7 | Mono- and triculture confocal imaging-based phenotypic characterization: cardiac maturation 
markers (Model #1-a–MCT-SF). (a-b) Confocal immunofluorescence microscopy of 3D hiPSC-CM mono- (a, upper panel) and 
3D hiPSC-CM/ECMC triculture (b, lower panel) microcapsules, in 10 µm thick cryosections, at the endpoint of the models (day 15 
post-microencapsulation), in similar culture circumstances. Data are representative maximum intensity z-projections from one 
independent experiment. Mono- (a, upper panel) and triculture (b, lower panel) immunostained (from left to right) for gap 
junctions (Cx43, red) and for immature ventricular/atrial/nodal CM phenotype (MLC-2a, red), and for cTnT and for definitive 
ventricular phenotype (MLC-2v, green). Nuclei were counterstained with DAPI (blue). (a-b) Insets indicate high magnification 
images of the corresponding white rectangles. All images acquired with a 63x 1.3NA oil immersion objective (Leica 
Microsystems). Scale bars, 50 µm. 
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(collagen type I, collagen type IV and fibronectin) are, however, verified in both cardiac models (Fig.4.8a  
and Fig.4.8b). 
Garzoni et al. (2009)[114] obtained similar results: expression of sarcomeric tropomyosin, Cx43, collagen 
type IV, fibronectin and laminin, using a 3D model of CM spheroids supplemented either with ECs or bone 
marrow-derived mesenchymal stroma cells[114]. 
 Looking at Fig.S4 (Annex 3.1), it is possible to detect an endothelial population (hiPSC-EC), through 
CD31, and a mesenchymal one (hiPSC-MC), via Vimentin, α-SMA and DDR2 stainings, yet in a very reduced 
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Figure 4.8 | hiPSC-CM/ECMC, in the triple model, appear to produce greater amounts of extracellular matrix 
proteins than hiPSC-CM alone (Model #1-a–MCT-SF). (a-b) Confocal immunofluorescence microscopy of 3D hiPSC-CM 
mono- (a) and 3D hiPSC-CM/ECMC triculture (b) microcapsules, in 10 µm thick cryosections, at the endpoint of the models (day 
15 post-microencapsulation), in similar culture circumstances. Data are representative maximum intensity z-projections from one 
independent experiment. Mono- (a) and triculture (b) immunostained (from left to right) for the ECM proteins collagen type I, 
collagen type IV and fibronectin (green) and for cTnT (red). Nuclei were counterstained with DAPI (blue). (a-b) Insets indicate 
high magnification images of the corresponding white or green rectangles. All images acquired with a 63x 1.3NA oil immersion 
objective (Leica Microsystems). Scale bars, 50 µm. 
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proportion relative to hiPSC-CM spheroids. So, we realized that, in the triculture model, due to (i) the 
nature of the chosen scaffold and (ii) the immunofluorescence procedure itself, in which cryosections with 
a very reduced thickness (10 μm) are subjected to several washing steps (for further detail, consult 
3.3.6.2), hiPSC-ECMC (single cells) were lost during the washes. Accordingly, we decided to adapt in toto 
immunofluorescence protocols that allowed us to study whole microcapsules, while maintaining their 
integrity.  
 Furthermore, it also seems that some that some of the hiPSC-EC (Annex 3.1, Fig.S4; CD31, observe 
inset of the corresponding green rectangle) and hiPSC-MC (Annex 3.1, Fig.S4; DDR2, observe insets of the 
corresponding white rectangles) have migrated from the peripheral space, around the spheroids, to their 
core. Noteworthy, α-SMA and Vimentin also seem to be more pronounced in the triculture model, which 
is in line with the hypothesis of a hiPSC-MC-induced remodelling of the cardiac microenvironment. 
 Expression of ZO-1 and Ki-67 was also evaluated for the two cardiac models and the results are 
exhibited in Annex 3.1, Fig.S5. Again, there seems to be a greater expression of ZO-1 (a tight junction-
associated protein) in the triculture model (Annex 3.1, Fig.S5; ZO-1), which together with the upregulation 
of Cx43 (Fig.4.7b), indicates an increase in cell-cell contacts, correlated with cardiac maturation. There is 
no evidence of proliferative cells inside the spheroids (Annex 3.1, Fig.S4; Ki-67), since hiPSC-CM exhibit a 
post-mitotic state[199,200].  
 
 4.4.2. Whole mount immunofluorescence is consistent with an overexpression of ECM 
proteins in the triple model 
 4.4.2.1. Multiphoton microscopy 
 Using multiphoton microscopy (for further detail, consult 1.5.5.2), whole capsules of the mono- and 
triculture models were also evaluated for the expression of cardiac (Fig.S6; cTnT and sarcomeric α-actinin) 
and cardiac maturation (Fig.S7; MLC-2a and MLC-2v) markers, with similar conclusions to those obtained 
in cryosections (Fig.4.6 and Fig.4.7). Partial 3D volume reconstructions (3D projects) were created using 
this technique (Annex 3.3, 3D Projects 1–12). Multiphoton imaging-based phenotypic characterization of 
whole monocultures for the pilot experiment (Pilot Model-M-SF) is compiled in Annex 3.2, Fig.S8. 
 Multiphoton 3D projects have turned out to be quite useful to confirm the hypothesis hitherto 
postulated: there is, in fact, an increased production of ECM proteins by hiPSC-CM/ECMC, in the triple 
model (Fig.4.9b; collagen type I, collagen type IV and fibronectin; observe insets), when compared to 
hiPSC-CM monocultures (Fig.4.9a).  
 
 4.4.2.2. Light-sheet fluorescence microscopy 
 Nevertheless, the utmost innovation in our imaging-based characterization, in comparison to that of 
similar models[53,114,115,124,201–204], comes from the use of light-sheet fluorescence microscopy, which allows 
us to get multi-views of the same sample, by rotating it, culminating in faithful and realistic 3D volume 
reconstructions that, lately, permit quantification of certain markers of interest (for further detail, consult 
1.5.5.4). Besides, there are no cases in the literature that report the use of LSFM to characterize this sort 
of cardiac models. Thus, this technique was used to image mono- and tricultures, with the specific aim of 
further characterizing the endothelial and mesenchymal populations, as exposed in Fig.4.10a. 
 As predicted, the 3D reconstructions (Annex 3.4, LSFM Movies 1–6) exhibit a much more 
representative cellular ratio between hiPSC-CM spheroids and hiPSC-ECMC single cells in the triple model 
(Fig.4.10a, upper and middle panels).  
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 In addition, it is noticed that hiPSC-EC (Fig.4.10a, upper and middle panels; CD31+ and VE-cadherin+, 
green) and hiPSC-MC (Fig.4.10a, upper and middle panels; α-SMA+ and Vimentin+, red) are surrounding 
the spheroids; still, a proportion of hiPSC-EC have migrated in the capsule and were then internalized, 




































Figure 4.9 | Multiphoton 3D projects are consistent with a higher production of ECM proteins by hiPSC-CM/ECMC, 
in the triple model, when compared to hiPSC-CM monocultures (Model #1-a–MCT-SF).  
Multiphoton immunofluorescence microscopy of whole mount microencapsulated 3D hiPSC-CM mono- (a, upper panel) and 3D 
hiPSC-CM/ECMC triculture (b, lower panel), in similar culture circumstances, at day 15 post-microencapsulation. Data are 
representative maximum intensity z-projections and 3D projects (consult Annex 3.3, 3D Projects 7–12) from one independent 
experiment. Mono- (a, upper panel) and triculture (b, lower panel) immunostained (from left to right) for the ECM proteins 
collagen type I, collagen type IV and fibronectin (green). Nuclei were counterstained with DAPI (blue). (a-b) Insets indicate high 
magnification images of the corresponding green dotted rectangles. All images acquired with a 40x 0.8NA water immersion 
objective (Olympus), adding an optical zoom up to 2.5x; total magnification: up to 100x. Scale bars, 50 µm. 
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Figure 4.10 | Light-sheet imaging-based phenotypic in toto characterization of whole mount mono- and tricultures 
(Model #1-a–MCT-SF). (a) Light-sheet immunofluorescence microscopy of the whole mount microencapsulated cardiac 
tissue models: 3D hiPSC-CM mono- (left panel) and 3D hiPSC-CM/ECMC triculture (right panel), in similar culture circumstances, 
at day 15 post-microencapsulation. Data are 3D volume reconstructions of the whole models (consult Annex 3.4, LSFM Movies 
1–6), along eight different angles per sample (0o to 360o), with an incremental step of 45o, from one independent experiment. 
Mono- (left panel) and triculture (right panel) immunostained (from top to bottom) for the endothelial cell surface markers CD31 
(green) and VE-cadherin (green), for the mesenchymal markers Vimentin (red), α-SMA (red) and for the ECM protein fibronectin 
(red). Nuclei were counterstained with DRAQ5 (cyan). All images acquired with a 16x 0.8NA water immersion objective (Nikon), 
placed perpendicularly to the excitation plane. Scale bars, 100 µm. (b) LSFM-based quantification of the total fibronectin volume 




































On the other hand, it seems that hiPSC-MC (conceivably CFs) are adjacent to the hiPSC-EC, along the 
rudimentary microvasculature that has formed within the spheroids or, alternatively, in monolayer, 
together with hiPSC-EC (giving structural support) and around the spheroids (consult LSFM Movies 1–4). 
 These findings demonstrate the feasibility of an in vitro 3D triculture cardiac tissue model, fully derived 
from hiPSC, in which spheroids and monolayers are established within a confined biomaterial. 
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 The deposition of ECM proteins, specifically fibronectin, was also evaluated via LSFM (Fig.4.10a, lower 
panel; and Fig.4.10b). An extensive fibronectin network, reminiscent of a tissue-like architecture, was 
found in the triculture (Fig.4.10a, lower panel, right). In monocultures (Fig.4.10a, lower panel, left), it is 
also possible to observe fibronectin deposited on the spheroids, as described beforehand for confocal 
immunofluorescence in cryosections (Fig.4.8a). 
 A 45.6-fold increase in relative fibronectin expression was found in tricultures, at day 15, compared to 
monocultures (Fig.4.10b). Although the quantification methods are still being optimized (consult 
3.3.6.3.4), fibronectin’s upregulation in the triculture is evident. 
 A higher deposition of fibronectin in the triple model (hiPSC-ECMC-mediated) may be due to an 
increase in cell-cell interactions (heterotypic communication), leading to the hypothesized remodelling of 
the cardiac microenvironment[205], which, in turn, favours important cell-ECM interactions. In vivo, 
fibronectin is expressed during early development and in adult heart, increasing enormously following 
injury[205,206].  
 Taken together, these data demonstrate that the 3D hiPSC-CM/ECMC triculture mimics certain cellular 
and molecular features of the composition of human heart tissue. 
 
4.5. Structural and ultrastructural assessment 
 4.5.1. Ultrastructural analysis shows improved sarcomere length and myofibrillar alignment 
in the triculture model 
 Relevant ultrastructural elements of mono- and triculture models were analysed via transmission 
electron microscopy (TEM). To follow up the results and provide insight into the anatomy of the cardiac 
sarcomere, a simplified diagram is shown in Fig.4.11a. 
 Specifically, at the ultrastructural level, it is possible to observe, in both cardiac models, at the endpoint 
(Fig.4.11b), registers of highly organized sarcomeres, displaying aligned myofibrils, Z lines, gap junctions 
connecting adjacent hiPSC-CM and density of mitochondria (Fig.4.11b; observe insets). These features 
were not observed at the beginning of both models (1 day after microencapsulation; Fig.4.12), meaning 
a dramatic structural maturation over time, from day 1 to day 15. 
 At day 1, disorganized and forming sarcomeres (with chaotic myofibrillar alignment and split Z lines), 
as well as shorter and few gap junctions were detected (Fig.4.12; observe insets). There do not seem to 
be noteworthy differences in the density or mitochondrial area between days 1 and 15. Moreover, as 
would be expected, at day 1, there are no significant ultrastructural differences between mono- and 
triculture, since in the triple model the three populations were in close contact for a very short period of 
time, scarce to induce notorious ultrastructural changes in hiPSC-CM. 
 At day 15, (Model #1-a-MCT-SF; Fig.4.11c and Fig.4.11d; Annex 4.1, Table S5), sarcomere length 
(Fig.4.11c; Annex 4.1, Table S5) and sarcomere angle dispersion (Fig.4.11d; Annex 4.1, Table S5) were 
evaluated. 
 The resting sarcomere length increased significantly from 1.433 ± 0.1907 μm, in the monoculture, to 
1.521 ± 0.1342 μm, in the triple model (Fig.4.11c and Annex 4.1, Table S5; ** P = 0.0047). Although 
triculture’s value is still lower than those of other studies reported in the literature: 2.2 μm in Ronaldson-
Bouchard et al. (2018)'s[207] and 1.81 μm in Lundy et al. (2012)’s[208], both with late stage, adult human 
ventricular myocytes, is an important indication of a structural maturation in the triculture model. 
  
 
Towards a bioinspired 3D triculture hiPSC-derived cardiac tissue model for human heart microenvironment recapitulation and 
drug testing 









































Figure’s caption is shown on the following page 
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Figure 4.11 | 15 days after microencapsulation, hiPSC-CM, in the triple model, reveal enhanced ultrastructure 
properties, compared to those displayed in the monocultures, suggestive of cardiac maturation (Model #1-a–
MCT-SF). (a) Simplified diagram of cardiac sarcomere anatomy [reproduced from Hwang and Sikes (2015)[150]]. Sarcomere is 
the functional contractile unit in heart cardiomyocytes. Thin filaments, constituted by actin, are anchored in the Z-disc (or Z-line) 
and form momentary sliding interactions with thick filaments, composed mainly of myosin. Each of the thick filaments is bounded 
by six parallel thin filaments. Through α-actinin, the latter form crosslinking networks between adjacent sarcomeres, at the Z-
disc. In addition to the Z-disc, I-band and A-band are relevant ultrastructural properties defined by their components (actin, 
myosin and cytoskeleton proteins) and appearance in polarized light. Through microscopy, it can be observed that the darker A-
band matches up to the thick filament, whereas the lighter I-band is crossed by the six thin filaments and the analogous six titin 
proteins. (b) Representative TEM micrographs of 3D hiPSC-CM mono- and 3D hiPSC-CM/ECMC triculture cardiac tissue models, 
at day 15 post-microencapsulation. Registers of sarcomeres, displaying aligned myofibrils (MF) and organized Z-discs (Z), gap 
junctions (GJ) connecting neighbouring hiPSC-CMs (denoted as CM1 and CM2) and density of mitochondria (M). Insets indicate 
high magnification images of the corresponding grey, black or cyan rectangles. Scale bars, 500 nm (in both figures and 
magnifications). (c-d) Quantification of ultrastructural features: (c) sarcomere length (n = 40-52 sarcomeres; two-tailed Mann–
Whitney nonparametric test, **P = 0.0047) and (d) sarcomere angle dispersion (n = 8-15 sarcomeres; two-tailed unpaired t-
student test (*P = 0.0379), in mono- and triculture, at day 15 post-microencapsulation. (c-d) Data are mean ± SD from one 
independent experiment.  
Figure 4.12 | Ultrastructural characterization of mono- and triculture, 1 day after microencapsulation (Model #1-
a–MCT-SF). Representative TEM micrographs of 3D hiPSC-CM mono- (upper panel) and 3D hiPSC-CM/ECMC triculture (lower 
panel) cardiac tissue models, at day 1 post-microencapsulation. Registers of sarcomeres, displaying misaligned myofibrils (MF) 
and split Z-discs (Z), as well as A- and I-bands, smaller gap junctions (GJ) connecting neighbouring hiPSC-CMs (denoted as CM1 
and CM2) and density of mitochondria (M). Insets indicate high magnification images of the corresponding grey, black or cyan 
rectangles. Scale bars, 500 nm (in both figures and magnifications). 
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 The sarcomeric myofibrillar alignment was also found to be significantly higher in the triculture model, 
as shown by the reduction in sarcomere angle dispersion (Fig.4.11d and Annex 4.1, Table S5; decrease of 
5.535 ± 3.419, in mono-, to 3.039 ± 1.589, in triculture; * P = 0.0379).  
The increase in anisotropic alignment in the triple model, supported by the apparent upregulation of Cx43 
and ZO-1 in this model (consult 4.1.1), is a further indication of an enhanced triculture’s structural 
maturity[25,84,144,207–209]. 
 Altogether, TEM data show that, over 15 days, there were noticeable ultrastructural changes in both 
models, consistent with cardiac maturation and, particularly, with a more advanced hiPSC-CM maturation 
stage in the triple model.  
 Despite these evident ultrastructural changes, we failed to identify any clear T-tubule formation or 
presence of multinucleation, losing, at the ultrastructural level, to other models, in which it was possible 
to reach more advanced stages of maturation[207]. 
 TEM micrographs for a biologically independent experiment (Model #1-b–MCT-SF), at the beginning 
(Fig.S9) and endpoint (Fig.S10) of both mono- and triculture cardiac tissue models, are also exhibited in 
Annex 4.1, validating the results discussed in this topic. 
 
 4.5.2. Histological/histochemical-based characterization 
 To characterize spheroids’ structure and morphology, we performed histological analysis of paraffin 
sections of mono- and triculture cardiac tissue models, from two separate experiments, at the endpoint 
(15 or 14 days after microencapsulation; Fig.4.13). Pilot experiment’s histological characterization, 
involving only microencapsulated monocultures, is accessible in Annex 4.2, Fig.S11. 
 H&E histological stain allows us to observe nuclei, in purple tones (stained by hematoxylin, which binds 
to negatively charged nucleic acids, due to its basic nature/positive charge; Fig.4.13 and Annex 4.2, 
Fig.S11), along with eosinophilic structures, viz. cytoplasm and extracellular proteins, in pale pink (labelled 
by eosin, since it is acidic/negatively charged and, therefore, binds to acidophilic substances, for instance 
side chains of positively charged amino acids; Fig.4.13 and Annex 4.2, Fig.S11).  
 Via PAS stain, we detected the presence of glycoproteins (pink) in both mono- (Fig.4.13 and Annex 
4.2, Fig.S11) and tricultures (Fig.4.13). 
 Being a basic dye, Toluidine Blue (TB) binds to nucleic acids, labelling nuclei and heteropolysaccharides, 
such as glycosaminoglycans (GAGs). There were no differences between mono- and tricultures (Fig.4.13 
and Annex 4.2, Fig.S11), which in line with our expectations, as an increase in GAG content (e.g. 
chondroitin sulfates, hyaluronic acid or heparin) in the adult human heart is associated with 
pathophysiological processes of heart muscle injury[210,211]. 
 Interestingly, we found the existence of lumens and deposition of fibrillar type I collagen within the 
spheroids, confirmed by H&E (Fig.4.13 and Annex 4.2, Fig.S11; pale pink) and Masson Trichrome (MT, 
Fig.4.13a; blue) stains. Particularly, MT seems to indicate a higher ECM production in Model #1-a-MCT-
SF (Fig.4.13a; blue) compared to Model #1-b-MCT-SF (Fig.4.13b) and Pilot Model-M -SF (Annex 4.2, 
Fig.S11. It should be also noted that single cells (hiPSC-ECMC) are rarely found in the histological sections 
(3 μm thickness), which is explained by the fact that they are lost during the sectioning procedure.  
 The fact that the spheroids’ structure is not entirely compact is another technical obstacle to the 
implementation of microscopy techniques (consult 1.5.5.4), owing to the increased light 
scattering[162,163,165,166,169,180]. However, as aforesaid, immunofluorescence (cryosections combined with in 
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Figure 4.13 | Histochemistry and morphology analysis of mono- and tricultures from two separate experiments 
(Model #1-a–MCT-SF and Model #1-b–MCT-SF). (a-b) Histochemistry characterization of 3 μm thick paraffin sections of 3D 
hiPSC-CM mono- and 3D hiPSC-CM/ECMC triculture microcapsules, taken at the endpoint of the models (days 15 and 14 post-
microencapsulation, respectively) and stained for H&E, TB, MT and PAS. Data are representative images from two independent 
experiments: (a, upper panel, Model #1-a–MCT-SF) and (b, lower panel, Model #1-b–MCT-SF). (a) Insets indicate high 
magnification images of the corresponding black rectangles. Abbreviations (from top to bottom): Hematoxylin and Eosin (H&E), 
Toluidine Blue (TB), Masson Trichrome w/ Aniline Blue (MT) and Periodic Acid-Schiff (PAS). (a) Scale bars, 250 μm; 100 μm in 
high magnification images. (b) Scale bars, 100 μm (in all images). 
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toto protocols; consult 4.4.1) has proved to be a much more robust technique for determining ECM levels 
and visualizing single cells. 
 In addition to detecting a collagen content much smaller than those noticed via immunofluorescence, 
MT (Fig.4.13) and PSR (Annex 4.2, Fig.S11) stains did not distinguish it between mono- and tricultures.  
 Nonetheless, Picrosirius Red (PSR) (Annex 4.2, Fig.S11) is a relevant method, given that it allows the 
quantification of fibrillar type I and III collagens, via polarization microscopy[212,213] . This method was used 
only in the pilot experiment’s monocultures (Annex 4.2, Fig.S11), as a routine characterization, since a 
broad microscopy-based phenotypic characterization toolbox and, particularly, that involving LSFM 
(consult 4.4.2.2), which allows very faithful quantifications, was implemented later. 
 Finally, several cardiac models reported the use of some of these stains with analogous results. Figtree 
et al. (2017)[204] demonstrated an increased ECM deposition, via PSR stain, in cardiac spheroids used to 
model cardiac fibrosis[204]. Siang Ong et al. (2017)[214] showed the presence of collagen (via H&E and MT), 
indicating the deposition of ECM after printing of 3D cardiac patches, created from spheroids containing 
hiPSC-CM, hiPSC-EC and hiPSC-FB[214]. 
 
4.6. Functional evaluation: live cell calcium imaging 
 To determine the functionality and maturity of the Ca2+ handling apparatus of hiPSC-CM, in both mono- 
and tricultures, intracellular Ca2+ spontaneous and pharmacologically induced-transients, from two 
independent experiments (Figs.4.14–4.17), were recorded at the endpoint of the models. For the values 
of the different parameters of calcium handling kinetics, along with a list of selected videos, consult Annex 
5.1, Table S6 and Table S7, and Annex 5.2, Fig.S12, respectively. 
 
 4.6.1. Assessment of spontaneous whole spheroid intracellular Ca2+ transients  
 Whole spheroid intracellular Ca2+ spontaneous transients were observed in both models, indicating 
the presence of a functional hiPSC-CM calcium handling machinery (Fig.4.14, mono- and triculture; and 
Fig.4.15a1, Fig.4.15b1). 
 Looking at Fig.4.14, in comparison with monoculture, hiPSC-CM triculture’s spontaneous calcium 
releases exhibited significantly higher peak to 50% (***; Fig.4.14f and Annex 5.1, Table S6) and to 80% 
(**; Fig.4.14g and Annex 5.1, Table S6) decay times and greater time between peaks (***; Fig.4.14h and 
Annex 5.1, Table S6), i.e. reduction of the beating rates (*; Fig.4.14i and Annex 5.1, Table S6). There were 
no significant statistical differences, from mono- to triculture, in the other parameters of calcium handling 
kinetics (ns; peak amplitude, upstroke velocity and rise to peak time; Fig.4.14b, Fig.4.14c and Fig.4.14e, 
correspondingly), with the exception of the decay velocity, which disclosed a significant reduction in 
triculture (*; Fig.4.14d and Annex 5.1, Table S6). 
 Taken together, Model #1-a-MCT-SF’s results (Fig.4.14, Fig.4.15 and Annex 5.1, Table S6) showed 
slower calcium handling kinetics in the triculture model (Fig.4.14a), as evidenced by the significant 
decrease in beating rate, from mono- to triculture (*; Fig.4.14i and Annex 5.1, Table S6), which may be 
correlated with a more mature Ca2+ handling apparatus in this model[96,152,215,216]. 
 Also, in this experiment, we sought to investigate the pharmacological response profile of the human 
engineered cardiac tissues to a β1-adrenergic receptor agonist (norepinephrine, 60 μM) (Figs.4.14b–i and 
Fig.4.15).  
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 Representative traces of Ca2+ transients in mono- and tricultures (Fig.4.15) revealed a comparable 
chronotropic response to norepinephrine, in both models, which translated into a significant decrease in 
rise to peak time (* in both mono- and tricultures; Fig.4.14e and Annex 5.1, Table S6) and in peak to 50% 
(** in mono- and *** in tricultures; Fig.4.14f and Annex 5.1, Table S6) and to 80% (**** in both mono- 
and tricultures; Fig.4.14g and Annex 5.1, Table S6) decay times, in both mono- and tricultures; Fig.4.14g 
and Annex 5, Table S6) decay times; and, more importantly, a significant decrease in time between peaks 
(**** in both mono- and tricultures; Fig.4.14h and Annex 5.1, Table S6), meaning a matching increase in 
beating rate (**** in both mono - and tricultures; Fig.4.14i and Annex 5.1, Table S6). 
Figure 4.14 | Impact of a β1-adrenergic receptor agonist (norepinephrine) on hiPSC-CM functionality, in both 
mono- and tricultures, assessed by live cell calcium imaging (Model #1-a–MCT-SF). (a) Representative tracing of 
calcium transients (upper panel), in mono- and tricultures that weren’t exposed to norepinephrine. (b-i) hiPSC-CM calcium 
handling kinetics (lower panel), in mono- and tricultures, in the absence and presence of 60 μM of norepinephrine. (b) Amplitude, 
(c) upstroke and (d) decay velocities, (e) rise to peak time, (f) time to 50% and (g) time to 80% decay, (h) time between peaks 
and (i) beating rate. Data are mean ± SD from one independent experiment. All kinetic parameters: n = 8-13. Ordinary one-way 
ANOVA analysis with Tukey’s post hoc test for multiple comparisons (ns – not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001). All parameters refer to 15 days after microencapsulation, for both mono- and triculture cardiac tissue models, 
under similar culture circumstances. Abbreviations: Norepi – Norepinephrine. Caption: Mono- and Triculture groups – conditions 
w/o drug exposure; Monoculture + 60 µM Norepi and Triculture + 60 µM Norepi – conditions exposed to norepinephrine. 
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 The results obtained via exposure to norepinephrine are in line with those described in the literature 
for other α-[215] (e.g. phenylephrine) or β-adrenergic agonists[97,215] (e.g. isoproterenol), namely the 
shortening of the decay times[217] and the increased beating rates[97,215]. 
 
 4.6.2. Evaluation of pharmacological responses to several cardioactive drugs 
 To assess the pharmacological and, in particular, the chronotropic responses (i.e. variations in the 
beating rate) of hiPSC-CM, in both mono- and tricultures, we treated the models with target cardioactive 
drugs, including 60 μM norepinephrine (β1-adrenergic receptor agonist ), 40 μM heptanol (gap junction 
uncoupler), 4 μM propranolol (non-selective β-blocker) and, finally, 4 μM propranolol and thereafter 60 
μM norepinephrine. The concentrations tested are in the range reported by other studies as non-
cytotoxic[97,215,218]. Exposure to cytotoxic chemotherapeutic drugs will be described in the ensuing topic. 
The mechanisms of action of the different cardioactive drugs tested are schematized in Fig.4.17a. 
 Model #1-b-MCT-SF’s calcium kinetic parameters, in the absence of pharmacological agents, show 
similar calcium kinetics (Fig.4.17a) between both cardiac models, with a significant decrease, from mono- 
to triculture, in upstroke (****; Fig.4.16b and Annex 5.1, Table S7) and decay (***; Fig.4.16c and Annex 
5.1, Table S7) velocities. There were no significant statistical differences, from mono- to triculture, in the 
other parameters of calcium kinetics (ns; peak amplitude, rise to peak time, peak to 50% and 80% decay 
time, time between peaks and beating rate; Figs.4.16b,e,f–i, correspondingly). Hence, there does not 
appear to be significant differences in the maturation level amongst the two models. 
  
 
Figure 4.15 | hiPSC-CM revealed a positive chronotropic response to norepinephrine in mono- and triculture 
models (Model #1-a–MCT-SF). (a1-b2) Representative traces of Ca2+ transients in mono- and tricultures, at day 15 post-
microencapsulation. (a1, b1) (Left panel) Ca2+ spontaneous release: (a1) mono- and (b1) triculture w/o drug exposure. (a2, b2) 
(Right panel) Norepi-induced Ca2+ release: (a2) mono- and (b2) triculture exposed to 60 µM of norepi. Abbreviations: Norepi – 
Norepinephrine. 
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Figure 4.16 | hiPSC-CM, in both mono- and tricultures, have the ability to pharmacologically respond to different 
cardioactive drugs (norepinephrine, propranolol and heptanol) (Model #1-b–MCT-SF). (a) Representative tracing of 
calcium transients (upper panel), in mono- and tricultures w/o drug exposure. (b-i) hiPSC-CM calcium handling kinetics (lower 
panel), in mono- and tricultures, in the absence and presence of different cardioactive drugs. (b) Amplitude, (c) upstroke and (d) 
decay velocities, (e) rise to peak time, (f) time to 50% and (g) time to 80% decay, (h) time between peaks and (i) beating rate. 
Addition (+) and subtraction (-) signals (below the charts) indicate which drugs are present in a given combination (either in mono- 
or triculture). Data are mean ± SD from one independent experiment. All kinetic parameters: n = 2-8. Ordinary one-way ANOVA 
analysis with Tukey’s post hoc test for multiple comparisons (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). All parameters 
refer to 14 days after microencapsulation, for both mono- and triculture cardiac tissue models, under similar culture 
circumstances. Abbreviations: Norepi – Norepinephrine. Caption: Mono- and Triculture groups – conditions w/o drug exposure; 
Monoculture + 60 µM Norepi and Triculture + 60 µM Norepi – conditions exposed to the β1-adrenergic receptor agonist, 
norepinephrine; Monoculture + 40 µM Heptanol and Triculture + 40 µM Heptanol – conditions exposed to the gap junction 
uncoupler, heptanol; Monoculture + 4 µM Propranolol and Triculture + 4 µM Propranolol – conditions exposed to the β-blocker, 
propranolol; and Monoculture + 4 µM Propranolol + 60 µM Norepi and Triculture + 4 µM Propranolol + 60 µM Norepi – conditions 
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Figure 4.17 | Pharmacological responses of 
hiPSC-CM to different cardioactive 
compounds (norepinephrine, propranolol 
and heptanol), in mono- and triculture 
models (Model #1-b–MCT-SF). (a) Scheme 
depicting the mechanisms of action of the 
cardioactive drugs tested: norepinephrine, 
propranolol and heptanol [reproduced from 
Gouveia et al. (2017)[97]]. (b1-f2) Representative 
traces of Ca2+ transients in mono- and tricultures, 
at day 14 post-microencapsulation. (b1, b2) Ca2+ 
spontaneous release: (a1) mono- and (b1) 
triculture w/o drug exposure. (c1, c2) Norepi-
induced positive chronotropic response: (c1) 
mono- and (c2) triculture exposed to 60 µM of 
norepi. (d1, d2) Heptanol-induced uncoupling of 
cardiac gap junctions: (d1) mono- and (d2) 
triculture exposed to 40 µM of heptanol. (e1, e2) 
Propranolol-mediated negative chronotropic 
response: (e1) mono- and (e2) triculture exposed to 
4 µM of propranolol. (f1, f2) Propranolol and 
norepi dual response: (f1) mono- and (f2) triculture 
exposed to 4 µM of propranolol and thereafter to 
60 µM of norepinephrine. Abbreviations: Norepi – 
Norepinephrine. 
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 As discussed for Model #1-a-MCT-SF, in Model #1-b-MCT-SF, hiPSC-CM revealed a positive 
chronotropic response to norepinephrine, in both models, evinced by the significant decrease in time 
between peaks (** in mono- and * in tricultures; Fig.4.16h, Figs.4.17b1,b2,c1,c2 and Annex 5.1, Table S7) 
and the agreeing increase of beating rate (**** in mono- and * in tricultures; Fig.4.16i, Figs.4.17b1,b2,c1,c2 
and Annex 5.1, Table S7). 
 In addition, similarly to what has been described in the literature for β-adrenergic receptor 
repression[97], propranolol-mediated negative chronotropic response appears to occur in both cardiac 
models, although the differences were not statistically significant. Specifically, representative traces of 
Ca2+ transients in mono- and tricultures (Figs.4.17b1,b2,e1,e2) appear to indicate, as expected, results 
opposing to norepinephrine’s: increase in time between peaks (Fig.4.16h and Annex 5.1, Table S7) and 
corresponding decrease in beating rates (Fig.4.16i, Figs.4.17b1,b2,e1,e2 and Annex 5.1, Table S7). 
 Remarkably, the low frequency of beatings induced by propranolol is recovered by the addition of 
norepinephrine, that reinstates the basal beating rates (values of mono- and tricultures w/o drug 
exposure). Thus, we can say the combined responses of the antagonist followed by addition of the β1-
adrenergic receptor agonist turn out to have a null balance.  
Propranolol and norepi dual response is characterized by a significant decrease in time between peaks (* 
in tricultures; Fig.4.16h and Annex 5.1, Table S7) and a matching increase in beating rates (* in tricultures; 
Fig.4.16i, Figs.4.17b1,b2,f1,f2 and Annex 5.1, Table S7). These tendencies were found in both models but 
were only statistically relevant for the triculture. 
 Lastly, upon the treatment with the cardiac gap junction uncoupler heptanol, hiPSC-CM, in both 
models, revealed asynchronous beating rates (Figs.4.17b1,b2,d1,d2 and Annex 5.1, Table S7) with peak 
amplitudes significantly lower (**** in mono- and * in tricultures; Fig.4.16b, Figs.4.17b1,b2,d1,d2 and 
Annex 5.1, Table S7), when compared to the w/o drug exposure counterparts.  
 As shown by Gouveia et al. (2017) a low concentration of heptanol reduces the propagation of action 
potentials in hiPSC-CM[97]. Higher concentrations (not tested) would probably completely block the 
beating rates. 
 All told, these observations indicate that β-adrenergic receptors (through stimulation or repression) 
and gap junction proteins were appropriately expressed on both models; yet, with respect to the 
pharmacological responses, only a few significant differences, not necessarily suggestive of a higher 
cardiac maturation in the triculture, were found between the two cardiac models. 
 
4.7. Functional evaluation: chemotherapeutic drug-induced cardiotoxicity 
 In clinical settings, a large majority of anticancer drugs may induce cell death of cardiomyocytes in 
some patients within hours of intravenous administration[11,21,22,219,220].  
 As a proof-of-concept that the 3D mono- and triculture cardiac tissue models’ setup allow the study of 
the effect of cardiotoxic drugs, we challenged them with the anthracycline doxorubicin and the taxane 
paclitaxel, two chemotherapeutic drugs with widely reported cardiotoxicity[13,19,21].  
 hiPSC-CM survival upon doxorubicin or paclitaxel treatment was determined via FDA-PI live/dead 
double staining (Fig.4.18a) and PrestoBlue resazurin-based dye assay (for metabolic activity 
quantification; Fig.4.18b). To this end, hiPSC-CM in, both mono- and tricultures, were exposed to an 
increasing concentration gradient, in the micromolar range (0 – Control, 1, 10 and 100 µM), using single 
dosing (exposure at the endpoint of both models for of 72-hour duration). 
Towards a bioinspired 3D triculture hiPSC-derived cardiac tissue model for human heart microenvironment recapitulation and 
drug testing 
P.G.M. Canhão Costa, September 2018 | 77 
 
 As a result, doxorubicin and paclitaxel induced cell death (as seen by the intensification in TO-PRO-3’s 
cyan staining) in a dose-dependent manner (Fig.4.18a). Besides, FDA-PI results also show us that, after a 
72h exposure at a concentration of 100 μM, cell viability was reduced to practically zero (Fig.4.18a), given 
that all the spheroids express TO-PRO-3. 
Figure 4.18 | 72-hour treatment of hiPSC-CM, in mono- and triculture cardiac tissue models, with increasing doses 
of cardiotoxic anticancer drugs (doxorubicin and paclitaxel) (Model #1-b–MCT-SF). (a) Assessment of 3D hiPSC-CM 
mono- and 3D hiPSC-CM/ECMC triculture cardiac tissue models’ cell viability, through a live/dead assay, after 72 h of exposure 
(corresponding to day 17 post-microencapsulation) to cardiotoxic anticancer drugs (doxorubicin and paclitaxel) (from left to 
right: doxorubicin and paclitaxel-induced cardiotoxicity, in mono- and tricultures, respectively; from top to bottom: control 
condition, indicating 0 µM, and increasing drug concentrations). Cultures were stained with FDA (fluorescein diacetate) – live 
cells, green, and TO-PRO-3 Iodide – dead cells, cyan. Scale bars, 200 µm. (b) Effect of doxorubicin (b1) and paclitaxel (b2) (72-
hour treatment) on hiPSC-CM viability, in mono- and triculture models, using a PrestoBlue resazurin–based dye assay. Data are 
mean ± SEM from one independent experiment and consist of three technical replicates (n = 3). Ordinary two-way ANOVA analysis 
with Tukey’s and Sidak’s post hoc tests for multiple comparisons (ns – not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P 
≤ 0.0001). 72 and 0 h fluorescence intensity values (RFU, relative fluorescence units) were initially normalized per spheroid. Final 
RFU values are the quotient between 72 and 0 h (untreated controls). Excitation and emission wavelengths were 560 and 590 
nm, respectively; gain was 176. 
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 Nonetheless, when metabolic activity is evaluated, the results appear to differ from those of FDA-PI 
(Fig.4.18b1; triculture condition).  
 PrestoBlue’s results confirm that doxorubicin significantly reduced the cell viability in the monoculture 
in a dose-dependent manner. Furthermore, at a 100 μM concentration, only approximately 25% of hiPSC-
CM remained viable in this model (Fig.4.18b1; monoculture condition). However, contrariwise to FDA-PI 
assessment, PrestoBlue’s demonstrate that 100 μM (highest concentration tested) is not sufficient to 
induce substantial cardiotoxicity effects in triculture’s hiPSC-CM. There were no statistically significant 
differences in the concentrations studied (Fig.4.18b1; triculture condition). This could be owing to a 
cardioprotective effect of the non-myocyte populations (e.g. hiPSC-EC) on hiPSC-CM[25,28,35,53], 
nevertheless we have not conducted any study to show that this is indeed the case.  
 On the other hand, the fact that we are working with encapsulated models and in a 3D configuration 
translates, in practical terms, into extra diffusion barriers and a higher cellular organization level, which 
may cause us to adopt, in the future, a wider range of concentrations. Several studies have been reporting 
that concentrations of anticancer drugs in the micromolar and nanomolar range are sufficient to perceive 
appreciable effects on cell viability[22,219–224]. However, these values are usually related to hiPSC-CM 
monolayers[219,221] or even to co-cultures[22], but in a 2D configuration[22].  
 Paclitaxel-induced cardiotoxicity was obvious and translated into a significant decrease in cell viability 
while drug concentration increased (Fig.4.18b2; mono- and tricultures). Also, the results seem to follow 
those of the FDA-PI (Fig.4.18a, Paclitaxel). At a concentration of 100 μM, hiPSC-CM display a viability of 
about 9%, in the monoculture, and approximately 10%, in the triculture. For each pair of concentrations, 
no significant differences, between mono- and tricultures, were detected. 
 Overall, these findings are still very premature and lack validation, but the generated models 
demonstrate potential to be applied in the in vitro screening of chemotherapeutic drugs. In the future, 
these results may be complemented with gene expression profiling of relevant biomarkers, ATP levels 
determination, proteomics/metabolomics or live cell calcium imaging in which these drugs are used in 
non-cytotoxic concentrations. 
 
4.8. Hydrogel-based scaffold characterization 
 4.8.1. FS-AFM mechanobiological properties indicate a dynamic remodelling of the cardiac 
microenvironment in the triple model 
 RGD-peptide coupled alginate microcapsules’ mechanobiological properties were studied using atomic 
force microscopy (AFM) in three distinct conditions: (i) scaffold alone (in the absence of cells), (ii) 
construct encapsulating monocultures or (iii) construct encapsulating tricultures, as depicted in Fig.4.19a. 
 AFM 2D and 3D phase (Fig.4.19b and Annex 6, Fig.S13a, for high magnification images) and 
topographical imaging (Fig.4.19c and Annex 6, Fig.S13b, for high magnification images) evidenced an 
alginate porous surface structure, displaying some inhomogeneity, primarily in the microcapsule 
constructs containing mono- and tricultures (Fig.4.19 and Annex 6, Fig.S13, for high magnification images; 
mono- and triculture conditions), which appears to be a first signal that cell-to-scaffold contacts do indeed 
exist. Also, these contacts may play a key role in biomaterial composition changes. Moreover, resorting 
to AFM images, a microcapsule average pore diameter, corresponding to 579.6 ± 137.0 nm (Fig.4.19e and 
Annex 6, Table S8) was determined. 
 Furthermore, to provide insight into these cell-to-scaffold contacts, a set of relevant biomechanical 
parameters, correlated with a makeover of the cardiac microenvironment[108,159], was quantified via Force 
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Spectroscopy mode-AFM (FS-AFM), for the scaffold alone and for mono- and triculture cardiac tissue 
models (endpoint quantification) (Figs.4.19d1–d4; Young's modulus, stiffness, hardness and adhesion, 
correspondingly). The values obtained for these parameters are summarized in Annex 6, Table S8. 
 The calcium alginate microcapsule biomaterial alone demonstrated a Young's modulus (also known as 
elastic modulus) corresponding to 188.0 ± 69.38 kPa, significantly higher than that of both cardiac models 
(****; Fig.4.19d1 and Annex 6, Table S8).  
 Considering that Young's modulus measures an object's resistance to being deformed elastically (i.e. 
non-permanently), this seems to indicate that the microenvironment in the presence of the cells is less 
stiff, when compared to the biomaterial alone. In addition, in comparison to monoculture, triculture's 
Young's modulus is significantly higher (***; Fig.4.19d1 and Annex 6, Table S8; triculture: 159.3 ± 27.27 
kPa and monoculture: 26.24 ± 10.44 kPa), which is consistent with a remodelling of the cardiac 
microenvironment from mono- to triculture, with the latter exhibiting a less plastic (i.e. stiffer) 
microenvironment. This can be explained by the fact that non-myocyte populations (mostly hiPSC-MC 
and, in particular, CFs) contribute to a higher ECM production in the tricultures, as proved earlier (consult 
4.4.2). In this context, Stevens et al. (2009) showed that the stiffness of multicellular cardiac patches 
derived from hESC-CM, MEFs and HUVECs was 4-fold higher than those composed of CMs only[115], which 
matches our results. 
 Given that Young's modulus is a measure of stiffness, stiffness’ results (Fig.4.19d2) exhibit a pattern 
consistent with those discussed so far: (i) microcapsule scaffold alone exhibited a significantly superior 
stiffness compared to mono- and triculture values (53.12 ± 21.29 mN/m, **** vs. mono and * vs. 
triculture; Fig.4.19d2 and Annex 6, Table S8); and (ii) significantly higher triculture’s stiffness, in 
comparison to that of the monoculture (****; Fig.4.19d2 and Annex 6, Table S8; triculture: 47.79 ± 8.074 
mN/m and monoculture: 13.63 ± 6.653 mN/m).  
 Hardness’ results also showed a similar tendency, without significant differences between the scaffold 
and the triple model (ns; Fig.4.19d3 and Annex 6, Table S8). Besides, monoculture’s hardness is lower 
than the rest (5,737 ± 1,718 kPa; **** vs. both RGD-modified alginate microbead and triculture; Fig.4.19d3 
and Annex 6, Table S8). 
 Noteworthy, the adhesion between the AFM tip and the biomaterial in the triple model (although with 
some dispersion of adhesion values) was significantly higher when compared to the others (2,913 ± 2,326 
nN, **** vs. both RGD-modified alginate microbead and monoculture ; Fig.4.19d3 and Annex 6, Table S8), 
which is consistent with the hypothesized remodelling of the cardiac microenvironment from mono- to 
triculture. A higher adhesion may also be owing to the interaction of CFs with the scaffold via RGD motifs. 
Figure 4.19 | FS-AFM characterization of the microcapsule scaffold, as well as the 3D cardiac cell-based models, 
biomechanical behaviour. (a) Scheme illustrating the contact between AFM cantilever tip and empty RGD-alginate 
microbead, mono- or triculture, resulting in a given measurement of force [adapted from Liu et al. (2012)[159]]. (b-c) AFM 2D 
and 3D images (left panel) of RGD-alginate microbead, mono- and triculture (wet scanning), referring to the endpoint of the 
models (days 15 or 14 post-microencapsulation). (b) AFM 2D and 3D phase imaging of RGD-alginate microbead and monoculture. 
(c) AFM 2D and 3D topographical imaging of RGD-alginate microbead, mono- and triculture. (b-c) A scan area of 4 µm2 (size: 2 x 
2 µm), for RGD-alginate microbead and triculture, and 100 µm2 (size: 10 x 10 µm), regarding monoculture, were used. For high 
magnification images, consult Annex 6, Fig.S13). (d1-d4) FS-AFM-based mechanobiological properties (right panel) of the 
microbead scaffold and mono- and triculture cardiac tissue models (endpoint quantification). (d1) Young’s modulus (n = 63-80), 
(d2) Stiffness (n = 63-80), (d3) Hardness (n = 71-81) and (d4) Adhesion (n = 69-77). Data are mean ± SD from one independent 
experiment (Pilot Model–M-SF), for RGD-alginate microbead, and two (Model #1-a–MCT-SF and  Model #1-b–MCT-SF), for 
mono- and triculture. Ranked one-way ANOVA analysis (Kruskal-Wallis nonparametric test) with Dunn’s post hoc test for multiple 
comparisons (ns – not significant, *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001). (e) Boxplot representing the biomaterial pore 
diameter (n = 61). Whiskers: 10-90 percentile. Outliers: plotted as discrete points. Data are mean ± SD from two independent 
experiments (Pilot Model–M-SF Model and Model #1-a–MCT-SF).  
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 In sum, our hydrogel-based scaffold seems to be suitable to recapitulate the human heart 
microenvironment[23], since hPSC-CM maturation is favoured on substrates with an elasticity within the 
same order of magnitude as that of the human cardiac muscle (Young's modulus of 10-15 kPa)[14,23,25]. 
 
 4.8.2. Biomaterial ultrastructure and spheroids structure 
 TEM imaging was conducted in order to characterize the ultrastructure of the scaffold microcapsule in 
the absence of cells.  
 TEM micrographs (Fig.4.20a and Fig.4.20a1) demonstrate that RGD-peptide coupled alginate 
hydrogels are mesh-like, fibrous networks with a nanosized pore structure, agreeing with AFM results 
(Fig.4.19e). This TEM pattern is similar to that found by Hsiong et al. (2008) in RGD-modified alginate 
disks[148]. 
 On the other hand, to complement the structure and ultrastructure results obtained for hiPSC-CM 
spheroids (consult 4.5), scanning electron microscopy (SEM) was employed. 
 The spheroids exhibit a solid and compact structure, as well as a topography with some heterogeneity 
(Fig.4.20b), in which cell-to-cell contacts can be discerned in higher magnification images (Fig.4.20b1). This 
topography is similar to those observed by Horton and Auguste (2012) on spheroids with ECM deposited 
on their surface[225], demonstrating that the ours are surrounded by an outer layer of ECM, agreeing with 

















Figure 4.20 | Biomaterial ultrastructure and hiPSC-CM spheroids structure characterization. (a-a1) Representative 
TEM micrographs (upper panel) of an empty RGD-modified calcium alginate microbead (50% of RGD peptide-coupled alginate), 
at day 15 post-microencapsulation. (b-b1) Representative SEM micrographs (lower panel) of a hiPSC-CM spheroid, at day 15 after 
microencapsulation. (a1, b1) Insets indicate high magnification images of the corresponding cyan or grey rectangles. (a-a1) TEM: 
Scale bars, 500 nm (in both images). (b-b1) SEM: Scale bars, 50 μm; 500 nm in high magnification images. 
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4.9. Scalability approaches using stirred-tank bioreactors 
 To perform the upscaling of the 3D cardiac tissue models (consult 3.5), a proof-of-concept, using, as a 
culture system, small-scale stirred-tank bioreactors (STBRs), operating in perfusion, was carried out. 
 As illustrated in Fig.4.21a, the pursued strategy is, in all respects, similar to that hitherto described 
(consult 4.1), including a first aggregation step, in which hiPSC-CM are inoculated as a single cell 
suspension, with the aim of forming cardiac spheroids (Fig.4.21a). Nevertheless, the aggregation process, 
Figure 4.21 | Bioreactor experimental strategy and phenotypic characterization of the 2D hiPSC-ECMC co-culture, 
prior to microencapsulation. (a) Schematic overview of the bioreactor culture strategy (upper panel) for obtaining the final 
3D triculture hiPSC-derived cardiac tissue model, as well as for the 3D monoculture control. Defined cardiovascular cell 
populations  (hiPSC-CM spheroids and hiPSC-ECMC) were systematically differentiated from hiPSC. Representations of the models 
are not to scale. The key model players are also exhibited. (b) Wide-field immunofluorescence microscopy representative images 
(lower panel) of the 2D hiPSC-ECMC co-culture, at day 10, prior to microencapsulation. 2D hiPSC-ECMC immunostained (from 
left to right) for the endothelial markers CD31 (green) and VE-cadherin (cyan), for the mesenchymal markers Vimentin and α-
SMA (green) and for the cardiac marker cTnT (green), as negative control. Nuclei were counterstained with DAPI (blue). Scale 
bars, 200 µm. 
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in view of a more straightforwardly scalable and reproducible process[51,139,226], was done in STBRs 
(Fig.4.21a). 
 Subsequently, it was further possible to carry out the microencapsulation step, in one (Model #2-b-
MT-BR-2) of the two bioreactor independent experiments performed, producing microencapsulated 
mono- and tricultures (Fig.4.21a, right), under conditions analogous to those described in 3.2 and 4.1. 
Owing to the fact that this was still an opening study, in which the focal goal was to increase the scale of 
the previously established models and not properly study the differences between mono- and tricultures, 
the 3D cardiac tissue models were only kept in culture for 6 days (Fig.4.21a) 
 In the same way to what has been demonstrated beforehand (consult 4.1 and Fig.4.2f), 2D hiPSC-
ECMC co-culture phenotype was assessed via immunofluorescence, prior to microencapsulation 
(Fig.4.21b). The results were similar to those already attained, which attests the robustness of hiPSC-
ECMC differentiation process: (i) presence of an endothelial population (CD-31+ and VE-cadherin+; 
Fig.4.21b) and, (ii) in greater number, a mesenchymal one (Vimentin+ and α-SMA+; Fig.4.21b). Neither 
hiPSC-EC nor hiPSC-MC express cTnT (negative control) cardiac marker, proving the absence of hiPSC-CM 
in culture (Fig.4.21b). 
 Noteworthy, the FC results, shown in 4.2, Figs.4.2a-c (hiPSC before differentiations, as well as hiPSC-
CM and hiPSC-ECMC, prior to microencapsulation, correspondingly), already include the bioreactor 
experiments.  
 
 4.9.1. hiPSC-CM aggregation dynamics in STBRs 
 hiPSC-CM aggregation profile in STBRs, concerning two biologically independent experiments (Model 
#2-a–BR-1 and Model #2-b–MT-BR-2; for further detail, consult List of Models), was studied in terms of 
cell viability (FDA-PI live/dead assay; Figs.4.22a,c, left panel) and spheroid size (Figs.4.22b,d, right panel), 
from day 7 (inoculation) until day 18 (last day prior to microencapsulation). 
 Albeit hiPSC-CM spheroids have remained viable during the culture time (Fig.4.22a), in the case of the 
first experiment (Model #2-a–BR-1) it is possible to note a low cell density (Fig.4.22a), reduced average 
spheroid diameters (e.g. 97.58 ± 40.32 μm at day 18; Fig.4.22b) and a high size dispersion (Fig.4.22b).  
 As discussed in 4.1, the difficulty in controlling spheroid size dispersion is the main drawback of STBRs, 
in comparison to AggreWell™ plates, which allow the generation of hiPSC-CM with a very reproducible 
size. We attempted to mitigate this factor by adjusting the stirring rate (shown in FDA-PI images; 
Figs.4.22a,c, left panel), in order to control the aggregation process and maintain an average spheroid 
diameter as homogeneous as possible: in the case of Model #2-a–BR-1, stirring rates between 60 and 70 
rpm, together with a dilution rate of 0.30 day-1 (consult Annex 7, Table S9), were found to be inadequate 
to uphold an homogeneous spheroid size. 
 On the basis of these first results, a new batch (Model #2-b-MT-BR-2) was carried out, in which higher 
stirring rates, between 80 and 90 rpm, were used, while the dilution rate was maintained (consult Annex 
7, Table S9). This gave rise to a noticeable increase in cell density over time, without compromising 
spheroid viability (Fig.4.22b), and led to higher average spheroid diameters (e.g. 132.2 ± 52.80 μm at day 
18, Fig.4.22d). However, there was still a high size dispersion (Fig.4.22b), so the process still lacks some 
optimization. 
 Cell concentration, over the 12 days of aggregation (from day 7 to day 18) shows a comparable profile 
in both experiments, with a decrease in cell concentration in the first days of aggregation (days 7 and 8), 
which later stabilized until day 18 (Fig.4.23a). These results agree with those of FDA-PI, displaying a 6.75-
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fold increase in cell density in Model #2-b-MT-BR-2, at day 18, when compared to its counterpart (BR-1: 
0.040 x 106 cell/ mL and BR -2: 0.27 x 106 cell/ mL; Fig.4.23a).  
 Interestingly, spheroid concentration (Fig.4.23b) appears to be the same at day 18 (BR-1 and BR-2: 
0.077 x 106 spheroids/mL; Fig.4.23b and Annex 7, Table S9) in both the models, indicating that BR-2’s 
spheroids are actually more compact (i.e. made up of a larger number of hiPSC-CM). Moreover, hiPSC-CM 
cell counts over time  show that, in BR-2, hiPSC-CM exhibit a cell viability significantly higher than in BR-1 
Figure 4.22 | Comparison of hiPSC-CM aggregation profile in stirred-tank bioreactors, from day 7 to day 18: cell 
viability and spheroid size (Model #2-a–BR-1 and Model #2-b–MT-BR-2). (a, c, left panel) Evaluation of hiPSC-CM 
spheroids viability in stirred-tank bioreactors, through a live/dead assay, throughout the culture time (day 7 to day 18, prior to 
microencapsulation). (a) Perfusion operation mode was activated at day 10, with a dilution rate of 0.30 day-1. Stirring rate was 
originally set to 60 rpm and, at day 9, was increased to 70 rpm and thus maintained until day 18. (c) Perfusion operation mode 
was started at day 9, with the aforesaid dilution rate. Stirring rate was initially set to 80 rpm and, at day 11, was increased to 90 
rpm and thus maintained until day 18. (b, d, right panel) Scatter dot plots displaying the hiPSC-CM average spheroid diameter, 
over time (day 7 to day 18, prior to microencapsulation). Line at mean with SD. Data are mean ± SD from two bioreactor 
independent experiments: (a, b, Model #2-a–BR-1) and (c, d, Model #2-b–MT-BR-2) (n ≥ 67 spheroids). Colour changes from light 
to dark grey, in the scatter dot plots, symbolise an increase in stirring rates. 
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(96.68 ± 1.838%; * vs. BR-2; Fig.4.23c). Some of the parameters related to the aggregation profiles in 
STBR, regarding the aforesaid experiments, are compiled in Annex 7, Table S9. 
 Hence, by joining all these results, BR-2 experiment was the chosen to proceed to the 
microencapsulation step.  
 
 4.9.2. Towards 3D microencapsulated mono- and triculture cardiac tissue models in STBRs 
 In Fig.4.24a it can be seen that the microencapsulated monoculture and triculture conditions remain 
viable for 6 days of culture. Nonetheless, the cell viability is inferior to that observed in the corresponding 
models established in shake flask (consult 4.2) and, particularly, some cell death, mainly in the tricultures, 
can be perceived (Fig.4.24a, triculture). Once again, a substantial spheroid size dispersion within the 
microcapsules may explain this factor. 
 Spheroids per microcapsule distribution (Fig.4.24b) on microencapsulation day, reveals a content of 0 
to 6 spheroids per microcapsule, in monoculture, and 0 to 5, in triculture, with the majority of the capsules 
encapsulating 2 spheroids Fig.4.24b). These values demonstrate a more shortened distribution than some 
of the experiments performed on shake flask (consult 4.2.1, Fig.4.3c). In addition, average microcapsule 
diameter values, concerning Model #2-b-MT-BR-2 (817.5 ± 41.52 μm) were likewise compiled in Annex 
2.2, Table S4 and Fig.S2.  
 Model behaviour’s results show that triculture’s spheroid (Fig.4.24c) and microcapsule (Fig.4.24d) 
concentrations are significantly lower than those of the monocultures (* vs. monocultures; Fig.4.24c and 
Fig.4.24d) . The very low density of spheroids and microcapsules can be explained due to some technical 
problems that have occurred during the microencapsulation process, which still requires an additional 
optimization. 
 Finally, the phenotype of monoculture’s cardiac spheroids was evaluated via confocal 
immunofluorescence in cryosections (Fig.4.24e). At the endpoint (6 days after microencapsulation), 
confocal analysis demonstrates the expression of specific structural cardiac markers, viz. cTnT and 
sarcomeric α-actinin (Fig.4.24e). Furthermore, it is possible to distinguish a striated pattern, typical from 
the sarcomeric myofibrillar structure (Fig.4.24e; observe insets). Besides, it appears that, at day 6, the 
Figure 4.23 | hiPSC-CM cell and spheroid 
concentration profiles, as well as cell 
viability, over 12 days of aggregation 
(Model #2-a–BR-1 and Model #2-b–MT-
BR-2). (a-b) Characterization of hiPSC-CM (a) 
cell and (b) spheroid concentration profiles 
along 12 days of aggregation (day 7 to day 18, 
prior to microencapsulation). (c) hiPSC-CM cell 
viability prior to microencapsulation. Error bars 
are mean ± SD from one bioreactor independent 
experiment and refer to cell viability values 
calculated over the time of the aggregation 
process (n = 4-6). Two-tailed Mann–Whitney 
nonparametric test (*P = 0.0107). Model #2-a–
BR-1 and Model #2-b–MT-BR-2 denote two 
independent bioreactor experiments. (in the 
charts: simply referred to as BR-1 and BR-2). 
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Figure 4.24 | Towards mono- and triculture cardiac tissue models using small scale stirred-tank bioreactors: cell 
viability, model monitoring and phenotypic characterization (Model #2-b–MT-BR-2). (a) Qualitative assessment of 3D 
hiPSC-derived cardiac tissue models’ (hiPSC-CM mono- and hiPSC-CM/ECMC triculture) cell viability over time (from left to right: 
0, 2, 4 and 6 days after microencapsulation), cultured under similar circumstances. Cultures were stained with FDA (fluorescein 
diacetate) – live cells, green, and PI (propidium iodide) – dead cells, red. Scale bars, 500 µm. (b) Spheroids per microcapsule 
distribution, in mono- and triculture, on the day of microencapsulation (day 0). (c) Characterization of the behaviour of the 
encapsulated models, in terms of (c1) spheroid and (c2) microcapsule concentration, in both mono- and tricultures. Error bars 
are mean ± SEM from one independent experiment, corresponding to the mean values of days 0 and 6, post-microencapsulation 
(n = 2). Two-tailed Mann–Whitney nonparametric test (*P ≤ 0.05). (d) Confocal immunofluorescence microscopy of 3D 
microencapsulated hiPSC-CM monocultures, in 12 µm thick cryosections, at the endpoint of the model (day 6 post-
microencapsulation). Data are representative maximum intensity z-projections from one independent experiment. hiPSC-CM 
spheroids immunostained (from left to right) for the cardiac markers cTnT and sarcomeric α-actinin (green), and also for Nkx2-
5 (green) and sarcomeric α-actinin (red). Nuclei were counterstained with DAPI (blue). Scale bars, 50 µm. 
spheroids do not express Nkx2-5 (one of the earliest markers of cardiac lineage, typically expressed in 
CPCs)[227]. 
 To sum up, the work presented in this last topic discloses that STBRs can be used as a technological 
platform to generate hiPSC-CM spheroids; yet, there is still a way to go when it comes to optimizing this 
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5. Concluding Remarks and Outlook 
 
 In this work, 3D mono- and triculture cardiac microtissues, that recapitulate in vitro certain features 
of the in vivo human heart microenvironment, have been developed, in a high throughput fashion. 
 The use of highly competent protocols for the differentiation of hiPSC toward myocytes (hiPSC-CM) 
and non-myocytes (hiPSC-EC and hiPSC-MC), coupled with the microencapsulation technology, using a 
biocompatible hydrogel, resulted in a robust system, fully hiPSC-derived and amenable for medium- to 
large-scale production. 
 Specifically, employing human cell sources to attain the various cardiac populations allows to mimic 
the heterotypic cellular crosstalk inherent to the human heart, whereas the RGD peptide-modified 
hydrogel provides a 3D controllable, inert and chemically defined microenvironment (advantageous 
when compared to undefined animal-derived preparations, e.g. Matrigel or collagen mixtures) for the 
cells to physically attach and communicate. 
 3D mono- and triculture human EHTs were successively microencapsulated and maintained in culture 
for a minimum of 15 days, with high cellular viabilities, which were confirmed via FDA-PI live/dead and 
PrestoBlue™ assays. Furthermore, early on, several cues of a heterotypic cellular communication in the 
triculture model were evident: noteworthy, hiPSC-ECMC, did not survive in the 3D coculture model, in the 
absence of hiPSC-CM. 
 In addition to the cellular crosstalk, another aspect explored in this work was hiPSC-CM maturation, 
studied through comparison between structure, ultrastructure, gene and protein expression, calcium 
kinetics, responsiveness to cardiac affinity and cardiotoxic chemotherapeutic drugs, and 
mechanobiological behaviour, amid mono- and tricultures. 
 After only 15 days of culture, gene expression profiling, imaging-based phenotypic characterization 
and ultrastructure analysis exposed clear evidence of a structural maturation over time in both models: 
(i) upregulation of MYL2, MYH7 and TNNI3 adult sarcomeric gene isoforms and increased MYL2/MYL7, 
MYH7/MYH6 and TNNI3/TNNI1 gene expression ratios, (ii) extremely organized ultrastructure (not 
observed at the beginning); and others consistent with a more advanced maturation stage in triculture 
at day 15, in comparison to its counterpart: (i) increased MYL2/MYL7 and TNNI3/TNNI1’s gene expression 
ratios, together with the upregulation of calcium (CACNA1C) and sodium (SCN5A) cardiac ion channels, 
(ii) apparent overexpression of gap junction proteins (Cx43 and ZO-1; confocal microscopy), (iii) enlarged 
production of ECM proteins (collagen type I, collagen type IV and fibronectin; confocal, multiphoton and 
LSFM) and (iv) significant improvement in sarcomere length and sarcomeric myofibrillar alignment. 
Particularly, through a LSFM-based quantification of 3D volume reconstructions of the microcapsules, we 
determined a 45.6-fold increase in relative fibronectin expression in tricultures, at day 15, compared to 
monocultures. 
 Moreover, we have also demonstrated that our models have the ability to support hiPSC-CM 
functionality and contractility. Live cell calcium imaging demonstrated slower calcium handling kinetics 
in the triculture model, as evidenced by the significant decrease in beating rates, from mono- to triculture, 
which may be correlated with a more mature Ca2+ handling apparatus in this model. Exposure to 
cardioactive drugs (norepinephrine, heptanol and propranolol) was likewise evaluated, with hiPSC-CM, in 
both mono- and tricultures, demonstrating chronotropic typical responses, indicating that β-adrenergic 
receptors and gap junction proteins were properly expressed on these models. Following the functional 
characterization, cardiotoxicity findings demonstrated that doxorubicin significantly reduced the cell 
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viability in the monoculture, in a dose-dependent manner, whilst paclitaxel presented a similar, but more 
sensitive response, encompassing both mono- and triculture. 
 The mechanobiological performance of the biomaterial was studied using AFM. Our scaffold proved 
suitable to recapitulate the heart microenvironment, since it exhibited a Young's modulus within the 
same order of magnitude of human cardiac muscle’s[14,23,25]. Also, FS-AFM provided insight into changes 
occurring within the scaffold (due to cell-to-cell and cell-to-scaffold contacts), by quantifying relevant 
biomechanical parameters (Young's modulus, stiffness, hardness and adhesion), suggestive of a hiPSC-
ECMC-induced remodelling of the cardiac microenvironment in triculture. 
 Finally, a proof-of-concept has established that it is conceivable to carry out the upscaling of the 3D 
cardiac models using perfusion STBRs, although the bioprocess still lacks optimization. 
 Altogether, we can conclude that the developed EHTs are a step forward in the study of heterotypic 
cellular communication between myocytes and non-myocytes and cardiomyocyte maturation, being 
compatible with medium- to large-scale production and high-throughput compliances, required in 
preclinical and clinical settings. 
 To finish, it would be interesting to develop a more robust and standardized cardiotoxicity platform 
(resorting to both cardiotoxic and cardioprotective agents). Another of the future prospects of this work 
will be to build a disease model, entirely based on patient-specific hiPSC, using a methodology and 
characterization toolbox similar to those settled. Furthermore, to reliably mimic in vitro the in vivo heart 
microenvironment the construct should ideally include all the critical cardiac cells beyond CMs and ECs. 
Certainly, increasing the complexity of our triculture format via inclusion of other cardiac cell types (e.g. 
pericytes and smooth muscle cells) and complex 3D architectures will be explored to further improve the 
model. 
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Annex 1 | Supplement to Materials and Methods. 
 
1.1 | Immunofluorescence phenotypic characterization. 
 A comprehensive list of primary and secondary antibodies and counterstains used in immunofluorescence 
characterizations (2D, cryosections and whole microcapsules) is compiled in Annex 1.1. Reference and supplier, host 
species, clonality, epitope localization and isotype and dilution and analytical method are also specified (Table S1 
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n.a. n.a. Nuclei 
1:500  
(LSFM) 
a Only primary antibodies and counterstains (DAPI, DRAQ5 and TO-PRO-3 Iodide), used in immunofluorescence microscopy, are 
listed. 
b The abbreviation in parentheses (italic) symbolises the imaging method in which a given identified antibody was used: CLSM – 
Confocal Laser Scanning Microscopy, MPLSM – Multiphoton Laser Scanning Microscopy and LSFM – Light Sheet Fluorescence 
Microscopy (consult List of Abbreviations and Conventions). CLSM was used in the context of cryosections immunofluorescence 
and MPLSM and LSFM in order to perform whole-mount immunofluorescence (with whole microcapsules). Conventional 
Widefield Fluorescence Microscopy was used as a routine technique and also in the characterization of 2D cell cultures, prior to 
microencapsulation. 2D IF refers 2D Immunofluorescence. 
* n.a. stands for not applicable. 
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Reference Supplier Host species Clonality 
Dilution and Analytical 
methodb 
Chicken anti-goat 














1:200 (MPLCM and LSFM) 






1:500 (2D IF and CLSM) 
1:200 (MPLCM and LSFM) 
Rabbit anti-mouse 














1:200 (MPLCM and LSFM) 
Goat anti-mouse 






(2D IF and CLSM) 
Donkey anti-goat 






(2D IF and CLSM) 
a Only secondary antibodies, used in immunofluorescence microscopy, are listed. 
b The abbreviation in parentheses (italic) symbolises the imaging method in which a given identified antibody was used: CLSM – 
Confocal Laser Scanning Microscopy, MPLSM – Multiphoton Laser Scanning Microscopy and LSFM – Light Sheet Fluorescence 
Microscopy (consult List of Abbreviations and Conventions). 2D IF refers 2D Immunofluorescence. 
Gene designationa Probe referenceb Labelc Amplicon length (bp) Function 
MYL2 Hs00166405_m1 FAM-MGB 98 Structural 
MYL7 Hs00221909_m1 FAM-MGB 58 Structural 
MYH7 Hs01110632_m1 FAM-MGB 73 Structural 
MYH6 Hs01101425_m1 FAM-MGB 67 Structural 
TNNI3 Hs00165957_m1 FAM-MGB 93 Structural 
TNNI1 Hs00913333_m1 FAM-MGB 77 Structural 
CACNA1C Hs00167681_m1 FAM-MGB 103 Ion channel 
SCN5A Hs00165693_m1 FAM-MGB 85 Ion channel 
GAPDH Hs99999905_m1 FAM-MGB 122 Housekeeping 
RPLP0 Hs99999902_m1 FAM-MGB 105 Housekeeping 
a MYL2 – myosin regulatory light chain 2, encoding the ventricular/cardiac muscle protein isoform (frequently referred to as 
MLC-2v), MYL7 – myosin regulatory light chain 7, encoding the atrial protein isoform (frequently referred to as MLC-2a),  MYH7 
– myosin heavy chain 7, encoding the cardiac beta-myosin heavy chain protein isoform (frequently referred to as MHC-β),  MYH6 
– myosin heavy chain 6, encoding the cardiac alpha-myosin heavy chain protein isoform (frequently referred to as MHC-α), 
TNNI3 – troponin I3, encoding the cardiac muscle isoform (frequently referred to as cTnI), TNNI1 – troponin I1, encoding the 
slow skeletal muscle isoform (frequently referred to as ssTnI), CACNA1C – calcium, L-type voltage-gated channel, alpha 1C 
subunit, encoding the calcium channel Cav1.2, SCN5A – sodium voltage-gated channel, alpha subunit 5, encoding the cardiac 
sodium channel Nav1.5, GAPDH – glyceraldehyde-3-phosphate dehydrogenase and RPLP0 – ribosomal protein lateral stalk 
subunit P0 (consult List of Abbreviations and Conventions). 
b TaqMan probes were purchased from Thermo Fisher Scientific. 
c The 5’ terminus of the probe is labelled with FAM (6-carboxyfluorescein), the fluorochrome. MGB stands for minor groove 
binder. 
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Annex 2 | Establishment of fully hiPSC-derived hydrogel-based 3D cardiac tissue models. 
 





















2.2 | Characterization after microencapsulation: average microcapsule diameter, cell viability, 





Average microcapsule diametera 
(µm) 
Pilot Model–M-SF 767.5 ± 27.43 
Model #1-a–MCT-SF 1546 ± 62.05 
Model #1-b–MCT-SF 832.7 ± 28.30 
Model #2-b–MT-BR-2 817.5 ± 41.52 
a Data are mean ± SD. Each one of the data sets matches to an individual experiment, accounting for a total of four independent 
experiments (Pilot Model–M-SF, Model #1-a–MCT-SF, Model #1-b–MCT-SF and Model #2-b–MT-BR-2). n ≥ 30 microcapsules. 
Statistically significant differences between experiments were assessed through an ordinary one-way ANOVA analysis with 
Tukey’s post hoc test for multiple comparisons (****P ≤ 0.0001). Asterisks (*) denote significant differences.  Whenever no 
statistical significance relationship is indicated in the graphs, consider it as ns – not significant, P > 0.05. 
Figure S1 | Culture monitoring before microencapsulations: cell viability and spheroid size (Model #1-b–MCT-SF 
and Pilot Model–M-SF).  
(a-b)  Evaluation of hiPSC-CM spheroids viability, through a live/dead assay, at days 15 (a) and 20 (b), prior to 
microencapsulation (Model #1-b–MCT-SF and Pilot Model–M-SF, respectively). Spheroids were stained with FDA (fluorescein 
diacetate) – live cells, green, and PI (propidium iodide) – dead cells, red. Scale bars, 200 µm.  
(c) Scatter dot plot exhibiting the hiPSC-CM average spheroid diameter, at day prior to microencapsulation. Line at mean with 
SD. Data are mean ± SD from two independent experiments (Model #1-b–MCT-SF and Pilot Model–M-SF) (n = 91 spheroids). 
 
Table S4. Average microcapsule diameter resulting from different experiments (Pilot Model–M-SF, Model #1-a–
MCT-SF, Model #1-b–MCT-SF and Model #2-b–MT-BR-2) 
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Figure S2 | Average microcapsule diameter resulting from four 
separate experiments (Pilot Model–M-SF, Model #1-a–MCT-SF, 
Model #1-b–MCT-SF and Model #2-b–MT-BR-2). Scatter dot plot 
displaying the average microcapsule diameter. Line at mean with SD. 
Data are mean ± SD. Each one of the data sets matches to an individual 
experiment, accounting for a total of four independent experiments (n ≥ 
30 microcapsules). Ordinary one-way ANOVA analysis with Tukey’s post 
hoc test for multiple comparisons (****P ≤ 0.0001). Whenever no 
statistical significance relationship is indicated in the graphs, consider it 
as ns – not significant, P > 0.05. 
Figure’s caption is shown on the following page 
Annex 
 














Annex 3 | Microscopy-based phenotypic platform. 
 



































Figure S3 | Pilot experiment, which led to the microencapsulation of only hiPSC-CM monocultures: cell viability, 
metabolic activity and model monitoring and characterization (Pilot Model–M-SF). (a) 3D hiPSC-CM monoculture 
cardiac tissue models’ cell viability over time, cultured under similar circumstances (from left to right: empty microcapsules and 
increasing concentrations of spheroids, per mL of alginate; from top to bottom: 1, 7 and 15 days after microencapsulation). 
Monocultures were stained with FDA (fluorescein diacetate) – live cells, green, and PI (propidium iodide) – dead cells, red. Scale 
bars, 500 µm. (b) 3D monocultures metabolic activity quantification at day 15 post-microencapsulation, using a PrestoBlue 
resazurin–based dye assay. Data are mean ± SD from one independent experiment and consist of three technical replicates (n = 
3). Ordinary one-way ANOVA analysis with Tukey’s post hoc test for multiple comparisons (*P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 
0.0001). Fluorescence intensity values (RFU, relative fluorescence units) were normalized per capsule and to the maximum of 
fluorescence intensity. Excitation and emission wavelengths were 560 and 590 nm, respectively; gain was 165. (c) Spheroids per 
microcapsule distribution, in monocultures, 1 day after microencapsulation. (d) Monocultures’ characterization in terms of (d1) 
spheroid and (d2) microcapsule concentration, over time (1, 7 and 15 days after microencapsulation). 
Figure S4 | Mono- and triculture confocal imaging-based phenotypic characterization: endothelial and 
mesenchymal markers (Model #1-a–MCT-SF). Confocal immunofluorescence microscopy of 3D hiPSC-CM mono- (upper 
panel) and 3D hiPSC-CM/ECMC triculture (lower panel) microcapsules, in 10 µm thick cryosections, at the endpoint of the models 
(day 15 post-microencapsulation), in similar culture circumstances. Data are representative maximum intensity z-projections 
from one independent experiment. Mono- (upper panel) and triculture (lower panel) immunostained (from left to right) for the 
endothelial cell surface marker CD31 (green) and for the mesenchymal markers Vimentin (red), α-SMA (red) and DDR2 (green). 
Nuclei were counterstained with DAPI (blue). Insets indicate high magnification images of the corresponding white or green 
rectangles. All images acquired with a 63x 1.3NA (consult List of Abbreviations and Conventions) oil immersion objective (Leica 
Microsystems). Scale bars, 50 µm. 
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Figure S5 | Mono- and triculture confocal imaging-
based phenotypic characterization: cell polarity and 
proliferation (Model #1-a–MCT-SF).  
Confocal immunofluorescence microscopy of 3D hiPSC-CM 
mono- (upper panel) and 3D hiPSC-CM/ECMC triculture 
(lower panel) microcapsules, in 10 µm thick cryosections, at 
the endpoint of the models (day 15 post-
microencapsulation), in similar culture circumstances. Data 
are representative maximum intensity z-projections from 
one independent experiment. Mono- (upper panel) and 
triculture (lower panel) immunostained (from left to right) 
for the polarity marker ZO-1 (green) and for CD31 (red), and 
similarly for the proliferation marker Ki-67 (green) and for 
α-SMA (red). Nuclei were counterstained with DAPI (blue). 
Insets indicate high magnification images of the 
corresponding white, red or green rectangles. All images 
acquired with a 63x 1.3NA oil immersion objective (Leica 
Microsystems). Scale bars, 50 µm. 
Figure S6 | Multiphoton imaging-based phenotypic characterization of whole mount mono- and tricultures: 
cardiac markers (Model #1-a–MCT-SF). Multiphoton immunofluorescence microscopy of whole mount microencapsulated 
3D hiPSC-CM mono- (a, upper panel) and 3D hiPSC-CM/ECMC triculture (b, lower panel), in similar culture circumstances, at day 
15 post-microencapsulation. Data are representative maximum intensity z-projections and 3D projects (consult Annex 3.3, 3D 
Projects 1–4) from one independent experiment. Mono- (a, upper panel) and triculture (b, lower panel) immunostained (from 
left to right) for the cardiac markers cTnT and sarcomeric α-actinin (red). Nuclei were counterstained with DAPI (blue). All images 
acquired with a 40x 0.8NA water immersion objective (Olympus), adding an optical zoom up to 2.5x; total magnification: up to 
100x. Scale bars, 50 µm. 
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Figure S7 | Multiphoton imaging-based phenotypic characterization of whole mount mono- and tricultures: 
cardiac maturation markers (Model #1-a–MCT-SF). Multiphoton immunofluorescence microscopy of whole mount 
microencapsulated 3D hiPSC-CM mono- (upper panel) and 3D hiPSC-CM/ECMC triculture (lower panel), in similar culture 
circumstances, at day 15 post-microencapsulation. Data are representative maximum intensity z-projections and 3D projects 
(consult Annex 3.3, 3D Projects 5 and 6) from one independent experiment. Mono- (upper panel) and triculture (lower panel) 
immunostained (from left to right) for immature ventricular/atrial/nodal CM phenotype (MLC-2a, red), and for definitive 
ventricular phenotype (MLC-2v, green). Nuclei were counterstained with DAPI (blue). All images acquired with a 40x 0.8NA water 
immersion objective (Olympus), adding an optical zoom up to 2.5x; total magnification: up to 100x. Scale bars, 50 µm. 
Figure S8 | Multiphoton imaging-based phenotypic characterization of whole mount monocultures (Pilot Model–
M-SF). Multiphoton immunofluorescence microscopy of whole mount microencapsulated 3D hiPSC-CM monocultures, at day 
15 post-microencapsulation. Data are representative maximum intensity z-projections from one independent experiment. hiPSC-
CM spheroids immunostained (from left to right) for the cardiac markers cTnT and Nkx2-5 (green), sarcomeric α-actinin (red) 
and sarcomeric α-actinin (green), and also for the endothelial cell surface marker CD31 (green) and for the mesenchymal marker 
Vimentin (red). Nuclei were counterstained with DAPI (blue). Insets indicate high magnification images of the corresponding 
white rectangles. All images acquired with a 40x 0.8NA water immersion objective (Olympus), adding an optical zoom up to 2.5x; 
total magnification: up to 100x. Scale bars, 100 µm. 
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3.3 | Multiphoton imaging-based phenotypic characterization: movies list. 
 A list of short 3D project movies (3D Projects 1–12), that were constructed from z-stacks, acquired in the context 
of multiphoton immunofluorescence microscopy (in addition to the maximum intensity z-projections), is compiled 
in Annex 3.3. Movies relate to mono- and triculture whole mount microcapsules, at day 15 post-
microencapsulation, labelled for cardiac markers (cTnT and sarcomeric α-actinin), cardiac maturation markers 
(MLC-2a and MLC-2v) and ECM proteins (collagen type I, collagen type IV and fibronectin).  
All the abovementioned materials, contained in this attachment, will be digitally provided. 
 
3D Project 1 (.gif format) | 3D hiPSC-CM monoculture immunostained for cTnT (red) and counterstained with DAPI (blue). 
3D Project 2 (.gif format) | 3D hiPSC-CM/ECMC triculture immunostained for cTnT (red) and counterstained with DAPI (blue). 
3D Project 3 (.gif format) | 3D hiPSC-CM monoculture immunostained for sarcomeric α-actinin (red) and counterstained with 
DAPI (blue). 
3D Project 4 (.gif format) | 3D hiPSC-CM/ECMC triculture immunostained for sarcomeric α-actinin (red) and counterstained 
with DAPI (blue). 
3D Project 5 (.gif format) | 3D hiPSC-CM monoculture immunostained for MLC-2a (red) and MLC-2v (green), and 
counterstained with DAPI (blue). 
3D Project 6 (.gif format) | 3D hiPSC-CM/ECMC triculture immunostained for MLC-2a (red) and MLC-2v (green), and 
counterstained with DAPI (blue). 
3D Project 7 (.gif format) | 3D hiPSC-CM monoculture immunostained for the collagen type I (green) and counterstained with 
DAPI (blue). 
3D Project 8 (.gif format) | 3D hiPSC-CM/ECMC triculture immunostained for the collagen type I (green) and counterstained 
with DAPI (blue). 
3D Project 9 (.gif format) | 3D hiPSC-CM monoculture immunostained for the collagen type IV (green) and counterstained with 
DAPI (blue). 
3D Project 10 (.gif format) | 3D hiPSC-CM/ECMC triculture immunostained for the collagen type IV (green) and counterstained 
with DAPI (blue). 
3D Project 11 (.gif format) | 3D hiPSC-CM monoculture immunostained for the fibronectin (green) and counterstained with 
DAPI (blue). 
3D Project 12 (.gif format) | 3D hiPSC-CM/ECMC triculture immunostained for the fibronectin (green) and counterstained with 
DAPI (blue). 
 
3.4 | Light-sheet imaging-based phenotypic characterization: movies list. 
 A list of 3D volume reconstructions (LSFM Movies 1–6), obtained via LSFM, is likewise compiled in Annex 3.4. 
These materials will also be digitally provided. 
 
LSFM Movie 1 (.avi format) | 3D hiPSC-CM monoculture immunostained for CD31 (green) and Vimentin (red), and 
counterstained with DRAQ5 (cyan). 
LSFM Movie 2 (.avi format) | 3D hiPSC-CM/ECMC triculture immunostained for CD31 (green) and Vimentin (red), and 
counterstained with DRAQ5 (cyan). 
LSFM Movie 3 (.avi format) | 3D hiPSC-CM monoculture immunostained for VE-cadherin (green) and α-SMA (red), and 
counterstained with DRAQ5 (cyan). 
LSFM Movie 4 (.avi format) | 3D hiPSC-CM/ECMC triculture immunostained for VE-cadherin (green) and α-SMA (red), and 
counterstained with DRAQ5 (cyan). 
LSFM Movie 5 (.avi format) | 3D hiPSC-CM monoculture immunostained for fibronectin (green) and counterstained with 
DRAQ5 (cyan). 
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Annex 4 | Structural and ultrastructural assessment. 
 





























3D cardiac tissue model 
Sarcomere lengtha 
(nm) 
Sarcomere angle dispersionb 
(SEM of sarcomere angles) 
hiPSC-CM Monoculture 1433 ± 190.7‡1 5.535 ± 3.419‡2 
hiPSC-CM/ECMC Triculture 1521 ± 134.2‡1 3.039 ± 1.589‡2 
a Sarcomere length – Data are mean ± SD from one independent experiment (Model #1-a–MCT-SF). n = 40-52 sarcomeres. 
**Statistically significant differences between Mono- and Triculture were assessed through a two-tailed Mann–Whitney 
nonparametric test (**P = 0.0047). b Sarcomere angle dispersion –  Data are mean ± SD from one independent experiment 
(Model #1-a–MCT-SF). n = 8-15 sarcomeres. *Statistically significant differences between mono- and triculture were assessed 
through a two-tailed unpaired t-student test (*P = 0.0379). Asterisks (*) denote significant differences. 
‡1 Sarcomere length was estimated by measuring two parallel segments, per sarcomere, joining adjacent Z lines. 
‡2 SEM of sarcomere angles, σM, was calculated by the quotient between the standard deviation of the original distribution of 
sarcomere angles’ means, σ,  and the square root of the number of sarcomeres, √N: 𝝈𝑴 =
𝝈
√𝑵
.  SEM stands for standard error 
of the mean. 
Table S5. Mono- and triculture cardiac tissue models ultrastructural features – sarcomere length and sarcomere 
angle dispersion – at day 15 post-microencapsulation. 
 
Figure’s caption is shown on the following page 
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Figure S10 | Ultrastructural characterization of mono- and triculture, 14 days after microencapsulation (Model #1-
b–MCT-SF). Representative TEM micrographs of 3D hiPSC-CM mono- (upper panel) and 3D hiPSC-CM/ECMC triculture (lower 
panel) cardiac tissue models, at day 14 post-microencapsulation. Registers of sarcomeres, displaying aligned myofibrils (MF) and 
organized Z-discs (Z), gap junctions (GJ) connecting neighbouring hiPSC-CMs (denoted as CM1 and CM2) and density of 
mitochondria (M). Insets indicate high magnification images of the corresponding grey, black or cyan rectangles. Scale bars, 500 
nm (in both figures and magnifications). 
Figure S9 | Ultrastructural characterization of mono- and triculture, 1 days after microencapsulation (Model #1-
b–MCT-SF). Representative TEM micrographs of 3D hiPSC-CM mono- (upper panel) and 3D hiPSC-CM/ECMC triculture (lower 
panel) cardiac tissue models, at day 1 post-microencapsulation. Registers of sarcomeres, displaying misaligned myofibrils (MF) 
and split Z-discs (Z), shorter gap junctions (GJ) connecting neighbouring hiPSC-CMs (denoted as CM1 and CM2) and density of 
mitochondria (M). Insets indicate high magnification images of the corresponding grey, black or cyan rectangles. Scale bars, 500 
nm (in both figures and magnifications). 
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Annex 5 | Functional evaluation: live cell calcium imaging. 
 



































































Figure S11 | Histochemistry and morphology analysis of 3D hiPSC-CM monocultures (Pilot Model–M-SF). 
Histochemistry characterization of 3 μm thick paraffin sections of 3D hiPSC-CM monoculture microcapsules (from left to right: 
increasing concentrations of spheroids, per mL of alginate), taken at day 15 post-microencapsulation and stained for H&E, TB, 
MT, PSR and PAS. Data are representative images from one independent experiment. Abbreviations (from top to bottom): 
Hematoxylin and Eosin (H&E), Toluidine Blue (TB), Masson Trichrome w/ Aniline Blue (MT), Picrosirius Red (PSR) and Periodic 
Acid-Schiff (PAS). Scale bars, 100 µm. 
Table S6. hiPSC-CM calcium transient kinetics in mono- and triculture and pharmacological response to a β1-
adrenergic receptor agonist, norepinephrine (60 µM), obtained by live cell calcium imaging. 
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a-h Data are mean ± SD from one independent experiment (Model #1-a–MCT-SF). All kinetic parameters: n = 8-13. Statistically 
significant differences between Mono, Mono + 60 µM Norepi, Tri and Tri + 60 µM Norepi groups were assessed through an 
ordinary one-way ANOVA analysis with Tukey’s post hoc test for multiple comparisons (ns – not significant, *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001). Asterisks (*) denote significant differences. 
‡1 These parameters refer to 15 days after microencapsulation, for both mono- and triculture cardiac tissue models, under 
similar culture circumstances. 
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a-h Data are mean ± SD from one independent experiment (Model #1-b–MCT-SF). All kinetic parameters: n = 2-8. Statistically 
significant differences between Mono, Mono + 60 µM Norepi,  Mono + 40 µM Heptanol,  Mono + 4 µM PPL,  Mono + 4 µM PPL 
+ 60 µM Norepi, Tri, Tri + 60 µM Norepi,  Tri + 40 µM Heptanol,  Tri + 4 µM PPL and Tri + 4 µM PPL + 60 µM Norepi  groups were 
assessed through an ordinary one-way ANOVA analysis with Tukey’s post hoc test for multiple comparisons (ns – not significant, 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). Asterisks (*) denote significant differences. Whenever no statistical 
significance relationship is indicated in the graphs, consider it as ns – not significant, P > 0.05. 
‡1 These parameters refer to 14 days after microencapsulation, for both mono- and triculture cardiac tissue models, under 
similar culture circumstances. 
‡2 Mono – Monoculture, Tri – Triculture, Norepi – Norepinephrine and PPL – Propranolol and (consult List of Abbreviations and 
Conventions). 
Table S7. hiPSC-CM calcium transient kinetics in mono- and triculture and pharmacological responses to several 
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5.2 | List of videos: spinning disk confocal microscopy. 
 Videos refer to hiPSC-CM spontaneous Ca2+ releases (conditions w/o drug exposure) and to hiPSC-CM 
pharmacological responses to different drugs with cardiac affinity, specifically norepinephrine, propranolol and 
heptanol, in both mono- and triculture cardiac tissue models. Videos are from two independent experiments (Model 
#1-a–MCT-SF and Model #1-b–MCT-SF). 





























Movie 1 (.gif format) | Ca2+ spontaneous releases in monoculture (monoculture w/o drug exposure), at day 15 post-
microencapsulation (Model #1-a–MCT-SF). 
Movie 2 (.gif format) | Ca2+ spontaneous releases in triculture (triculture w/o drug exposure), at day 15 post-
microencapsulation (Model #1-a–MCT-SF). 
Movie 3 (.gif format) | Monoculture exposed to 60 µM of norepi, at day 15 post-microencapsulation (Model #1-a–MCT-SF). 
Movie 4 (.gif format) | Triculture exposed to 60 µM of norepi, at day 15 post-microencapsulation (Model #1-a–MCT-SF). 
Movie 5 (.gif format) | Ca2+ spontaneous releases in monoculture (monoculture w/o drug exposure), at day 14 post-
microencapsulation (Model #1-b–MCT-SF). 
Movie 6 (.gif format) | Ca2+ spontaneous releases in triculture (triculture w/o drug exposure), at day 14 post-
microencapsulation (Model #1-b–MCT-SF). 
Movie 7 (.gif format) | Monoculture exposed to 60 µM of norepi, at day 14 post-microencapsulation (Model #1-b–MCT-SF). 
Movie 8 (.gif format) | Triculture exposed to 60 µM of norepi, at day 14 post-microencapsulation (Model #1-b–MCT-SF). 
Figure S12 | Live cell calcium imaging microscopy videos from two separate experiments (Model #1-a–MCT-SF 
and Model #1-b–MCT-SF). Calcium imaging spinning disk confocal microscopy videos of 3D hiPSC-CM mono- and 3D hiPSC-
CM/ECMC triculture cardiac tissue models, in similar culture circumstances, recorded at day 15 post-microencapsulation. Videos 
show two distinct moments: i) resting (low intracellular Ca2+ concentration) and ii) depolarization (high intracellular Ca2+ 
concentration). Data are representative videos from two independent experiments: (a, upper panel, Model #1-a–MCT-SF) and 
(b, lower panel, Model #1-b–MCT-SF). All videos acquired with a 20x 0.75NA dry objective (Nikon). Scale bars, 200 µm. 
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Movie 9 (.gif format) | Monoculture exposed to 40 µM of heptanol, at day 14 post-microencapsulation (Model #1-b–MCT-SF). 
Movie 10 (.gif format) | Triculture exposed to 40 µM of heptanol, at day 14 post-microencapsulation (Model #1-b–MCT-SF). 
Movie 11 (.gif format) | Monoculture exposed to 4 µM of propranolol, at day 14 post-microencapsulation (Model #1-b–MCT-
SF). 
Movie 12 (.gif format) | Triculture exposed to 4 µM of propranolol, at day 14 post-microencapsulation (Model #1-b–MCT-SF). 
Movie 13 (.gif format) | Monoculture exposed to 4 µM of propranolol and thereafter to 60 µM of norepinephrine (Model #1-
b–MCT-SF). 
Movie 14 (.gif format) | Triculture exposed to 4 µM of propranolol and thereafter to 60 µM of norepinephrine (Model #1-b–
MCT-SF). 
 







































188.0 ± 69.38 53.12 ± 21.29 72.06 ± 21.82 0.5053 ± 0.6219 
579.6 ± 137.0 
Monoculture 26.24 ± 10.44 13.63 ± 6.653 5.737 ± 1.718 0.5743 ± 0.5503 
Triculture 159.3 ± 27.27 47.79 ± 8.074 77.07 ± 32.27 2.913 ± 2.326 
a-d Data are mean ± SD from one independent experiment (Pilot Model–M-SF), for RGD-alginate microbead, and two (Model #1-
a–MCT-SF  and  Model #1-b–MCT-SF), for mono- and triculture. Young’s modulus and Stiffness: n = 63-80, Hardness: n = 71-81 
and Adhesion: n = 69-77. Statistically significant differences between RGD-alginate microbead, Mono- and Triculture groups 
were assessed through a ranked one-way ANOVA analysis (Kruskal-Wallis nonparametric test) with Dunn’s post hoc test for 
multiple comparisons (ns – not significant, *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001). Asterisks (*) denote significant differences. 
e Data are mean ± SD from two independent experiments (Pilot Model–M-SF Model and Model #1-a–MCT-SF). n = 61. 




Figure S13 | AFM 2D and 3D imaging characterization of the microcapsule scaffold and 3D hiPSC-CM monoculture 
model (high magnifications). (a) AFM 2D and 3D phase imaging (left panel) of RGD-alginate microbead and monoculture. (b) 
AFM 2D and 3D topographical imaging (right panel) of the same groups. (a-b) A scan area of 0.25 µm2 (size: 0.5 x 0.5 µm), for 
RGD-alginate microbead, and 25 µm2 (size: 5 x 5 µm), for monoculture, were used. Data are representative images from one 
independent experiment (Pilot Model–M-SF), for RGD-alginate microbead, and two (Model #1-a–MCT-SF and Model #1-b–MCT-
SF), for monoculture. 
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 Model #2-a–BR-1a,*1 Model #2-b–MT-BR-2a,*1 
Working volume (mL) 200 200 
Inoculum (x106 cell) 100 100 
Inoculum concentration (x106 cell/mL) 0,31 (0,5)*2 0,78 (0,5)*2 
Final cell concentration (x106 cell/mL) 0,04 0,27 
Final spheroid concentration (x 104 spheroid/mL) 0,077 0,077 
Stirring rate (rpm) 60 (d7-d8); 70 (d9-d18) 80 (d7-d10); 90 (d11-d18) 
a Small-scale software-controlled stirred-tank bioreactors (DasGip cellferm-pro bioreactor system, Eppendorf AG, Hamburg, 
Germany). 
*1 Other culture parameters: Temperature – 37 oC, Dissolved Oxygen (DO) – 3% O2 tension (15% of air with 21% of oxygen; 
atmospheric hypoxia environment), Dilution Rate (DR) – 0.30 day-1 and Hydraulic Residence Time (HRT) – 3,33 day. Model 
#2-a–BR-1 and Model #2-b–MT-BR-2 denote two independent bioreactor experiments. *2 The number in parentheses (italic) 
represents the corresponding theoretical inoculum concentrations. 
Table S9. Quantitative characterization of hiPSC-CM aggregation profile in stirred-tank bioreactors, from day 7 to 
day 18. 
 
 
